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ABSTRACT 
Current treatment options are limited for patients with myocardial infarction or heart failure.  Cellular 
cardiomyoplasty is a promising therapeutic strategy being investigated as a potential treatment, which 
aims to deliver exogenous cells to the infarcted heart, for the purpose of restoring healthy myocardial 
mass and mechanical cardiac function.  While several cell types have been studied for this application, 
only bone marrow cells and human mesenchymal stem cells (hMSCs) have been shown to be safe and 
effective for improving cardiac function in clinical trials.  In both human and animal studies, the delivery 
of hMSCs to infarcted myocardium decreased inflammatory response, promoted cardiomyocyte survival, 
and improved cardiac functional indices. 
 
While the benefits of using hMSCs as a cell therapy for cardiac repair are encouraging, the desired 
expectation of cardiomyoplasty is to increase cardiomyocyte content that will contribute to active 
cardiac mechanical function.  Delivered cells may increase myocyte content by several different 
mechanisms such as differentiating to a cardiomyocyte lineage, secreting paracrine factors that increase 
native stem cell differentiation, or secreting factors that increase native myocyte proliferation.  
Considerable work suggests that hMSCs can differentiate towards a cardiomyocyte lineage based on 
measured milestones such as cardiac-specific marker expression, sarcomere formation, ion current 
propagation, and gap junction formation.  However, current methods for cardiac differentiation of hMSCs 
have significant limitations.  Current differentiation techniques are complicated and tedious, signaling 
pathways and mechanisms are largely unknown, and only a small percentage of hMSCs appear to exhibit 
cardiogenic traits. 
 
In this body of work, we developed a simple strategy to initiate cardiac differentiation of hMSCs in vitro.  
Incorporating environmental cues typically found in a myocardial infarct (e.g. decreased oxygen tension 
and increased concentrations of cell-signaling factors), our novel in vitro conditioning regimen combines 
reduced-O2 culture and hepatocyte growth factor (HGF) treatment.  Reduced-O2 culturing of hMSCs has 
shown to enhance differentiation, tissue formation, and the release of cardioprotective signaling factors.  
HGF is a pleiotropic cytokine involved in several biological processes including developmental 
cardiomyogenesis, through its interaction with the tyrosine kinase receptor c-Met.  We hypothesize that 
applying a combined conditioning treatment of reduced-O2 and HGF to hMSCs in vitro will enhance 
cardiac-specific gene and protein expression.  Additionally, the transplantation of conditioned hMSCs 
into an in vivo infarct model will result in differentiation of delivered hMSCs and improved cardiac 
mechanical function. 
 
In testing our hypothesis, we show that reduced-O2 culturing can enhance hMSC growth kinetics and total 
c-Met expression.  Combining reduced-O2 culturing with HGF treatment, hMSCs can be conditioned to 
express cardiac-specific genes and proteins in vitro.  Using small-molecule inhibitors to target specific 
effector proteins in a proposed HGF/c-Met signaling pathway, treated reduced-O2/HGF hMSCs show a 
decrease in cardiac gene expression.  When implanted into rat infarcts in vivo, reduced-O2/HGF 
conditioned hMSCs increase regional cardiac mechanics within the infarct region at 1 week and 1 month.  
Further analysis from the in vivo study showed a significant increase in the retention of reduced-O2/HGF 
conditioned hMSCs.  Immunohistochemistry showed that some of the reduced-O2/HGF conditioned 
hMSCs express cardiac-specific proteins in vivo.  These results suggest that a combined regimen of 
reduced-O2 and HGF conditioning increases cardiac-specific marker expression in hMSCs in vitro.  In 
addition, the implantation of reduced-O2/HGF conditioned hMSCs into an infarct significantly improves 
cardiac function, with contributing factors of improved cell retention and possible increases in myocyte 
content.  Overall, we developed a simple in vitro conditioning regimen to improve cardiac differentiation 
capabilities in hMSCs, in order to enhance the outcomes of using hMSCs as a cell therapy for the 
diseased heart.  
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CHAPTER 1: Overview  
1.1. Introduction 
According to the 2011 heart disease statistics published by the American Heart Association, an 
estimated 16.3 million Americans ≥20 years of age are living with coronary heart disease (CHD), which 
is reported as the most prevalent cause of death of American men and women.1  As a leading indication of 
CHD, 7.2 million of these American adults have also experienced a myocardial infarction (MI), or heart 
attack.1  Though the severity of MIs can vary, all MIs result in the death of cardiomyocytes, which 
compromises the heart’s functional capability and endangers one’s survival.  Current treatment options 
are limited for MI patients.  Despite novel surgical and pharmaceutical interventions aiming to treat 
scarred myocardium, they fail to address the fundamental need to replace the necrotic cardiomyocytes 
with new contractile cells in order to restore active cardiac mechanical function.2  Currently, heart 
transplantation is the only viable treatment for the replacement of necrotic myocardium.  However, less 
than 2,200 hearts are donated per year,1,3 which does not satisfy the demand of MI patients in need.  
Developing methods and techniques for generating new cardiomyocytes, which can replace necrotic 
myocardium and be made available to a wider audience of patients, will have a significant impact on the 
long-term survival of millions of Americans. 
Over the past decade, a strong focus in regenerative medicine has aimed to develop strategies that 
treat the diseased heart.  Cardiomyocytes were once thought to be a post-mitotic cell-type, incapable of 
self-regeneration.  However, new endogenous and exogenous cell therapies for myocardial regeneration 
have emerged from an increasing understanding of cardiac development, cardiomyocyte cell biology, 
stem cell biology, and cardiomyoplasty.  Recent data suggests that 1-4% of cardiomyocytes are capable of 
proliferation in vivo,4,5 the heart can recruit the body’s own endogenous stem cells to regions of 
myocardial injury,6,7 and the heart may also contain its own resident population of stem cells that can aid 
in self-repair.8,9  Studies involving exogenous strategies have found that a small percentage of biopsied 
cardiomyocytes can be coerced to proliferate under specific conditions in vitro, and several different types 
of stem cells (i.e. mesenchymal stem cells, embryonic stem cells, cardiac stem cells, and induced 
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pluripotent stem cells) can differentiate towards a cardiac lineage.10-14  While the achieved progress of 
endogenous methodologies warrants continued research, it has been shown that only 4% of the 
approximated 3 billion native cardiomyocytes in the left ventricle undergo proliferation.5  With an 
estimated loss of about 1 billion cardiomyocytes during a severe MI,15 it is unlikely that the new 
cardiomyocytes generated in situ from the 4% proliferative native myocytes can significantly improve or 
sustain function.  Conversely, exogenous strategies for cardiomyocyte regeneration, by in vitro stem cell 
differentiation and cell expansion, have shown that it may be possible to generate enough new 
cardiomyocytes to replace the amount lost during an MI.16-20 
Since exogenously generated cardiomyocytes are developed in vitro, the cells must be implanted in 
the heart for therapeutic applications.  Cardiomyoplasty is a surgical approach which aims to deliver cells 
to the infarcted heart, for the ultimate purpose of restoring healthy myocardial mass and mechanical 
cardiac function.  Delivered cells may restore myocardial mass by differentiating into cardiomyocytes that 
contribute mechanical function; however, delivered cells can also restore myocardial mass by secreting 
paracrine factors that can enhance native cardiomyocyte survival,21 promote native myocyte 
proliferation,10,22 recruit endogenous stem cells to the infarct area,6,23,24 and possibly differentiate 
endogenous stem cells to cardiac phenotypes.  While several cell types have been studied for this 
application,13,14 only bone marrow cells (BMCs) and human mesenchymal stem cells (hMSCs) have been 
shown to be safe and effective for improving cardiac function in clinical trials.25  In both human and 
animal studies, it has been shown that delivering hMSCs (and the subsequent paracrine factors) to 
infarcted myocardium decreases inflammation,26-28 promotes cardiomyocyte survival,21,29 and improves 
cardiac functional indices such as left ventricular systolic pressure, volume, and ejection fraction.12,25,30-32  
While the benefits of using hMSCs as a cell therapy for cardiac repair are encouraging, the desired 
expectation of cardiac cell therapy is to deliver new contractile cardiomyocytes that will contribute to 
active cardiac mechanical function.  A considerable body of work suggests that hMSCs can differentiate 
towards a cardiomyocyte lineage based on measured milestones such as cardiac-specific marker 
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expression, sarcomere formation, ion current propagation, and gap junction formation (assessed and 
reviewed by Schuldt et al.).13   
Despite the achievements of hMSC cardiac differentiation, however, these studies demonstrate 
considerable limitations.  Only a small percentage of the cells express cardiac markers and it remains 
unclear if hMSCs can generate a mature, contractile cardiomyocyte phenotype.  Since Anversa’s initial 
study in 2001 suggesting that bone marrow cells could regenerate infarcted myocardium,12 several groups 
have dedicated substantial time and resources to study the potential of bone marrow cells and bone 
marrow stem cells in cardiac repair.  And while many of these researchers believe in the promise of 
cellular therapy for treating the diseased heart, conflicting results and reports raise a concern of whether 
bone marrow cells or hMSCs are appropriate cell-types for the task.33  However, hMSCs remain a 
plentiful autologous cell source, which have been shown to be safe and effective for short-term 
improvement of ejection fraction for MI patients in clinical studies.25  Herein lies the current controversy 
over the use of hMSCs as a cell therapy for cardiac repair.  While some researchers have dismissed 
hMSCs in favor of new cell types and strategies, others continue to study hMSCs for new cardiac repair 
mechanisms and differentiation techniques. 
In 2010, Behfar et al. showed that bone-marrow derived hMSCs harvested from coronary artery 
patients could be conditioned with a cocktail of recombinant factors for guided cardiopoiesis.16  Treating 
hMSCs with transforming growth factor β1, bone morphogenetic protein-4, Activin A, retinoic acid, 
insulin-like growth factor-1, fibroblast growth factor-2, alpha-thrombin, and interleukin-6, they were able 
to increase expression of cardiac transcription factors such as Nkx 2.5, TBX5, MESP1, and MEF2C in 
vitro.  Implanting these treated hMSCs into infarcted mouse hearts demonstrated an increased functional 
output, with sarcomeric and gap junction marker expression co-localized with human nuclear staining.  
These outcomes suggest that pre-emptive conditioning of hMSCs for cardiac lineage specification may 
improve their therapeutic benefit, claiming increased cardiomyocyte content from hMSCs and improved 
cardiac mechanical function. 
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Behfar et al.’s work is the latest study to suggest that hMSCs derived from adult bone marrow may 
have the capacity to regenerate myocardium.16  However, this work iterates a unique paradigm in cell 
therapy: primitive multipotent cells, which have been conditioned to express fundamental organ-specific 
genes and proteins, can further differentiate into mature phenotypes once implanted in vivo, by being 
equipped with the appropriate cellular “machinery” to respond and adapt to the organ’s 
microenvironmental cues.  In 2008, our lab also used this paradigm to describe how mechanical 
manipulation of hMSCs by hanging drops could partially differentiate hMSCs towards a cardiomyocyte 
lineage to show cardiac marker expression and L-type calcium channel currents in vitro, while also 
improving mechanical function in vivo.34  The paradigm certainly concedes that we do not fully 
understand the possible mechanisms involved in hMSC cardiac differentiation, but the idea of pre-
conditioning hMSCs for early cardiopoiesis prior to implantation is gaining popularity.35,36  A recent 
review by Marban and Malliaras, suggests that conditioning hMSCs in a “boot camp” of natural and 
embryonic signaling factors prior to implantation may improve both direct and indirect mechanisms of 
cardiac repair.36  A simplistic strategy with fewer steps and factors for hMSC cardiac differentiation is 
likely to be more clinically applicable as it would simplify the FDA approval process and be easier to 
implement.  In addition, a facile hMSC differentiation strategy is likely to garner industry support due to 
ease, decreased incubation time, and reduced resources.  Exploring new conditioning regimens may help 
to overcome the current limitations of hMSC cardiac differentiation, and thereby improve hMSC cell 
therapy for the diseased heart. 
 
1.2. Overall Goal and Hypothesis  
The overall goal of this project is to enhance the effectiveness of using hMSCs for cardiomyoplasty 
by analyzing the effects of a unique in vitro conditioning regimen on hMSC growth kinetics, c-Met 
receptor expression, cardiac marker expression, HGF/c-Met pathway involvement in cardiac marker 
expression, and the changes in cardiac mechanical function when conditioned hMSCs are implanted into 
MIs in vivo.   
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We hypothesize that applying a combined conditioning treatment of reduced-O2 and HGF to 
hMSCs in vitro will enhance cardiac-specific gene and protein expression.  Additionally, the 
transplantation of conditioned hMSCs into an in vivo MI model will result in cardiac specific 
differentiation of delivered hMSCs and improved cardiac mechanical function. 
 
In this study, early cardiac differentiation is defined as the expression or upregulation of cardiac 
genes, as well as the expression and localization of cardiac proteins.  The expected outcome of this thesis 
is a novel and simplistic conditioning regimen to initiate cardiogenic differentiation of hMSCs in vitro, 
which allows for more mature cardiomyocyte differentiation in vivo and contribution to cardiac 
mechanical function. To systematically test this hypothesis, this thesis was separated into three parts, with 
five objectives. 
 
1.3. Part I: Evaluation of reduced-O2 conditions on mesenchymal stem cell function 
1.3.1. Objective 1: Determine effect of reduced-O2 on hMSC growth kinetics and c-Met 
expression  
Culturing hMSCs in a reduced-O2 environment challenges the normal convention of traditional hMSC 
cell culture, which typically employs atmospheric O2 concentrations.  However, reduced-O2 culturing of 
hMSCs has been shown to have a significant effect on signaling and response mechanisms that can affect 
proliferation, differentiation, and tissue formation.21,28,37-40  In Chapter 3 of this thesis, we evaluated the 
effects of reduced-O2 conditions on the growth potential of hMSCs.  In addition, as HGF has been 
implicated in cardiac differentiation, we evaluate the expression of its receptor, c-Met tyrosine kinase.  By 
defining a 7-day passaging parameter and controlling for the cell-seeding concentration at each passage, 
we systematically quantified the growth rate of hMSCs cultured in reduced-O2 versus normal-O2 
conditions.  Taking the average of multiple cell counts at each 7-day growth period, initial and final cell 
concentrations were used in an exponential function to calculate the number of population doublings.  We 
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found that reduced-O2 conditions significantly increased the total number of population doublings, 
doubling rate, and the number of passages before the cells become senescent.  Additionally, we analyzed 
the expression of total c-Met in hMSCs over a time-course of reduced-O2 culture.  Quantifying expression 
by ELISA normalized to total protein, we found that expression for total c-Met was significantly 
increased at day 7 compared to other time points.  Comparing the two oxygen conditions, reduced-O2 
cultured hMSCs also showed a significant increase in total c-Met expression at day 7.  The growth results 
of this study serve to support a debated contention that reduced-O2 can increase MSC proliferation, while 
the findings on c-Met expression help to define a parameter for our conditioning regimen to increase the 
number of receptors available for HGF binding and HGF/c-Met signaling. 
 
1.4. Part II: Conditioning of hMSCs with reduced-O2 and HGF to express cardiac markers 
1.4.1. Objective 2A: Determine effect of combined conditioning on cardiac marker expression 
Previous studies suggest that hMSCs have the potential to express cardiac markers.  However, tedious 
mechanical manipulation or complicated growth factor treatments, with unknown differentiation 
mechanisms, can only produce a small percentage of cardiogenic hMSCs.  For the purpose of exploring 
novel methods that will initiate cardiac-differentiation of hMSCs and improve upon current limitations, 
we developed a simplistic in vitro conditioning regimen based on two aspects described in the MSC 
literature.  In Chapter 4 of this thesis, we evaluated the effects of a combined treatment of reduced-O2 and 
HGF conditioning on the expression of cardiac markers in hMSCs in vitro.  Based on the c-Met 
expression results from Objective 1, hMSCs were first conditioned in reduced-O2 with growth medium 
for 7 days to increase the c-Met receptor expression.  On day 7, growth medium was removed and 
replaced with DMEM supplemented with only HGF (20 ng/mL), and hMSCs were cultured for another 7 
days.  Using different plating formats depending on post-treatment analysis; cells were either harvested 
for RNA isolation or fixed in preparation for immunocytochemical analysis for cardiogenic protein 
expression.  By RT-PCR, we found that a combined reduced-O2/HGF conditioning regimen increased or 
elicited the expression of several cardiac genes including transcription factors, sarcomeric components, 
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and L-type calcium channel subunits.  By immunocytochemistry, we found that conditioned cells also 
expressed cardiac proteins, which were localized to the appropriate cellular regions.  These results 
indicate that a simplistic conditioning regimen using reduced-O2 and HGF can initiate cardiac 
differentiation of hMSCs in vitro.  
  
1.4.2. Objective 2B: Evaluate the role of HGF/c-Met signaling in cardiac marker expression 
In an effort to determine the involvement of HGF/c-Met signaling in the activation of downstream 
gene transcription for cardiac differentiation, we sought to analyze a proposed HGF signaling pathway.  
We treated reduced-O2/HGF conditioned hMSCs with two small-molecule inhibitors that interact with 
specific targets in the HGF pathway.  Each small-molecule inhibitor was tested separately with 
concentrations comparable to what is reported in the literature.  Small molecule inhibitor PHA-665752 
was used to block phosphorylation of the intracellular domain of c-Met.  Small molecule inhibitor 
LY294002 was used to selectively inhibit the activity of phophatidylinositol 3-kinase (PI3K).  Separate 
inhibitor-treated samples were harvested for RNA isolation and analyzed by RT-PCR for cardiac-specific 
genes.  Results from this study suggest that inhibition of multiple points in the HGF signaling pathway 
causes decreased cardiac marker expression. 
 
1.5. Part III: Implantation of conditioned hMSCs into a myocardial infarct model 
1.5.1. Objective 3A: Evaluate regional cardiac function of cell-treated MIs  
Although we have investigated the effects of reduced-O2/HGF conditioning on cardiac-specific 
marker expression of hMSCs in vitro, we were also interested in delivering reduced-O2/HGF conditioned 
hMSCs to acute MIs in vivo to assess the effects on cardiac function.  In this study, we delivered 
conditioned cells to MIs created in male athymic rats, and determined cardiac function at 1 week and 1 
month time points.  Cell therapy strategies for cardiac regeneration aims to overcome the chief limitation 
of current MI treatments by replacing necrotic cardiomyocytes with viable cells that can restore cardiac 
mechanics.  Several different cell types that have been delivered to the heart in clinical and pre-clinical 
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studies have been shown to regenerate cardiac mechanical function.  This leads to a fundamental question 
of whether the delivered cells increase active function by adding contractile elements, or whether they 
improve passive function by increasing the compliance within the region of the developed scar. 2,41  Using 
techniques to study regional mechanical cardiac function, however, it is possible to study small defined 
areas in the heart.  And by using a high spatial-resolution imaging technique called high density mapping 
(HDM), it is possible to determine area deformation within small infarct regions with a high degree of 
accuracy, precision, and repeatability.42  By correlating measured changes in area with measured 
intracavitary pressure over the course of a heartbeat, we used HDM to calculate regional stroke work 
(RSW) and systolic area contraction (SAC) as indicators of active function in cell-treated MIs.  Results 
from this study indicate that MIs treated with reduced-O2/HGF conditioned cells significantly improved 
both RSW and SAC after 1 week, compared to untreated MIs and all other cell treatments.  In addition, 
MIs treated with reduced-O2/HGF conditioned cells could significantly improve both RSW and SAC after 
1 month.  Further analysis indicated that there was no significant change in RSW or SAC in any of the 
treatment groups from 1 week to 1 month.  These results indicate that the implantation reduced-O2/HGF 
conditioned cells can improve mechanical function of infarcted hearts. 
 
1.5.2. Objective 3B: Determine retention and cardiac differentiation of delivered cells  
Since our novel conditioning regimen was partially designed to mimic some known MI 
environmental cues, hMSCs that are pre-conditioned with reduced-O2/HGF in vitro prior to implantation 
in vivo may able to adapt more easily to MIs than traditionally cultured hMSCs.  In effect, implanting 
cells that can adapt and survive more easily in an MI will improve cell retention.  By treating hMSCs to 
express cardiac-specific markers in vitro prior to implantation,  cells are primed with the physiological 
and organ-appropriate cellular machinery, which may be more suitable for suitable for survival, mature 
differentiation, tissue incorporation, and function.36  Transplanting “cardiogenic” hMSCs into a cardiac-
niche may allow for further cardiac differentiation, which may include enhanced cardiac protein 
expression and mature sarcomere formation.  Furthermore, implanting hMSCs that have only been 
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partially differentiated towards a cardiac lineage may allow cells to commit to region-specific cardiac cell 
types.34  To determine the retention and cardiac differentiation of delivered cells, we analyzed cell-treated 
MIs of male athymic rats after the 1-week time point.  Results from this study indicate that there was a 
significantly higher retention of reduced-O2/HGF conditioned hMSCs than unconditioned, normal-
O2/MSCGM hMSCs.  In addition, some of the retained reduced-O2/HGF conditioned hMSCs were found 
to express sarcomeric α-actinin or myosin heavy chain proteins.  
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CHAPTER 2: Background 
2.1. Introduction   
2.1.1. The Heart 
The heart is a complex and vital organ, which functions as an electromechanical pump to drive the 
body’s circulatory system.  Under normal healthy conditions, synchronous contraction of the cardiac 
muscle maintains the homeostatic, rhythmic beating of the heart with the primary objective of delivering 
blood throughout the body.1  The human heart resides in the thoracic cavity, located posterior to the 
sternum and lungs, and anterior to the vertebral column.  It is encased in a fluid filled bi-layered sac 
called the pericardium, which serves to support the anatomical position, protect the heart from other 
organs, and provide lubrication needed to maintain mechanical function.2  Anatomically, the major 
vasculature attaches to the superior end of the heart, which is often referred to as the “base” of the heart.  
The free, inferior end of the heart is often referred to as the “apex”.   
The heart consists of four chambers, having two atria sitting superior to two ventricles.  With respect 
to functionality, the heart is also considered to have a right side and a left side, with both sides having an 
atrium and a ventricle.2  The right side of the heart is primarily responsible for pulmonary circulation, by 
collecting circulated deoxygenated blood from the body and pumping it to the lungs to be re-oxygenated.  
The left side of the heart is primarily responsible for systemic circulation, by collecting re-oxygenated 
blood from the lungs and pumping it to all organs and tissues within the body.  The atria are thin-walled, 
low-pressure chambers, which contribute about 10-15% of the total cardiac output by collecting blood 
and pumping it to their respective ventricles.1  The ventricles are thick-walled, high-pressure chambers 
that drive the blood to either pulmonary or systemic circulation.  The ventricles are much larger and 
thicker than the atria because of the additional muscle mass needed to pump blood throughout the body.1  
In addition, the left ventricle is typically thicker and more muscular than the right ventricle because it 
must develop more force to deliver blood to all bodily organs and extremities,1 whereas the right ventricle 
only pumps blood proximally to the lungs located within the thoracic cavity. 
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Two types of cardiac valves aid in the unidirectional flow of blood through the heart.  
Atrioventricular valves separate the atria from the ventricles, and semilunar valves separate the ventricles 
from their respective major arteries (the aorta and the pulmonary artery).  The valves consist of two-
leaflet or three-leaflet cusps composed of endothelium-covered fibrous tissue.  Valve cusps are convex in 
the direction of blood flow to allow forward progression, and concave in the opposite direction to prevent 
back-flow of blood once a valves close. 
The heart, itself, is an oxygen and nutrient dependent organ that requires a substantial blood supply to 
maintain normal healthy function.  Therefore, perhaps it is inherently deliberate that the first two blood 
vessels to branch off of the aorta are the coronary arteries.  The coronary arteries supply re-oxygenated 
blood to the cardiac tissue.  The left main coronary artery divides into the left anterior descending 
coronary artery and circumflex coronary artery branches to supply the left side of the heart, whereas the 
right main coronary artery supplies the right side of the heart. 
Cardiac tissue consists of several cell-types (e.g. muscle cells, fibroblasts, conducting pacemaker 
cells, and possibly resident cardiac stem cells), which function within an extracellular matrix (ECM) that 
serves as a complex lattice of interacting proteins (e.g. collagen I, collagen III, laminin, elastin, and 
fibronectin).  The muscular walls of the atria and ventricles are largely composed of cardiac muscle cells, 
called cardiomyocytes.  Cardiomyocytes can attach to other cardiomyocytes or to the ECM, and form 
branched muscle fibers.  Muscle fibers are separated by intercalated disks, which contain gap junctions 
composed of connexin proteins that facilitate conduction of action potentials throughout the myocardium.  
This structure allows cardiac muscle to function as a syncytium, so that stimulus applied to any one part 
of the cardiac muscle results in synchronized contraction of the entire heart. 
 
2.1.2. Cardiomyocyte Structure and Sarcomere Function 
Cardiomyocytes contain several contractile protein units called myofibrils, which are composed of 
bundles of both thick myosin filaments and thin actin filaments (Figure 2.1A).  Myofibrils can be further 
subdivided into sarcomeres (Figure 2.1B), which are the most basic contractile structures that repeat 
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throughout each cardiomyocyte and give their signature striated phenotype.  Sarcomeres are denoted by 
the overlapping actin and myosin filaments between two Z-lines (Figure 2.1B), which form cross-bridges 
that function to shorten and lengthen cardiomyocytes. 
To sustain repeated contraction and relaxation of the heart during one’s lifetime, cardiomyocytes also 
contain a large number of mitochondria.  Mitochondria contain the necessary enzymes and proteins that 
allow for oxidative phosphorylation, which is a process that oxidizes substrates for the synthesis of 
adenosine triphosphate (ATP).  An increased number of mitochondria allows for increased oxidative 
phosphorylation, which generates enough ATP to meet the metabolic energy demands of the 
myocardium.  However, in order to supply the heart with enough oxygen and substrate so that the 
mitochondria can produce ATP, the myocardium also contains a unique capillary bed called the 
transverse tubular system.  The transverse tubular system localizes intimately with myofibrils for short 
diffusion distances between cardiomyocytes and the blood supply, which allows for gas exchange (O2 and 
CO2), nutrient delivery, calcium diffusion, and waste removal.  The transverse tubular system is thought 
to be a deep extension of the sarcolemma.  The sarcolemma is another unique feature of cardiac and 
skeletal striated muscle types, which surrounds and envelops groups of myofibrils to also facilitate gas 
exchange, nutrient delivery, and waste removal. 
As stated above, sarcomeres are the basic contractile structures in cardiomyocytes, which contain 
overlapping filaments of actin and myosin.  Thick myosin filaments are endowed with globular heads that 
ratchet along binding positions located on the thin actin filaments.  In order for this movement to take 
place, the cross-bridges cycle between relaxed and active states to shorten sarcomeres.  In the relaxed 
state, ATP is partially hydrolyzed and myosin remains unattached to actin.  As calcium enters the cell 
through the sarcolemma and transverse tubules, the globular heads of myosin attach to their binding sites 
on the actin filaments to activate the cross-bridge cycle.  As the ATP becomes completely hydrolyzed, a 
conformational change to the myosin causes the globular head to pull the actin filament closer to the 
center of the sarcomere.  A new ATP molecule is then required to bind to myosin for cross-bridge release.  
Partial hydrolysis of the ATP molecule reconfigures the relaxed position of the globular head, so that the 
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cycle can repeat.  During contraction, myosin globular heads ratchet along actin filaments, which 
decreases the distance between Z-lines by essentially pulling the Z-lines closer towards the M-line (Figure 
2.1B).  Contraction also decreases the widths of the I-bands and H-zones (Figure 2.1B), while widths of 
the A-bands remain the same. 
 
 
Figure 2.1. Cardiac muscle structure.  (A) Cardiomyocytes contain several long, branched strands of myofibrils, 
which are composed of sarcomeres that give a striated appearance.  (B) Sarcomeres are the basic contractile unit of 
cardiac muscle, which are organized into overlapping thick and thin filaments.  During contraction, myosin globular 
heads attach to and pull the thin actin filaments, causing a shortening of the sarcomere.  During shortening, the 
distance between Z-lines decreases, and the widths of the I-bands and H-zones decrease as well. 
 
 
 
2.2. Heart Disease  
Coronary Heart Disease (CHD) presents as a narrowing of the coronary arteries that supply the heart 
with blood and oxygen.  Recognized as one of the leading causes of death worldwide, CHD cases resulted 
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in 7.6 million deaths globally in 2005 and are projected to reach 11.1 million by 2020.3,4  As the single 
most common cause of death in Europe, CHD accounts for 1.92 million deaths each year, with 741,000 of 
those deaths occurring in the European Union.3  The American Heart Association (AHA) reports that 16.8 
million Americans suffer from CHD, and projects an incidence of 785,000 new cases each year.5 
Myocardial ischemia results when narrowing coronary arteries inhibit delivery of oxygen-rich blood 
to a region of the heart, failing to meet the metabolic demand of the myocardial tissue.  Such ischemic 
events can lead to cardiomyocyte cell-death called myocardial infarction (MI, heart attack), resulting in a 
region of necrotic heart muscle.  Of the 16.8 million Americans living with CHD, the AHA reports that 
7.9 million have also experienced an MI.5  In 2008 alone, the AHA estimated that CHD contributed to 
approximately 1 million MIs and 451,000 deaths.4,6   Though severity can range, the consequences of an 
MI can be dire as necrotic myocardium impairs cardiac performance.  This can lead to the onset of heart 
failure (HF) as myocardial necrosis reduces the heart’s function as a rhythmic pump, thereby inhibiting 
the delivery of sufficient blood flow to the rest of the body organs.4,7,8  With CHD and MI as major 
contributors, 5.7 million Americans suffer from HF, with an incidence rate of 1/100 people over the age 
of 65 that surmounts to about 500,000 deaths annually.5  The frequency of new HF cases has increased by 
159% over the last decade without improvement in reducing the mortality rate, driving associated medical 
costs for Americans to an estimated $37.2 billion in 2009.5,7 
 
 
2.3. Current Therapeutic Strategies  
Once a patient exhibits HF, his or her long-term survival is significantly jeopardized.9-11  Despite 
considerable advancements in many areas of cardiovascular disease, the current treatment options for HF 
have shown limited improvements in the discouraging survival rate of this progressive disease.11  For 
patients suffering from end-stage HF, the only viable treatment is transplantation in which the damaged 
heart is surgically replaced with a functional donor heart.  With roughly two thousand transplants in the 
U.S. each year,5 however, this option is only available for a small fraction of HF patients.  Devices such 
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as implantable cardioverter-defibrillators, cardiac resynchronization pacemakers, and heart pumps offer 
an alternative to transplantation.  However, these options aim to correct or sustain the electrical and 
mechanical functions of the heart without treating the cause of reduced function.  Current 
pharmacological treatments such as ACE inhibitors, beta blockers, and diuretics are prescribed to address 
the associated physiologic consequences of HF (i.e. high blood pressure, increased water retention), but 
again offer limited or no treatment for the damaged myocardium. 
The chief limitation of current treatments is the failure to address the need to replace the lost 
contractile myocytes that are responsible for normal cardiac mechanical function.  In order to effectively 
treat MI and HF patients, functional myocytes must be regenerated to restore the lost contractile mass.  
Recent research advancements in both gene and cell therapies have been proposed to target this need.  
While these treatments are in their infancy as therapeutic approaches, they provide optimism for 
generating new contractile myocytes.  Herein, we review the strategies of these regenerative therapies 
with consideration to the milestones achieved and the challenges that lie ahead. 
 
2.4. Cardiac Regeneration 
Regenerative medicine has emerged to the forefront of cardiac research, marrying discoveries in both 
basic science and engineering to develop viable therapeutic approaches for treating the diseased heart.  
Significant advancements in gene therapy, stem cell biology, and cardiomyoplasty provide new optimism 
for regenerating damaged myocardium.  Exciting new strategies for endogenous and exogenous 
regeneration have been proposed, however questions remain as to whether these approaches can provide 
enough new myocyte mass to sufficiently restore mechanical function to the heart.  Here, we consider the 
mechanisms of endogenous cardiomyocyte regeneration and exogenous cell differentiation (with respect 
to myoblasts, stem cells, and induced pluripotent cells being researched for cell therapies).  We review 
some of the cues being harnessed in strategies of gene/cell therapy for regenerating myocardium.  We 
also consider some of the technical challenges that remain in determining new myocyte generation, 
tracking delivered cells in vivo, and correlating new myocyte contractility with cardiac function.  
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Strategies for regenerating the heart are being realized as both animal and clinical trials suggest that these 
new approaches provide short-term improvement of cardiac function.  However, a more complete 
understanding of the underlying mechanisms and applications is necessary to sustain longer-term 
therapeutic success.  
Adult human cardiac myocytes have long been thought to be a terminally differentiated cell type that 
also lacks the ability to proliferate.  Support for this traditional theory lies in the fact that the heart is 
unable to fully repair itself or restore function post-infarction, nor do cardiomyocytes expand in culture 
once they are harvested from biopsies.  However, Bergmann and colleagues recently demonstrated that 
cardiomyocyte turnover does in fact occur over the human lifespan, with a decrease in renewal as one 
ages.12  The likely mechanisms by which myocardium is regenerated are either native myocyte 
proliferation or stem cell differentiation.  While a complete approach for cardiac regeneration is still 
uncertain, it may be possible to exploit aspects of these two likely regeneration strategies to establish 
viable therapies.  Given a more complete understanding of the cues responsible for native myocyte 
turnover, it may be possible to elicit these responses for greater renewal following an MI.  In addition, 
many animal and clinical studies have demonstrated improved mechanical function in hearts receiving 
stem cell therapy.8,13,14  If mechanisms of cardiac regeneration could be identified and developed into 
clinical therapies, it would give realistic hope in extending the life expectancy for millions of patients 
suffering from HF, which are projected to have a mortality rate of greater than 60% within 5 years of 
diagnosis.15 
 
2.4.1. Endogenous Repair 
Myocyte Proliferation  
Traditionally, the heart was believed to be incapable of regeneration upon injury.7,8,16-18  This is to say 
that cardiomyocytes were thought to be a terminally differentiated cell type lacking the ability to 
proliferate, further complicating the prognoses for patients suffering from MI or cardiomyopathy.  
However, recent work in cardiac regeneration suggests that cardiomyocytes may have a limited ability to 
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enter the cell cycle following MI.19,20  Anversa’s laboratory found evidence of cell-cycle protein 
expression in cardiomyocytes cultured from biopsies of heart transplant patients.21  The same laboratory 
then reported that a small number of adult cardiac myocytes lying within the peripheral border-zone of an 
infarct stained positive for the cell-cycle marker Ki-67.19  Results from these studies challenge traditional 
dogma, suggesting that human cardiomyocytes may hold limited proliferative capacity. 
Myocyte proliferation has also been noted in many other species, including zebrafish,22 mice,23 rats24 
and dogs.25  Zebrafish are able to regenerate myocardium through myocyte proliferation after amputation 
of 20% of their ventricle.22 The MRL mouse, which has a reduced scarring response, appears to 
regenerate myocardium through proliferation after MI.23  Progenitor cells may release factors to induce 
native myocytes to enter the cell cycle in the rat heart.24  We recently documented the expression of cell 
cycle markers in the canine heart implanted with an extracellular matrix (ECM) isolated from the porcine 
urinary bladder.25  The ECM has previously been shown to attract bone marrow derived cells,26 which 
may include mesenchymal stem cells.  However, a definitive relationship between the release of factors 
from stem or progenitor cells and myocyte proliferation has yet to be demonstrated. 
The use of myocyte proliferation to restore function to the heart lies with either inducing myocyte 
proliferation in vivo or expanding adult myocytes in culture in vitro before delivering them to the heart.  
Biopsied cardiomyocytes have shown expression of cell-cycle markers in vitro, which have previously 
been shown to regulation the proliferation of non-cardiomyocyte cells.  For example, transfecting 
cardiomyocytes isolated from 21-day old rats with a gene to over-express cyclin D2, a cell cycle protein, 
induces myocyte proliferation.27  Inhibition of p38 MAP kinase also increases proliferation in 21-day old 
rat cardiomyocytes in vitro.28  However, it has yet to be determined whether genetic manipulation or 
interference with regulation of specific genes can target effector myocytes in the border-zone of an MI to 
induce site-specific myocyte proliferation.  
Instead of using factors to induce myocytes to proliferate in vivo, a small population of cardiac 
myocytes can be biopsied, as is currently done with heart transplant recipients.  Cardiac myocytes could 
be isolated from the tissue, expanded in culture and returned to the heart.  A similar procedure has been 
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proposed for growing cardiac stem cells.29 Given the death of approximately 1 billion myocytes in infarct 
mediated heart failure, however, a large quantity of myocytes need to be grown in culture. 
 
2.4.2. Exogenous Repair 
Cardiomyoplasty 
Since the 1990s, the field of regenerative medicine has been exploring methods for regenerating the 
heart via cell therapy.  Cellular cardiomyoplasty is an experimental surgical intervention, in which newly 
differentiated functional cardiomyocytes are delivered to the infarcted heart as a therapeutic technique to 
restore mechanical function.  Several cell-types have been considered as possible cell-therapy candidates 
for cardiomyoplasty, including skeletal myoblasts, embryonic stem cells, bone marrow stem cells, cardiac 
stem cells, and induced pluripotent stem cells.30,31  In addition, several biological techniques have been 
employed to elicit cardiac differentiation in these different cell types.  In a recent review article, we have 
defined a set of criteria for assessing the different cell-therapy approaches based on milestones of 
cardiomyocyte differentiation and achieved improvements in mechanical cardiac function.30  With regards 
to differentiation in vitro and in vivo, the criteria outline a succession of events that help to determine if 
the key cardiomyocyte characteristics are being met (i.e. cardiac protein expression, mature sarcomere 
formation, functional contractility, cardiac action potentials, and electrical integration).  In vitro 
characterization provides proof of concept and easier methods for measuring degree of differentiation.  
However, the in vivo assessment determines if the cardiomyocytes retain their characteristics and 
integrate with native myocardium when they are delivered to the heart.  Importantly, in vivo studies also 
can provide higher-order milestones of improved regional and global cardiac function, though a 
correlation between new myocyte number and functional improvement has yet to be determined.  To 
complement this previous work, this section considers the cell types that have been used for 
cardiomyoplasty, the current state of the field, and the limitations that need to be overcome. 
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2.4.3. Cell Types and Milestones  
Skeletal Myoblasts 
Skeletal myoblasts were one of the first isolated cell types used clinically to regenerate mechanical 
function in the infarcted heart.32  Skeletal myocyte progenitor cells can differentiate into striated muscle 
cells and have been afforded considerable attention for their availability, ease of culturing, work potential, 
and graft potential.33-35  When delivered to the heart, these cells have been shown to improve mechanical 
function in infarcted animals.  However, skeletal myoblasts do not appear to express gap junction proteins 
after differentiation into myotubes, and are thus unlikely to contract in sync with the native 
myocardium.36  This lack of integration may be responsible for arrhythmias reported with skeletal 
myoblast therapy.37,38  Due to the high incidence of ventricular arrhythmias, internal cardiac defibrillators 
are implanted in patients receiving skeletal myoblasts.  
 
Embryonic Stem Cells 
Embryonic stem cells (ESCs) harvested from the inner cell mass of blastocyst-stage embryos of both 
mice and humans appear to have the strongest capacity for cardiomyocyte differentiation.30,39-41  Their 
unique pluripotent nature provides them with the potential to differentiate into cell-types derived from all 
three germ layers, including cardiomyocytes, without genetic manipulation.  While it is clear that 
harvested ESCs will not develop as an embryo in culture, the environmental cues and cell signaling that 
ESCs encounter during culture and differentiation may have commonalities to those in fetal organ 
development. 42 
In vitro differentiation of ESCs by aggregated embryoid body (EB) formation has produced 
differentiated cells that upregulate cardiac-specific genes and proteins (i.e. Nkx2.5, GATA-4, Wnt3A, 
MEF2C, sarcomeric α-Actinin, myosin heavy chain, and cardiac Troponin I) with a subsequent loss of 
“stemness” markers such as Oct-4.39,40,42,43  In addition, ESC-derived cardiomyocytes display myofibril 
formation and can spontaneously contract in culture.39,40,44,45  Connexin-43 protein expression suggests 
that the differentiated ESCs form gap-junction proteins important for cardiomyocyte cell-cell attachment 
Chapter 2 | 22  
 
and propagation of cardiac action potentials.  Further investigation of ESC-derived cardiomyocytes has 
shown that they have the ability to generate action potentials of different cardiac phenotypes, and even 
develop specific cardiac ion currents (e.g. Ito1, IKr, If, IK1, ICa,L, and INa+) over prolonged periods of 
differentiation.39,44  While the expression of cardiac ion currents is encouraging, ESC-derived 
cardiomyocytes have mixed action potentials, with some cells expressing nodal like action potentials and 
others expressing ventricular like action potentials, which could leave the heart prone to fibrillation when 
implanted together.39,40   
One of the major caveats of the EB differentiation method, however, is the limited number of 
cardiomyocytes that can be purified from a mixed batch of ESCs.  Initial studies reported using 5 million 
ESCs to form sets of EBs, with cardiomyocyte differentiation efficiencies of <10%.40,46  Under the best 
circumstances, this method produced 5x105 ESC-derived cardiomyocytes, amongst a variety of other 
differentiated ESC-derived cell-types.  Current work on in vitro ESC-cardiomyocyte strategies has 
focused on improving the differentiation efficiency, in order to produce enough myocytes to meet the 
needs for treating an MI.  Recent cardiomyocyte-purification methods by Percoll density separation or 
cardiac marker detection have increased the efficiency to >30%.41,47,48  Novel direct differentiation 
strategies based on cues from developmental cardiogenesis, such as the Activin-A/BMP-4 treatment 
method, have also improved efficiency to >30%. 41,42  Even more intriguing is the combination of direct 
differentiation and separation methods with reported yields of >70% differentiation efficiency based on 
starting cell numbers. 41   
Another strategy for increasing the number of cells available for cardiomyoplasty may lie in one of 
the definitive differences between mouse and human ESC-derived cardiomyocytes.  Human ESC-
cardiomyocytes are capable of proliferation, whereas mouse ESC-cardiomyocytes do not appear to have a 
proliferative ability.49-51  Recent work by McDevitt et al. has identified the IGF/PI 3-kinase/Akt signaling 
pathway as one of the major regulators of human ESC-cardiomyocyte proliferation, though a complete 
understanding has not been achieved.52  Strategies regulating cardiomyocyte proliferation may prove to be 
delicate, as proliferation may be beneficial for improving cardiomyocyte number in vitro, but could be 
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detrimental during in vivo applications unless proliferation can be terminated when the appropriate 
number of myocytes has been regenerated. 
Despite these significant improvements, a complete strategy that recapitulates all of the complexities 
involved in developmental cardiomyogenesis remains elusive.  While these studies are exciting, there are 
scientific concerns that need to be investigated before ESC-derived cardiomyocytes can be implanted into 
patients.  One of the most pressing scientific concerns is being able to deliver a pure population of 
cardiomyocytes to the heart, as it has been shown that delivering undifferentiated ESCs in vivo will form 
teratomas.53  Another concern is being able to control the proliferation of ESC-derived cardiomyocytes, in 
which uncontrolled proliferation may cause hypertrophic cardiomyopathy in vivo.  Yet another serious 
medical concern is that ESC-derived cardiomyocytes may elicit a strong immune response, based on the 
compatibility of ABO blood-group antigens or embryo-specific antigens between delivered cells and host 
systems.54,55  In addition to scientific concerns, ethical barriers regarding the origin of ESCs and limited 
knowledge about medical consequences has slowed the progression of the use of these cells in clinical 
studies. 
 
Bone Marrow Derived Stem Cells 
Since the late 1990’s, multipotent stem cells isolated from adult bone marrow have gained 
considerable attention for their ability to transdifferentiate into several cell types including endothelium, 
lung, neural, liver, and bone.56-60  In 2001, a study by Orlic et al. suggested that the delivery of bone 
marrow cells (BMCs) could regenerate ischemic myocardium.8  By delivering Lin-, c-kit+ mouse BMCs 
carrying enhanced green fluorescent protein (EGFP) to a murine infarct model, they demonstrated 
regeneration of new myocytes in the infarct zone and improved ventricular function after nine days.  This 
initial report suggested considerable promise for the use of BMCs in myocardial repair; however, 
additional studies have not been able to repeat these results.61,62  Despite controversy, BMCs remain an 
attractive candidate for cardiomyoplasty as they can be obtained from autologous sources and expanded 
easily in culture.  In vitro cardiomyocyte differentiation and in vivo heart applications remain a focus of 
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continued research on BMCs, as the full extent of their multipotency and therapeutic value have yet to be 
determined. 
 
Differentiation – In Vitro 
Since the landmark study by Orlic et al., several groups have tried to determine possible mechanisms 
for transdifferentiating BMCs into cardiomyocytes in vitro.  Studies based on separation of the c-kit+ 
BMC subpopulation showed partial cardiac differentiation in experiments with rat neonatal 
cardiomyocyte co-culture and BMP4/TGF-β treatment methods.63  Results showed that transdifferentiated 
cells expressed cardiac markers (i.e. MEF2C, GATA-4, sarcomeric α-Actinin), but lacked the ability to 
form gap junctions and generate action potentials characteristic of fully differentiated cardiomyocytes.  
Subpopulations of both bone-marrow derived mesenchymal stem cells (MSCs) and stromal cells, 
however, have been able to form gap junctions and elicit cardiac action potentials.64-67  In vitro treatment 
of marrow stromal cells (containing a high fraction of MSCs) with 5-azacytadine, a DNA demethylation 
agent, induced about 30% of the cells to differentiate towards a cardiac lineage, with expression of 
cardiac markers, evidence of mature sarcomeres, and propagation of cardiac-specific action potentials 
(nodal and ventricular) for spontaneous contractions.65  Based on literature from fetal heart development 
and ESC-derived cardiomyocytes, other groups have experimented with cardiac-inducing cytokine 
treatments (i.e.  retinoic acid, hepatocyte growth factor, and platelet derived growth factor) to show partial 
cardiac differentiation by gene and protein expression.68-71  Our laboratory has employed three-
dimensional aggregation of human MSCs for spheroid formation (similar to EB formation) to show that 
50% of the hMSCs can differentiate towards a cardiac lineage detected by protein expression within 2 
weeks.67  Patch-clamping analysis of these “cardiogenic” cells indicate that 16% of the differentiated 
hMSCs display large L-type Ca2+ currents, indicating that some of the differentiated hMSCs may be 
capable of producing cardiac-specific action potentials.  Using specific milestones for in vitro cardiac 
differentiation, BMCs and BMC-subpopulations have demonstrated the capacity for protein expression, 
sarcomere organization, cardiac electrical currents, electrical integration by gap junctions, and functional 
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contractility (Figure 2.2).30  These results provide optimism that BMCs have the potential to become 
fully-differentiated cardiomyocytes, even though BMCs do not differentiate as readily as ESCs.  Greater 
success in in vitro differentiation of BMCs may lie in defining all the necessary factors for complete 
differentiation.  
 
 
 
Figure 2.2. Cardiac Differentiation Spectrum.  A schematic depicting the cardiac differentiation spectrum as 
bone marrow cells or marrow-derived mesenchymal stem cells differentiate towards a cardiomyocyte lineage.  
Stages indicate changes in cell characteristics.  As multipotent stem cells differentiate towards a cardiomyocyte 
lineage, stem cell markers are lost as early cardiac transcription factors start to be expressed.  Early cardiac 
transcription factors function to further differentiate cardiogenic cells, to elicit later-stage cardiac proteins.  Fully 
differentiated cardiomyocytes arrange later-stage cardiac proteins to form sarcomeres with electromechanical 
functionality. 
 
Cardiac Applications In Vivo 
Delivering BMCs (including MSCs) as a cell therapy for in vivo applications has been shown to 
improve wound healing in several tissue types by homing to injury sites, secreting therapeutic cytokines 
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and growth factors, and differentiating into injured-tissue phenotypes.72-78  The study by Orlic et al. 
suggested that the delivery of undifferentiated BMCs in vivo to a murine infarct model resulted in the 
generation of new cardiomyocytes and improved cardiac function.8  Since then, BMC delivery for cell 
therapy to the heart in both animal and clinical trials have focused on the local therapeutic benefits of 
delivered BMC signaling, the possibility of in vivo BMC-cardiomyocyte differentiation, and the 
restorative effects on regional and global cardiac function.  The delivery of MSCs to infarcts has shown to 
increase paracrine signaling that mediates inflammation, enhances angiogenesis, promotes cardiomyocyte 
survival, and aids in maintaining cardiomyocyte contractile function.77-83  These regional signaling factors 
indicate that the BMCs provide cardio-protective benefits to the infarcted heart, which may limit 
cardiomyocyte loss and help to generate new vasculature for reperfusion of ischemic myocardium. 
With respect to in vivo cardiomyocyte differentiation, recent studies have reported cardiac-specific 
protein expression by delivered BMCs.8,67,84,85  However, additional studies report that delivered BMCs 
fail to exhibit cardiac proteins.61,62,86,87  A contributing cause of uncertainty is that most cell-types used in 
cardiomyoplasty can fuse with cardiac myocytes, making it difficult to distinguish delivered BMCs from 
native cardiomyocytes which frequently are multinucleated.38,86,88  Due to apparent autofluorescence of 
heart tissue and challenges with tracking delivered cells, evaluation of in vivo differentiation of BMCs 
remains difficult.  Our laboratory has recently experimented with quantum-dot (Q-dot) nano-particle cell 
tracking for identification of delivered BMCs.89  Q-dots were passively loaded into the cytoplasm of 
MSCs by endocytosis before in vivo delivery, which provided greater contrast for cell tracking by co-
localizing the Q-dot signal with cardiac-marker expression when visualized under a fluorescent 
microscope.  Using this tracking method, our results suggest that delivered cardiogenic cells derived from 
spheroid-treated MSCs can express cardiac markers with mature sarcomeres.67  In terms of further 
milestones of in vivo cardiac-differentiation, there is limited evidence to definitively determine if 
delivered BMCs or MSCs can generate action potentials, form gap junctions with native cardiomyocytes, 
or functionally contract.30   
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While in vivo cardiac differentiation of BMCs is still being studied for these measures, evidence from 
animal and clinical trials suggest that BMCs delivered to MIs can improve both regional and global 
cardiac function.8,67,84,90-94  Though overall functional improvement has shown to be positive, studies 
disagree on the level of therapeutic effect.14,91-93,95  Some studies report significant functional 
improvement from BMC cell therapy within a short-term period of 6 months, whereas other studies of the 
same duration do not.  The only longer-term study to evaluate cardiac function for 18 months after BMC 
delivery, the BOOST (Bone marrow transfer to enhance ST-elevation infarct regeneration) trial also 
indicated therapeutic inconsistency over time.96  While results at 6 months indicated enhanced left 
ventricular ejection fraction, results at 18 months did not appear to sustain the short-term functional 
improvements compared to the controls.  Importantly, the data from these clinical trials supported the 
safety of BMC cell therapy for MIs.  There may be several confounding factors contributing to the 
differences reported for cardiac function.30  Since in vivo studies have been performed with both mixed 
BMCs and isolated BMC subpopulations (i.e. MSCs and mononuclear marrow cells), it remains unclear 
as to which BMC population is better for improvement of function.  Furthermore, BMC population 
characteristics can differ based upon handling and preparation prior to delivery, which may also affect 
cell fate in vivo and potential therapeutic benefits.67,93,94  Further, while BMC dosage does not appear to 
correlate with functional outcome, results from the 18 month BOOST study suggest that repeated cell 
doses over time may help to sustain therapeutic benefits.14,92,96  Improved tracking and evaluation methods 
will aid in determining if delivered BMCs can fully differentiate into new contractile cardiomyocytes, and 
if the presence of new myocytes quantitatively correlates with increased cardiac function.  These methods 
may also provide further understanding of the cardio-protective mechanisms of BMCs, which may also 
play a role in improving function immediately post-MI.77-83  While it is clear that clinical studies have 
demonstrated short-term efficacy and increased function, studies carried out over greater durations are 
needed to demonstrate longer-term benefits of delivering BMCs as a cell therapy for MIs. 
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Cardiac Stem Cells 
Though the heart was initially thought to be an unlikely source of progenitor cells, evidence suggests 
that populations of resident cardiac stem cells (CSCs) can be isolated from myocardium.  First described 
by Beltrami et al in 2003, a population of adult rat heart cells displaying a Lin-/c-kit+ profile were shown 
to be self-renewing and multipotent.97  These cells were detected in both the atrial and ventricular 
myocardium, and could partially differentiate into cardiomyocytes, endothelial cells, and smooth muscle 
cells in vitro and in vivo.  Administering Lin-/c-kit+ CSCs to a rat infarct model by both direct 
intramyocardial and intracoronary injection has been shown to regenerate cardiomyocytes in the infarcted 
heart and improve left ventricular function.97,98  However, the morphological presentation of the newly 
generated myocytes has been questioned, and new myocyte contractility was not correlated with 
ventricular function.30,38 
Shortly after the discovery of Lin-/c-kit+ progenitors, Oh et al isolated a second population of CSCs 
from adult mouse hearts that displayed a Sca-1+ profile (also found to be c-kit-).99  While the isolated Sca-
1+ cells did not express cardiac-specific markers, upregulation of cardiac genes were induced by DNA 
demethylation with 5’-azacytidine.  However, this differentiation method failed to produce functionally 
contracting myocytes in vitro.  Intravenous delivery of Sca-1+ CSCs in vivo were shown to home to the 
infarcted mouse heart, express cardiac-specific proteins, and demonstrate cardiac differentiation through 
fusion with native myocardium.  A third population of CSCs called “side population cells” has been 
isolated from mouse hearts by Hoechst dye exclusion.100,101  Side population CSCs have been described as 
Sca-1+ with low-level c-kit expression, and are reportedly capable of cardiomyocyte differentiation by co-
culture with rat cardiomyocytes through intercellular coupling mechanisms (not fusion).101  A fourth CSC 
population isolated from neonatal mouse hearts was identified by Isl-1+ expression (Sca-1- and c-kit-), 
which is a marker previously described for cells that contribute to heart formation during development.102  
Isl-1, or islet-1, was originally discovered during embryogenesis of pancreatic islets of Langerhans, but 
was recently found to be a marker of the second heart field during mammalian cardiogenesis.103  Isl-1+ 
CSCs showed expression of cardiac-specific transcription factors (i.e. Nkx2.5 and GATA-4), along with 
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the capability of cardiac-differentiation in vitro and in vivo displaying sarcomere formation, action 
potentials, and calcium currents. 
Due to the minimal regenerative potential exhibited by the heart, it is surprising that the heart is a 
source of multiple populations of progenitor cells.  Even more confounding is why these progenitors 
remain seemingly unresponsive to myocardial injury.  However, it is speculated that CSCs may be 
involved slower repair mechanisms, which could account for the recent reports describing the heart’s 
limited potential for myocyte turnover.12,19,30,46  While the evidence of CSCs is significant, there are still 
several concerns that must be addressed prior to their use in clinical applications.  Each of the distinct 
CSC populations indicates partial levels of cardiac-differentiation potential, while their efficacy for 
generating new functional myocytes is uncertain.  Of the four candidates, Lin-/c-kit+ CSCs appear to be 
the most well characterized, but a more complete understanding of their electrophysiological properties is 
necessary.  While it appears that both Sca-1+ and Lin-/c-kit+ CSCs can improve global cardiac function 
when delivered to MI models, additional in vivo studies are needed to determine the effects of side 
population cells and postnatal isl-1+ CSCs on this experimental measure.  The isl-1+ population are the 
only CSCs that have been shown to generate action potentials, which are comparable to neonatal 
cardiomyocytes.102  However, it remains to be determined if isl-1+ CSCs can generate mature action 
potentials, or if they can be isolated from adult hearts.   
In addition to efficacy, another major caveat regarding CSCs is their limited availability.  With 
reported isolation efficiencies from cardiac biopsies ranging from 0.001-0.03%, CSCs are considered to 
be a rare cell-type.30,97,99  Recently, Messina et al have tried to overcome this limitation by separating 
“phase-bright cells” from mouse and human myocardium to form cardiospheres that could be expanded in 
culture.104  Additional work with cardiospheres has shown that they can generate cardiac action potentials 
when co-cultured with neonatal rat cardiomyocytes in vitro, and also improve ventricular function when 
delivered to the infarcted heart.29  However, it remains unclear if human cardiospheres can generate new 
myocytes.  Given the limited availability of CSCs from biopsies, extensive in vitro expansion will be 
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necessary to generate the number of cardiomyocytes needed to replace the contractile mass lost due to 
infarction. 
 
Induced Pluripotent Stem Cells 
Transdifferentiation is a phenomena used to describe how cells committed to one lineage may be 
induced to express the phenotype of a lineage originating from a different germ layer.46  As an example of 
normal differentiation, multipotent mesodermal BMCs naturally become various blood cell types, as well 
as fat, cartilage, and bone.  However, transdifferentiation occurs when BMCs are encouraged to 
differentiate to alternate lineages, such endodermal epithelial cells or ectodermal neural cells.56,59  Though 
mechanisms for these transitions are not completely understood, one hypothesis is that differentiated cells 
may be able to de-differentiate to a more pluripotent state and then re-differentiate into other cell-types.  
In 2007, a landmark study by Takahashi et al. demonstrated that human somatic cells can be 
reprogrammed to exhibit ESC-like properties.31  By transfecting human dermal fibroblasts with Oct3/4, 
Klf4, Sox2, and c-Myc, they were able to induce the expression of several ESC-specific markers.  Further 
studies revealed that the ESC-like fibroblasts could differentiate into cell types arising from all three germ 
layers, as well as form teratomas when delivered in vivo (a hallmark indication of ESCs).  The 
combination of these results suggested that human dermal fibroblasts could seemingly be de-
differentiated towards an ESC-like state, as induced pluripotent stem cells (iPS cells).  
As part of their evidence for ESC-like pluripotency, Takahashi et al. used an established ESC-dervied 
cardiomyocyte differentiation protocol, treating with Activin-A/BMP4 to show that iPS cells could 
express cardiac markers (i.e. Nkx2.5, MEF2C, cTnT, MYL2A, and MYHCβ) and spontaneously contract 
after 12 days.  Other studies have applied differentiation methods to iPS cells based on established 
methods adopted from ESC-derived cardiomyocyte literature (e.g. EB formation).  Co-culture of iPS cells 
with OP9 stromal cells was found to enhance cardiac-specific markers and show organized striated 
phenotypes, with some of the cells producing nodal-like action potentials.105  Using an EB-like 
differentiation process, iPS cell aggregates were able to express cardiac proteins, form sarcomeres, 
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contract in vitro, express gap junction proteins, and exhibit functional electrical coupling.106  Most 
recently, Ieda et al. showed that retroviral transduction of a combination of three developmental 
transcription factors (Gata-4, Mef2C, and Tbx5) could directly and efficiently reprogram dermal 
fibroblasts to cardiomyocyte-like cells, without passing through an intervening pluripotent state.107  
Directly induced cardiomyocytes (iCMs) have a higher efficiency of cardiomyocyte differentiation, and 
have shown further cardiac cell maturation in successive weeks by sarcomere organization, increased 
contractility, and developed electrical properties. 
One of the major questions that must be addressed regarding iPS cells is which genes are required to 
induce pluripotency and whether different combinations induce essentially the same pluripotent cell 
types.  In addition, the work done with iCMs raises the question of whether it is necessary to reprogram 
cells back to a pluripotent state, or whether a more direct reprogramming approach is more effective for a 
cardiac cell types.  The identification of specific factors responsible for reprogramming cells to exhibit 
ESC-like “stemness” is a marked achievement, however the viral vectors employed may cause 
unpredictable genetic dysfunctions.  In addition, regulating the expression of these factors and their 
downstream effects may prove to be both difficult and problematic.  This aspect of iPS cell research has 
encouraged groups to explore alternative methods for initiating these effective pluripotency mechanisms.  
Some groups have experimented with different gene delivery mechanisms, such as the use of removable 
transposons to deliver a multi-protein expression vector to minimize genetic modification.108  Other 
groups suggest that iPS cells can be generated without genetic manipulation, by delivering 
“reprogramming proteins” fused to cell-penetrating peptides.109  Recent studies have also suggested that 
fibroblast growth factor in low oxygen culture conditions increases nuclear expression of stem cell factors 
in adult human fibroblast.110  Differentiation of adult human cells without genetic manipulation is likely 
to reduce the potential for mutagenic effects.  Though these studies did not look for cardiogenic 
differentiation, they showed that their respective iPS cells can generate cell types that arise from all three 
germ layers.  Another major concern with iPS cells is their propensity to form teratomas in vivo, even 
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though this is a well-recognized indication of true ESC-like pluripotency.  As with ESCs, further studies 
are needed to show the safety and efficacy of differentiated iPS cells before they can be used in the clinic. 
 
2.5. Mechanical Cardiac Function 
Myocardial infarction (MI) and heart failure (HF) result in cardiomyocyte cell-death; thereby eliciting 
a remodeling cascade that not only reduces the number of contractile units, but also generates a scar that 
compromises both the integrity and compliance of the myocardial wall.  With respect to the heart as an 
electromechanical pump, healthy cardiomyocytes respond to cyclic electrical impulses to shorten their 
sarcomeres.  Synchronous action by cardiomyocytes permits the contraction of the myocardial walls, 
which act to pressurize atrial and ventricular cavities to pump blood for systemic circulation.  
Cardiomyocyte cell-death reduces active contraction within a region of the heart due to the decrease of 
working sarcomeres, impairing the heart’s function as a mechanical pump.  Necrosis and scarring within 
the affected region changes the material properties of the myocardial wall, creating a stiff area that may 
not comply with the dynamics of either surrounding contractile cardiomyocytes or developed pressures 
within heart cavities.  Aiming to improve these outcomes, the ultimate goal of cardiac regeneration for the 
treatment of myocardial infarction and heart failure is to restore mechanical function to the injured heart. 
Consequently, the effectiveness of any novel therapy for the improvement of myocardial function 
must be based on the resulting changes it demonstrates on mechanical function.  Currently, there are 
several techniques that can be applied for measuring global or regional mechanical cardiac function, 
which have been used in either clinical or pre-clinical studies.  In addition there are several parameters 
that can be measured as indicators of cardiac function, but inevitably the chosen technique can often limit 
the parameters that can be measured.  Unfortunately, resource availability can present logistical 
challenges in choosing an appropriate technique.  Oftentimes, investigators are limited by equipment 
expense or availability.  In addition, the need for technological expertise may limit the experimental 
approach or flexibility in choosing unfamiliar methods.  Knowing the capabilities of different 
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measurement techniques and the metrics that can be determined from acquired data should allow 
investigators to better interpret their findings regarding myocardial function. 
 
2.6. Techniques for Measuring Mechanical Cardiac Function 
Clinically, echocardiography and magnetic resonance imaging are the most commonly used 
techniques to assess cardiac mechanical function in patients.111-122  Both methods provide options that are 
non- or minimally invasive, and have also been applied in experimental and pre-clinical studies.  While 
studies on smaller animals require the appropriate equipment and procedure, the data acquisition and 
analysis methods are most similar to what clinicians use on human patients.  
Echocardiography (ECHO) is a cardiac ultrasound technique, which employs a system to send and 
receive high-frequency sound waves to create either 2D or 3D images of the heart.  The system requires 
the use of a probe to send sound across the chest cavity, which then reflects off of internal tissue.  The 
reflection signature is then received by a transducer and translated to visualize the structure and motion of 
the tissue.  The probe used for ECHO can either be placed externally on the outside of the chest for 
transthoracic signaling, or inserted down the esophagus for a transesophageal approach.  These 
applications can be used to examine both the shape and velocity of the heart tissue in real time, allowing 
for the determination of wall movement, wall thickness, and blood velocity.  While ECHO is a relatively 
inexpensive technique, it does have experimental limitations.  The spatial resolution of ECHO has been 
reported to be on the order of 5 mm with a temporal resolution of 15 milliseconds, which is more suited 
for evaluating global function (compared to regional function) for short term cardiac-cycle analysis.123  
However, technological advances are continually improving upon these spatial and temporal constraints.  
ECHO is also subject to processing limitations, such as “noise” resulting from interference or image-
variability depending on probe orientation.123,124  While transthoracic ECHO is a less invasive approach, 
some regions of the ventricle can be difficult to image.125  And though transesophageal ECHO may 
provide better access for tissue imaging, it is a slightly more invasive procedure.   
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Magnetic resonance imaging (MRI) is another non-invasive technique used to determine cardiac 
function, commonly used by radiologists to visualize detailed structure and function of internal body 
tissues.  In this system, an MRI machine uses a radio frequency transmitter to energize photons to a 
resonance frequency, creating an electromagnetic field.126  When a patient lies within the machine, the 
energized photons re-orient the spin of aligned hydrogen protons in water molecules within myocardial 
tissue.126  When the machine is turned off, the protons return to their natural spin state, releasing energy in 
the form of photons which can be detected by a scanner to generate images of the heart.126  Tagged MRI 
can provide more regional information than shape and size data obtained with conventional MRI. This 
technique uses intersecting “presaturation” planes that form “tag lines” throughout the myocardial tissue, 
in which intersections serve as markers that move with the heart wall.  The movements of the 
intersections can be tracked, allowing for the determination of three-dimensional deformation and the 
enhancement of region-specific analysis.  Despite these improvements, the data acquisition process for 
this technique can be time consuming as usually only one plane can be imaged at a time.  After the data is 
acquired for one plane, the procedure is then repeated for the next plane (usually orthogonal to the base-
apex axis).  As a result, the total amount of time for data acquisition can take 35-40 minutes.127  The 
spatial resolution of the technique (as defined as the distance between tags) is generally on the order of 5 
mm.  Improvements in image detail are limited, as better resolution comes at the risk of the MRI tags 
disappearing before the end of the diastolic/systolic interval being examined.118  In addition to laborious 
data acquisition, data analysis is also complicated and time-consuming.  Due to the required equipment 
and expertise needed, MRI can be very expensive.  Despite the limitations, however, MRI is routinely 
used to evaluate hearts in pre-clinical studies of mice and rats, as well as clinical studies.92,95,96,128,129  
Another clinical technique gaining popularity involves the electromechanical mapping of the heart 
with magnetic fields, through the use of a NOGA system (originally developed as the NOGA Cardiac 
Navigational System by Biosense Webster Inc. in 1997).  In this system, a catheter is inserted into the 
ventricular cavity through the ventricular wall.  A magnetic pad lying underneath the patient is used to 
generate a low level magnetic field, providing a three-dimensional orientation for guiding the catheter.  
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The catheter can then be positioned to sample several different points on the endocardial surface of the 
ventricle.  The point measurements are then used to create a map of the endocardial surface, detailing 
information regarding mechanical deformation and unipolar voltage.  With a spatial resolution of 1 mm, 
this technique is very useful for determining the movement of the ventricular wall at multiple locations 
and defined regions.   
In the animal laboratory setting, sonomicrometry is commonly used to determine regional function of 
the heart in-vivo.117,130-133  Sonomicrometry is a uni-axial technique involving the use of ultrasonic 
transducers, in which one transducer sends a sound wave to another transducer that receives the signal.  
The distance between the two transducers is proportional to the time it takes for the sound to travel, 
thereby providing a continuous measure of the distance between the two transducers as the heart expands 
and contracts.  The transducer crystals must be implanted or sutured into the heart wall and the tissue 
should be homogeneous to sound waves for the signal to pass correctly.  Sonomicrometry assumes a 
homogenous deformation between the transducers (~7-20 mm) and can only determine function along 
this axis.  One pair of transducers provides distance measure along one axis, while two pairs of 
transducers can be used along two orthogonal axes to measure area deformation.  If three pairs of 
transducers are used at three orthogonal axes, the volume of the ventricle can be calculated making the 
assumption the ventricle is an ellipsoidal in shape.  In a regional setting, sonomicrometry can be used to 
determine changes in distance surrounding a specific area of the myocardium (e.g. an infarct region).  
This method is commonly used to determine ventricular volume, regional area, segment length, and wall 
thickening. 
A major limitation of sonomicrometry, however, is that the implantation of the transducer crystals is 
more invasive and consequently more “fixed” in terms of region.  To measure multiple regions would 
require either re-implanting the transducers to new locations or implanting more transducers, both of 
which result in more invasiveness and possible damage to the heart wall.  As myocardial infarction 
usually results in a region (or regions) of the heart becoming dysfunctional, a technique to determine 
regional function over many regions (whole field) in the heart may be more helpful.  To determine whole 
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field function, Prinzen et al. used 40-60 paper markers (1.5 mm diameter) arranged on the epicardium to 
determine epicardial wall displacements.134  By tracking the markers, they were able to determine 2D wall 
displacements.  And while using several markers, they could generate mechanical deformation data at 
multiple locations on the heart surface for whole field analysis. 
To improve the spatial resolution of the epicardial-marker technique, an innovative phase correlation 
algorithm called Computer Aided Speckle Interferometry (CASI) was developed.135  In this system, 
silicon carbide particles (40 µm in diameter) are applied to the epicardium, which are then illuminated 
with white light to create a speckled contrast for particle tracking (Figure 2.3).  The phase correlation 
algorithm allows for increased computational efficiency compared to conventional particle tracking or 
digital correlation techniques.  This algorithm has been shown to determine uni-axial strain that is 
equivalent to what can be obtained with sonomicrometry in isolated rabbit hearts.135  Unlike 
sonomicrometry, however, CASI is a whole field technique that is able to determine two dimensional 
deformations with high spatial resolution.   
Further improvements to the accuracy and precision of CASI were made by incorporating a sub-pixel 
algorithm called High Density Mapping (HDM), based on a method proposed by Foroosh and Zerubia.136  
In order to determine regional function over the course of a heartbeat, measured displacements must be 
summed between many images.  HDM is used to model the result of CASI phase correlation as a sinc 
function, which is interpolated to determine subpixel motion.  The sinc function, or cardinal sine function, 
is used to interpolate bandlimited discrete-time signals with respect to sampling rate and time by using 
uniformly spaced samples of each signal.  To determine the accuracy of HDM, images of the heart were 
digitally shifted resulting in a 0.25, 0.50, or 0.75 pixel displacement.  HDM was able to determine the 
pixel shift with an accuracy of 0.09 pixels, a precision of 0.04 pixels, and repeatability of measuring 
regional work loops in the beating heart of 0.04 mm Hg (normalized to end diastolic area).137  These 
results demonstrate the ability of the technique to accurately, precisely, and repeatably determine regional 
deformation. 
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In order to determine regional function with HDM, the heart must be exposed to allow for a region to 
be imaged.  A region of interest is then divided into subimages, with the displacement of each subimage 
being determined between consecutive images through Fourier transform. Through this algorithm, 
displacement can be determined at hundreds of locations, providing a whole field measurement (Figure 
2.4).  Regional stroke work can then be determined in very small regions based on the change in area 
between four neighboring points.  So instead of constructing a work loop out of every four neighboring 
points, the average change in a sub-region consisting of 16-25 different areas is used.  This method 
determines function in regions of less than 10 mm2, as opposed to sonomicrometry in which the regional 
areas are generally greater than 100 mm2.  This technique has been used to determine regional function in 
the isolated rabbit heart, the in vivo porcine heart, and the in vivo canine heart.25,67,138-140 
While the methods described herein provide data for both systolic and diastolic function, there are 
several limitations to them as well.  Both MRI and ECHO require expensive equipment to image the 
heart.  Along with this equipment, a lot of time is invested to collect data using MRI.  The spatial 
resolution of both methods is less than optimal.  Sonomicrometry and optical methods require exposure of 
the heart leading to an invasive procedure.  In addition, optical methods generally require placement of 
non-sterile tracking markers making it useful only during the terminal phases of an experiment. 
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Figure 2.3.   Determination of regional cardiac function using High Density Mapping (HDM).  (A) 
Representative image of a porcine heart containing region of interest (ROI) (B) Image containing ROI, same area 
from (A), prepared with silicon carbide particles and retroreflective beads, creating speckled contrast for particle-
tracking. (C) An identified ROI outlined in blue in the upper-left quadrant.  An enlargement of the ROI in the 
undeformed state at T0 is shown in the upper-right and lower-left quadrants (the same image is used for u, v 
reference points), with the location of a particle marked in red. An enlargement of the ROI in the deformed state at 
T1, with the location of a particle marked in yellow, shown in the lower-right quadrant, indicating the shift of 
speckle particles throughout the cardiac cycle.  (D) Schematic drawing of how several areas within the ROI can be 
tracked through the cardiac cycle. As the heart expands during diastole, regions of normal functioning myocardium 
also expand. By applying this algorithm to several areas in the ROI, regional mechanical function can be determine 
in a whole field manner, with high spatial resolution. (JP Guyette and GR Gaudette chapter, “Assessing Regional 
Mechanical Function after Stem Cell Delivery” in the text, Regenerating the Heart)141 
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Figure 2.4.  Regional stroke work in the regionally ischemic porcine heart for whole field measurement. The 
color map denotes the change in regional stroke work across the ischemic border (orange represents the highest 
function, whereas blue represents the lowest function).  The insert in the lower left corner shows some of the 
regional work loops determined with HDM in the region of interest.  For clarity, only 20 out of the 60 regional work 
loops computed in the region of interest are shown.  Notes: 1) This assessment was taken on the epicardial surface of 
the left ventricle, in an ischemic porcine heart; 2) The loops in the lower left are actually reversed in direction 
(clockwise), denoting negative regional work; 3) The dotted line represents the ischemic border.  (JP Guyette and 
GR Gaudette chapter, “Assessing Regional Mechanical Function after Stem Cell Delivery” in the text, Regenerating 
the Heart)141  
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2.7. Parameters for Assessing Mechanical Cardiac Function  
Having discussed the clinical and experimental techniques used for analyzing heart structure and 
function, it is also necessary to review the relevant parameters that can be measured or calculated as 
functional indicators of cardiac mechanics.  As the heart operates as an electromechanical pump, it 
functions to perpetuate and control circulation.  While the right ventricle pumps deoxygenated blood to 
the lungs (within relatively close proximity in the chest), the left ventricle pumps oxygenated blood 
throughout the body (accessing all internal and extremity tissues/organs).  Consequently, the left ventricle 
performs more work than the right ventricle and has a thicker wall due to increased muscularity.  There 
are several measures that can be used to assess the function of the heart as a whole, though most are 
measures of left ventricular function in consideration of its vital purpose.  The functional measures 
include stroke volume, stroke work, ejection fraction, tau (τ), maximum change in pressure over time 
(dP/dtmax), and minimum change in pressure as a function of time (dP/dtmin). 
In describing these measures, it is useful to review the basic physiological dynamics that constitute a 
cardiac cycle.  A cardiac cycle involves the complete succession of one phase of ventricular contraction 
known as systole, followed by one phase of ventricular relaxation known as diastole (Figure 2.5A).  
Ventricular systole begins as the mitral valve closes at the end of atrial contraction, and consists of two 
main stages known as isovolumic contraction and ejection (Figure 2.5A, point “A”).  Isovolumic 
contraction is the brief period of time between the onset of systole and the opening of the aortic valve, 
during which the ventricular volume remains constant as the ventricular pressure increases sharply.  As 
pressure continues to increase within the ventricle, the aortic valve opens (at ~80 mmHg in a healthy 
heart), marking the end of isovolumic contraction and the onset of ejection.  Ventricular pressure 
continues to rise during rapid ejection, forcing blood from the ventricle to the aorta as myocardium 
contracts and ventricular volume decreases.  As pressure between the ventricle and aorta becomes more 
equalized, pressure within the ventricle begins to decrease for reduced ejection.  When the ventricle fully 
contracts to a minimum volume and the aortic pressure is greater than that of the ventricle, the aortic 
valves close to mark the end of the contraction phase (called end-systole; Figure 2.5A, point “B”).  End-
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systole also signifies the onset of the diastolic ventricular relaxation phase.  Diastole begins with 
isovolumic relaxation, in which ventricular pressure decreases sharply as ventricular volume remains 
steady.  During this period, the atria are reaching maximum volume and pressure as they fill with blood.  
The isovolumic relaxation stage ends as the mitral valve opens, signifying the start of diastolic filling.  
During the filling stage, ventricular volume rapidly increases, allowing the ventricular pressure to remain 
low for efficient blood flow from the high-pressure atrium.  When the ventricle is fully relaxed and the 
ventricular pressure exceeds atrial pressure, the mitral valve closes to mark the end of the relaxation phase 
(called end-diastole; Figure 2.5A, point “A”), thus completing the cycle. 
Another key concept of cardiac physiology is the effective preload and afterload on cardiac muscle.  
Preload can be described as the stretching of cardiomyocytes that make up the intact heart, effectively 
represented by the end-diastolic ventricular volume at the end of filling.  Several conditions can either 
increase or decrease preload, thereby having a direct effect on end-diastolic volume and the amount of 
blood filling the ventricle.  Afterload can be described as the amount of pressure that must be generated 
by the left ventricle in order to overcome aortic pressure, which is necessary for the ejection of blood into 
the aorta.  Just as with preload, there are a number of conditions that can either increase or decrease 
afterload.  And while preload and afterload do not directly effect each other, there is a well-known 
relationship in which the heart can change its contractile force in response to venous return of blood.  This 
phenomenon is known as the Frank-Starling mechanism.  Venous return affects ventricular filling, 
thereby affecting left ventricular end-diastolic pressure (LVEDP, or preload).  Ventricular filling also 
affects end-diastolic volume (preload), and changes in sarcomere length affect force generation in the 
form of stroke volume (SV).  The Frank-Starling mechanism can be represented by plotting SV as a 
function of LVEDP (Figure 2.5B).  The dynamic relationship shows how increases in LVEDP can 
increase SV and decreases in LVEDP can decrease SV (Figure 2.5B).  The relationship can also have a 
significant effect on cardiac cycle pressure-volume work loops.  Afterload can be controlled in 
experimental settings using animal models in order to study cardiac mechanics.  Herein, this section will 
focus on measured parameters with reference to the described cardiac cycle and physiologic phenomenon.  
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Stroke volume (SV) is a practical volumetric measure, defined as the amount of blood that can be 
pumped to the aorta in one cardiac contraction (Equation 1).  Stroke volume is calculated by subtracting 
the end-systolic volume (ESV; the minimum ventricular volume) from the end-diastolic volume (EDV; 
the maximum ventricular volume). 
 
 
SV = EDV − ESV     (1) 
 
 Also considered to be a measure of the contractility of the heart, stroke volume can be used for 
calculating additional cardiac functional parameters.142  For example, integrating stroke volume with 
respect to ventricular pressure (P) yields stroke work (SW) as shown in equation 2.   
 
∫ ⋅= dPSVSW     (2) 
 
Stroke work is the amount of work performed by the ventricle as it ejects blood to the aorta in one cycle, 
or beat.142  As a dynamic measure that can change based on metabolism, the generated kinetic energy can 
range from ~5% during rest to ~50% during high exertion.  Stroke work can also change with the 
presentation of cardiomyopathies (e.g. myocardial infarction), resulting from physiological changes in 
ventricular volume and/or pressure. 
Many clinical and experimental studies have also used ejection fraction as a measure of contractility.  
Ejection fraction (EF) is the ratio of the volume of blood ejected into the aorta in one cycle (i.e. end-
diastolic volume EDV minus end-systolic volume ESV, which is equivalent to stroke volume SV) to the 
end-diastolic volume, as shown in equation 3. 
 
EDV
SV
EDV
ESVEDVEF =−=    (3) 
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Different from stroke volume, ejection fraction provides an indication of contractile efficiency by 
calculating the percentage of blood pumped out of the ventricle with respect to the maximal ventricular 
volume. 
Parameters such as stroke volume, stroke work, and ejection fraction are relatively easy to determine 
in the clinic with commonly available equipment.  This advantage allows the same variable to be 
measured at multiple testing sites and times.  In addition, it offers a way to assess patients and compare 
the effects of potential treatment options.  However, these parameters can be altered by ventricular 
aneurysms, valve incompetence, or changes in the overall ventricular size.  In addition, changes in the 
passive properties of infarcted myocardium can lead to improved diastolic filling without improving the 
active contractile properties of the ventricle.  Measurements of regional parameters that are synced with 
the ventricular pressure or EKG are better for determining improved contractile function.   
Wall thickening, regional strain and systolic contraction can be acquired clinically to provide 
information on the contractile status of the ventricular wall.  It is important to determine if the wall is 
contracting in synchrony with the rest of the ventricle.  A passive material in the heart that is loaded with 
intracavitary pressure will decrease in thickness, whereas a contractile material will increase in thickness 
(which leads to the increase in intracavitary pressure).143  A material that decreases in thickness will tend 
to be less compliant in that it cannot withstand intracavitary pressure, which may eventually lead to 
ventricular aneurysm.  A material that increases in thickness could also be less compliant in that it may 
become too stiff, and may therefore impede the normal contractile force of the ventricle. 
Animal models provide more opportunity for measuring independent of variables that are not easy to 
control in the clinic (e.g.  heart rate and afterload).  Preload recruitable stroke work (PRSW) has been 
used to evaluate the global function of the heart.  PRSW, the linear relationship of the stroke work to end 
diastolic volume, is independent of heart rate and afterload.1  Measurements such as end systolic volume, 
end systolic pressure-volume relationship (ESPVR), change in ventricular pressure over time (dP/dt), can 
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provide valuable information on the contractile status in the global heart, but can also be dependent on 
heart rate and aortic pressure (Figure 2.5 C, D). 
While many techniques focus on systolic function, diastolic function also plays an important role in 
heart failure as stiffness and wall thickness can affect relaxation and filling.  Diastolic function has 
commonly been assessed based on a global measurement of the time constant of isovolumic pressure 
decay, tau (τ).  The isovolumic relaxation constant was determined by Weiss et. al by assessing pressure 
fall during isovolumic beats.144  They found pressure fall, dP/dt, was exponential during isovolumic 
relaxation and was characterized by a time constant of relaxation, τ.  More recently, apical recoil or 
untwisting and the temporal change in this variable, have been used to assess diastolic function of the 
ventricle.145  As this can be measured at different locations within the ventricle, it can be used to define 
regional diastolic function. 
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Figure 2.5.  Variables used in determining regional function in the heart.  (A) Pressure-volume work loop of 
the left ventricle through one cardiac cycle. Point A indicates “end-diastole” and Point B indicates “end-systole”. 
Integrating for the area within the loop provides the amount of work done by the left ventricle over the course of one 
cardiac cycle. By substituting regional area for left ventricular volume, a regional stroke work loop is constructed, 
with regional stroke work being determined from the integral of left ventricular volume with respect to regional 
area.  (B) Frank-Starling curves show the effects that preload can have on stroke volume, which is directly related to 
stretching during diastolic filling.  Line A indicates a normal operating curve, whereas Line B indicates a decreased 
contractility and Line C indicates increased contractility.  (C) End systolic pressure volume relationship (ESPVR) is 
determined by plotting this point for several different sized work loops.  The size of the work loop can be altered by 
changing the preload on the ventricle.  Preload recruitable stroke work, the linear relationship between stroke work 
and end-diastolic volume, can also be determined with the information from this plot.  (D) Maximum (or minimum) 
dP/dt (change in pressure per change in time) can be obtained by plotting the left ventricular pressure as a function 
of time.  This relationship can be altered, providing a measure of the mechanical function in the left ventricle.  (JP 
Guyette and GR Gaudette chapter, “Assessing Regional Mechanical Function after Stem Cell Delivery” in the text, 
Regenerating the Heart)141 
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2.8. Regional Cardiac Mechanics  
Myocardial defects such as smaller myocardial infarctions can occur within definite, localized regions 
of the heart.  In order to study these effects and potential treatments, it is necessary to be able to determine 
the mechanical function in the defined regions. Clinically, these measurements can be taken with several 
techniques including MRI, ECHO, and NOGA.  Tagged MRI is a method that can noninvasively measure 
the internal motions within the heart wall.146,147  As mentioned, tagged MRI is advantageous because it 
can be used to determine 3D measurements of both stroke volume and stroke work.  It can also be used 
for local strain measurements to determine function in regions of the myocardium that may be damaged 
from ischemia, hypertrophy, or infarction.148-151  Dong et. al. have also used tagged MRI on canines to 
measure the angle displacement of the base of the heart relative to the apex.152  The displacement angles 
were indicative of the twisting of the heart due to an applied force in the circumferential direction, 
resulting in ventricular torsion.  Torsion measurements determined during diastole could then be 
correlated to the global measure of the diastolic relaxation time constant, tau, during isovolumic 
relaxation. 152   
ECHO is also used to determine regional changes in wall size, wall movements, wall stiffness, and 
cavity size.  Most recently, ECHO has been used to determine strain and strain rate in the myocardium.  A 
new method of ECHO called ultrasound speckle tracking imaging (STI) has been employed, which uses 
B-scan ultrasound to give the appearance of speckle patterns within the tissue.  Motion analysis can then 
be done on the speckles to determine strain and ventricular torsion.153   
Using the aforementioned methods, deformation can be determined in the beating heart leading to the 
determination of engineering strain, defined in the uni-axial case as the change in length divided by the 
original undeformed length.  The heart is exposed to three dimensional deformations, leading to strain 
along 3 axes and shear stress acting on orthogonal planes. There exists an orientation in which there is no 
shear strain. In this orientation, the maximum and minimum strain exists. The maximal strain is the 
principal strain in the 1 direction and the minimal strain I s the principal strain in the 2 direction which is 
orthogonal to the 1 direction.   
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The strain in the 1 direction is the expansion of the myocardium during systole.  Since the 
myocardium is incompressible and hence the volume needs to be conserved, expansion has to be coupled 
with contraction in a different direction in the wall.  Principal strain changes in both magnitude and angle 
resulting from cardiac events.154-156  Using MRI to measure principal strain changes in mice with heart 
failure Hankiewicz et. al. found that the principal strain in the 1 direction decreased with advancement of 
heart failure compared to controls.155  In addition, they detected decreases in principal strains prior to 
dilation of the ventricle.155  Cupps and colleagues156 used MRI to measure the principal strain orientation 
in the normal human left ventricle.  Their results suggested that principal strain in the maximal 
contraction direction occurs in the circumferential-longitudinal plane that aligns with the apex to base axis 
of the heart.156  Their work shows that orienting displacement data along the apex to base cardiac axis will 
provide the maximal contractile strain for the heart. 
 
2.9. Active and Passive Mechanical Function 
Mechanical function in the heart consists of both active and passive components, both of which are 
potential targets for regenerative therapy.  The active function is manifested by the contraction of 
cardiomyocytes, which is primarily responsible for the systolic phase of the cardiac cycle. Active function 
(i.e. systolic contraction) decreases during myocardial infarction and heart failure, due to the loss or 
dysfunction of cardiomyocytes.  Just as important as active function, the passive function of the ventricle 
also plays an important role by providing a compliant structure. In the cardiac cycle, the compliance of 
the myocardium allows for maximal shortening during systolic contraction and maximal expansion 
during diastolic relaxation.   
Myocardium is a complex tissue type, comprised of contractile cardiomyocytes that interact with each 
other and several other cell types (e.g. vascular smooth muscle cells, endothelial cells, fibroblasts, etc.) in 
an extracellular matrix (ECM) composed of structural proteins (e.g. collagen, elastin, laminin, and 
fibronectin).  While cardiomyocytes are responsible for active function, the interactions of cells and ECM 
are responsible for passive function.  Cell-ECM interactions provide the structural network for anchoring 
Chapter 2 | 48  
 
cardiomyocytes and translating the sarcomeric shortening of individual myocytes into organized 
myocardial contraction.  The network also provides elasticity and integrity during diastole, allowing for 
maximal expansion while preventing overstretching or rupture. 
Active and passive function can both be compromised during myocardial infarction (MI). During an 
MI, the heart undergoes a wound response that typically includes inflammation, cellular turnover, and 
extracellular matrix remodeling.  Dead or afflicted cells (including cardiomyocytes) are replaced with 
new cellular components such as fibroblasts and vascular cells.  The content and organization of the 
cardiac extracellular matrix is remodeled by both reparative and reactive fibrosis, causing the degradation 
of normal matrix and increasing the deposition of collagen.157  The resulting scar is stiffer than healthy 
cardiac extracellular matrix and leaves the affected area devoid of cardiomyocytes.  Not only does the 
infarct region lose contractile elements necessary for active function, but passive function is also impaired 
as the stiffer matrix is more difficult to deform during systolic contraction and diastolic expansion.  
Considering the spared cardiomyocytes at the border-zone of an MI or in the case of a non-transmural MI, 
cell-infarct interactions compromise systolic contraction as myocytes have a more difficult time 
shortening when anchored to a non-compliant substrate. 
To repair the outcomes of an MI and restore mechanical function, regenerative therapies can be 
targeted to improve active function, passive function, or both.143  Adding contractile elements to the 
infarct may increase active contraction.  Whether delivering exogenous cells (i.e. stem cell derived 
cardiomyocytes), or recruiting endogenous cells to home and differentiate to cardiomyocytes, it may be 
possible to restore contractile function.4  Alternatively, improving the compliance of the infarct region 
may increase passive function.143  Whether surgically replacing the infarct with a more compliant 
biomaterial, or delivering/recruiting cells that improve cardiac tissue remodeling, it may be possible to 
decrease stiffness or increase elasticity for improved passive function.  Implanting a more-compliant 
biomaterial seeded with cardiomyocytes, or implanting a biomaterial that actively recruits 
cardiomyocytes, may combine efforts to improve both active and passive mechanical function.143 
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It is difficult to distinguish the active contractile properties from the passive properties in vivo.  In 
normal myocardium, the increase in intracavitary pressure results from the contraction of myocytes.  If 
one were to look at a cross-section of left ventricle, the area of this region would decrease with increased 
load such as intracavitary pressure (Figure 2.6).  However, if a material void of cells and contractile 
properties is implanted in the heart, it will expand under an increase intracavitary load.   This is similar to 
what happens when an elastic balloon is filled with water; the balloon expands as the pressure inside the 
balloon increases.  If the balloon was composed of a stiff material, the balloon would still increase, 
however the increase may be microscopic.  When an accelluar compliant scaffold, such as isolated 
porcine urinary bladder ECM, is implanted in the ventricular wall, the area of the scaffold will increase 
with intracavitary pressure (Figure 2.6).  Most biological materials are non-linear in the elastic range.  If 
the scaffold is a stiff material, such as Dacron, the load is not enough to cause a significant change in the 
area of the implanted scaffold.  Hence, changes in intracavitary pressure do not deform the scaffold, 
similar to the effects of a stiff scarred region.  Therefore, a more compliant scaffold tends to improve 
function by allowing for passive properties such as expansion and elasticity, whereas stiff scaffolds do not 
offer much functional benefit beyond the originals scar. 
If contractile cells begin to populate the implanted region, they must be able to deform the scaffold 
prior to performing useful mechanical work that contributes to pump function.  If the material is 
expanding during contraction (Figure 2.6), then the contractile cells in this region must generate enough 
force to balance the tensile forces due to the increased intracavitary load.  If the region is stiff, as is often 
the case in collagen populated infarcts, the contractile cells must be able to deform the region in order to 
contribute to a decreased systolic volume in the heart.  For example, contracting embryoid bodies are able 
to deform surrounding attached cells, but they do not deform the stiff cell culture dish.  Thus, if a small 
number of myocytes were regenerated in a stiff infarcted region of the heart, they could not generate 
enough force to improve contraction in the heart.  Thus, there appears to be a critical number of new 
myocytes that needed to contribute to active function in the heart.  And this critical number of myocytes 
may be dependent on the passive mechanical properties of the region. 158 
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Figure 2.6.  Variable tissue properties of a passive region can lead to changes in ventricular function.  For a 
region that is passive, that is one that does not have any contractile elements, its deformation is dictated by the 
intracavitary pressure.  Unlike normal myocardium, which contracts with increasing intracavitary pressure, passive 
materials will elongate (resulting in a thinner wall) under intracavitary loads.  (A) The normal cross sectional area of 
the left ventricle is schematically demonstrated as a red circle on the right of the panel.  (B) If the mechanical 
properties of a region of the heart are altered (e.g. myocardial infarct, scar, scaffold implantation), the shape of the 
cross section of the ventricle can be altered. As the pressure increases in the normal heart, the entire cross section of 
the ventricle contracts (far left).  In the case of a stiff scar, the region cannot contract, leading to a region of the 
ventricle that does not change in shape (second from left).  If the scar is compliant, it will deform with the ventricle, 
although it will not contract if it is passive (second from right).  However, if the scar is thin and very compliant, it 
will balloon out as the pressure inside the ventricle (far right).  (JP Guyette and GR Gaudette chapter, “Assessing 
Regional Mechanical Function after Stem Cell Delivery” in the text, Regenerating the Heart)141 
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2.10. Regional Mechanical Function in the Diseased Heart 
Most animal models used to evaluate cell therapy aim to develop a well-defined region of 
dysfunction.  However, mechanical function in ischemic or infarcted hearts is generally heterogeneous.  
For example, Figure 2.4 demonstrates work loops from regions within the ischemic porcine heart.  
Mechanical function in the border zone, the region between infarcted tissue and normally perfused tissue, 
is very different compared to normally perfused tissue or tissue in the center of the ischemic zone.  The 
work loops from the border zones (Regions 2, 6, 11, 15 and 20 in Figure 2.4) in general show very little 
work, as evident by the lack of any significant area within the work loop. Regions within the ischemic 
zone (regions 4, 8, 12, and 16 in Figure 2.4) show reversed work loops, suggesting the contraction of 
these regions is out of sync with ventricular contraction.  While regions of normally perfused tissue are 
contracting, resulting in increased intracavitary pressure, the ischemic regions are dyskinetic and 
expanding due to the increased load on the tissue.  Therefore, the ventricle (as a whole) is producing less 
contractile force, which thereby causes an increased end-systolic volume during the cardiac cycle and a 
decreased ejection fraction. 
Similar to myocardial ischemia, various ranges of dysfunction can occur within the infarcted 
myocardium depending on the severity of the infarct, the time of recovery and the location (Fomovsky & 
Holmes, 2009).  For more details on the mechanical properties of myocardial infarcts, see Holmes, Borg 
& Covell, 2007.   
In order to evaluate the effects of cell therapy in the dysfunctional heart, the region of cell delivery 
must first be identified.  Delivery by intravenous or intracoronary methods can lead to dispersion of cells 
throughout the heart, making the location of cells difficult to identify.  To clearly identify the delivery 
region, we have employed the use of a cell seeded myocardial patch composed of an extracellular 
matrix.67  When this patch is used to replace a full thickness defect in the ventricular wall, a region for 
mechanical analysis is well defined. Using HDM (previously described) allowed for determination of 
function in regions approximately 5 x 5 mm.  Upon implantation of unseeded scaffold, there is no 
contractile function.  As the load inside the ventricle increases, the scaffold passively deforms increasing 
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in area.  Such a response is expected of any compliant, passive material when it is exposed to an increase 
in intracavitary pressure.  A stiff material, such as Dacron, is also a passive material and does not 
demonstrate any deformation when the heart contracts.158  The deformation is limited due to the stiff 
(non-compliant) nature of the material. Eight weeks after implantation of scaffolds seeded with human 
mesenchymal stem cells, regional stroke work is positive.  This suggests that the scaffold region is 
contracting in sync with the rest of the heart because the scaffold region is contracting while the 
intracavitary pressure is increasing. 
 
2.11. Challenges with Cellular Therapy for the Heart  
Despite the initial successes with cell therapy, there are still many issues facing the field.  Cell 
retention in the beating heart remains a challenge.  Intravenous and intracoronary delivery of cells results 
in low engraftment in the heart.  Cell retention is increased with intramyocardial injections, but 3-11% 
retention rates are still very inefficient.159,160  Delivery of cells by applying a cell seeded scaffold onto the 
epicardial surface of the heart can further increase cell engraftment, but this requires a more invasive 
procedure.161  In addition, only a small percentage of cells migrate through the heart wall to the 
endocardium, where most clinical myocardial infarctions reside.161  Novel methods of cell delivery 
include loading cells on biological sutures that can then be delivered to the heart wall.162  However, much 
work needs to be done to determine how many cells can be delivered with this method. 
Tracking delivered cells can also be an issue.  Injured myocardial tissue is known to be highly auto-
fluorescent leading to difficulties when using green fluorescent proteins to track cells.38  Iron oxide 
labeled cells can be tracked with MRI but it is difficult to track small numbers in the whole heart. 
Accurate determination of the numbers of engrafted cells will be important in evaluating the dose 
response curves of different cell types.  Engraftment rates are also important in determining if improved 
regional function correlates with the number of cells retained by the heart. Regional mechanical function 
can be determined by a number of techniques, but few offer the high spatial resolution needed to assess 
function in the small region surrounding cell delivery sites.   
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The expression of cardiac specific proteins has been documented in many different differentiated 
cells.  However, the organization of cardiac specific proteins into functionally relevant sarcomere 
formations is unclear or questionable.  The ability of a cell to express cardiac proteins is an important 
initial step in differentiation, but formation of sarcomeres and other functionally essential apparatus in the 
cell are necessary for improved function.30  While the addition of non-contractile cells may improve 
mechanical function in the heart, full regeneration will require the contractile elements.143 
Many studies have demonstrated “proof of principle” for the benefits of cardiac cell therapy, by 
increasing cardiomyocyte content by either myocyte proliferation or stem cell differentiation.  Both 
methods have their advantages and there is no evidence to suggest the two methods cannot be used 
synergistically to regenerate function at a higher rate than either alone. Success with either or both of 
these approaches will improve the prognosis for millions of Americans suffering from myocardial 
infarction and/or heart failure. 
 
2.12. Mechanical Function Post Stem Cell Delivery  
A number of clinical trials have been initiated to assess the resultant function of various cell therapies 
delivered to the heart.  The results from trials have been mixed, with some trials indicating improved left 
ventricular EF ranging from 2.5 to 6.0 percentage points with BMCs at 4-6 months compared to 
controls,163-165 and others showing no effect from cell therapy (treatment effect of +0.6 and +1.0 
percentage points on LVEF).152,166  Despite short-term improvements in function, it is unclear whether 
long term enhancement in EF can be sustained as another study showed loss of improvements at 18 
months after cell delivery.167  In order to make these measurements in small animals such as mice and 
rats, echocardiography and MRI are frequently used.  Both of these techniques are able to determine 
global volume of the heart, allowing assessment of global function in the heart.  However, the limited 
spatial resolution of the techniques decreases the ability to accurately assess regional function in the heart 
of small animals.  In addition to echocardiography and MRI, sonomicrometry, conductance catheters168 
and digital imaging techniques have been used in large animal models.   
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One major limitation facing the field is that the use of different parameters (e.g. ejection fraction, 
stroke work, developed pressure, wall thickness, etc.) makes it difficult to compare different studies.  
Therefore, it is difficult to compare the various cell types being used (as described throughout this text), 
which confounds the determination of an optimal cell type for cardiomyoplasty.  Another major limitation 
that is often not considered is the use of human cells in animal models, whose hearts beat much faster 
than human hearts (e.g. 60 bpm in humans, and ~400 bpm in rats).  It remains to be determined if human 
cells delivered in the human heart will engraft with similar efficiency and improve functional parameters 
similar to that of animal models.  As mentioned previously, it is also difficult to separate the passive 
component versus the active component of cardiac mechanical function.  Moving forward, more studies 
are needed to correlate the improvement of mechanical function with the evidence of increased contractile 
mass.  This correlation will help to distinguish whether the improvements can be attributed to 
regenerated, actively contracting cardiomyocytes, or whether the improvements are due to more optimal 
tissue-compliance with the delivered cellular mass. 
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CHAPTER 3: Effects of reduced-O2 on hMSC growth kinetics and c-Met expression 
3.1. Introduction 
Traditional conditions for culturing adult, bone marrow derived hMSCs typically employ a 
conventional gas composition consisting of 95% atmospheric air (containing ~19% O2 and ~76% N2) and 
5% CO2, maintained at 37°C.  However, recent studies suggest that culturing hMSCs in reduced oxygen 
concentrations (reduced-O2) is more appropriate for mimicking physiological conditions of cells and 
tissues in vivo.1-4  Physiological ventilation and perfusion relationships support this argument, as oxygen 
concentrations decrease from when it enters the body, circulates in the bloodstream, and diffuses into 
bodily tissues.  The partial pressure of O2 in ambient air is ~160 mm Hg (~21% of normal atmospheric air 
pressure, 760 mm Hg), but decreases to ~150 mm Hg (~19% O2) as it mixes with water vapor in the 
mouth and trachea.5  When inspired gas reaches the alveoli of the lungs, O2 is transported across alveolar 
membrane into the blood and CO2 is transported from the capillaries to the alveoli.  Gas exchange causes 
a flux of decreasing O2 and increasing CO2 fractions in the alveoli, causing changes in the partial pressure 
of O2 in the alveoli.  Using the alveolar gas equation to account for this physiological phenomenon, the 
partial pressure of O2 in the alveoli has been calculated to be ~102 mm Hg (~13% O2).5  During transport 
into systemic circulation, oxygen mixes with relatively constant physiological levels of CO2 (pCO2 = 40 
mm Hg), H2O (pH2O at 37°C = 47 mm Hg), and N2 (pN2 = 571 mm Hg).  In combination, these gases 
must maintain a homeostatic balance with atmospheric pressure of 760 mm Hg, which causes the partial 
pressure of O2 in systemic arterial blood to drop to ~90 mm Hg (~12% O2).5  
The rationale for culturing hMSCs in reduced-O2 is further supported by consideration of both the 
hMSC niche environment (i.e. bone marrow) and the target tissues where hMSCs are implanted for cell 
therapy (e.g. myocardial infarcts).  Studies estimate that the oxygen tension within bone tissue is in the 
range of 1-12% O2, with estimates of O2 levels in the bone marrow in the range of 1-7%.4,6,7  Furthermore, 
a pre-clinical study done on rat myocardial infarcts detected the pO2 of the infarcted tissue to be 3 mm Hg 
(~0.4% O2) at day 0 and 13 mm Hg (~1.7% O2) after 4 weeks.8  Taken together, these data suggest that 
reduced-O2 culturing of hMSCs might be more “normal” in terms of physiological relevance than the 
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conventional norm of culturing hMSCs in atmospheric O2.  However, the idea and practice of reduced-O2 
conditioning is still a relatively new paradigm, and the effects of reduced-O2 conditioning on hMSCs are 
not well understood. 
Several groups have begun to study the effects of reduced-O2 conditions on mesenchymal stem cells 
(MSCs), using a range of oxygen concentrations spanning 0.5-5.0% O2.1-4,6,7,9-14  Some studies report that 
reduced-O2 conditioning can increase MSC proliferation,3,4,9 while other studies report reduced-O2 
decreases MSC proliferation,6,13,14 and yet others report that reduced-O2 has no effect on MSC self-
renewal.1  In addition, some studies report that reduced-O2 conditioning can increase MSC differentiation 
potential,9,10,14 while other studies report reduced-O2 decreases MSC differentiation potential,7,13 and yet 
others report that reduced-O2 conditioning of MSCs can elicit the expression of de-differentiation markers 
such as Oct-4 and Rex-1.3,4  Upon further analysis, it was found that reduced-O2 conditioning of MSCs 
can increase prosurvival marker expression (e.g. Akt, HIF-1α, and survivin),1,10,11 growth factor secretion 
(e.g. VEGF, HGF, and FGF-2),2,11,15 and growth factor/cytokine receptor expression (e.g. VEGFR1, c-
Met, and CXCR4).1,6,11,12  In vitro and in vivo studies have also shown that reduced-O2 conditioned MSCs 
can increase tissue formation,4 enhance motility/homing to injury sights,1 improve engraftment/retention 
in injured tissue,2,6 and upregulate angiogenesis;1,2 all of which would be advantageous in therapeutic 
applications for tissue regeneration and wound healing. 
Despite the therapeutic potential, inconsistent results plague the field, and continued research is 
required for a more comprehensive understanding of the effects involved in reduced-O2 conditioning on 
MSCs.  Discrepancies in the literature may be largely due to the use of different MSC species (e.g. 
human,1,3,4,7,14 rat,9-11,15 and mouse2,12,13), different cell sources (e.g. tibial bone marrow,7 iliac crest bone 
marrow,1,3,4 and adipose13,14), different oxygen concentrations (0.5-5.0% O2), varying durations of 
reduced-O2 exposure (hours vs. days), and different applications.  In sifting through the literature, we 
sought to draw from and build upon studies that were relevant to our MSC species, source, and 
application.   
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We are using human MSCs (hMSCs) derived from bone marrow harvested from iliac crests of adult 
donors, for cell therapy applications in myocardial infarcts where oxygen tension ranges from 0.4-1.7% 
O2.8  Keying in on three specific studies that used hMSCs from iliac crest bone marrow, several beneficial 
cellular and therapeutic effects have been found when conditioning these cells in 1-3% O2,1,3,4 with one 
study concluding that culturing hMSCs at 2% demonstrated a “switch” in metabolic pathways and 
enhanced proliferation potential.3  As 2% O2 appeared to elicit advantageous effects without adversely 
affecting hMSC growth, it was also close to the physiological oxygen tension found in myocardial 
infarcts.  Therefore, we selected 2% O2 for our reduced-O2 conditioning studies.  To create a 2% O2 
environment, we used an incubator system that allowed for an increased nitrogen intake to displace 
ambient oxygen, as described further in the materials and methods below.  Once the reduced-O2 
conditioning system was established, we examined the effects of our system on hMSC growth kinetics 
and c-Met expression.  Recently, c-Met has been shown to elicit cardiac specific markers in mouse MSCs, 
by interacting with its pleiotropic cytokine HGF.16  In addition, c-Met has been shown to be an important 
factor in the motility and migration of hMSCs to sites of injured tissue.1,16  As recent studies suggest that 
reduced-O2 conditioning can increase c-Met receptor expression in hMSCs,1 we are interested in 
determining if we can do the same in order to exploit the therapeutic potential or cardiac differentiation 
mechanisms in hMSCs. 
 
3.1.1. Determining the effects of reduced-O2 on hMSC growth kinetics 
For a more complete understanding of how reduced-O2 conditioning affects hMSC growth kinetics 
over time, we evaluated cumulative population doublings and doubling rate of hMSCs maintained in 
either normal-O2 (20% O2) or reduced-O2 (2% O2) conditions.  Since there are conflicting results in the 
literature as to whether reduced-O2 conditioning increases,3,4 decreases,6 or has no effect1 on hMSC 
proliferation, we sought to conduct our own controlled study to better understand our reduced-O2 system 
and contribute to the body of literature.  Again, reported discrepancies regarding reduced-O2 effects on 
hMSC growth kinetics  may lie in the parameters chosen in the study set-up (e.g. reduced-O2 exposure 
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duration, length of the study, or treatment with/without serum) and the methods used to evaluate (e.g. cell 
cycle analysis, cell counts, fold-expansion, or colony formation).  From experience, we know that hMSCs 
cultured in normal-O2 conditions have an approximate doubling-time of ~7 days, and they remain viable 
and proliferative until ~passage 10.  Using the 7-day doubling-time as a benchmark parameter, we 
compared hMSC growth in reduced-O2 versus normal-O2, seeding all flasks from the same initial vial of 
cells and taking cell counts at each passage (every 7 days).  Data obtained from cell counts were used to 
calculate population doublings at each passage.  Population doublings were compared across cell-
passages to evaluate doubling rate over time.  In addition, population doublings were compounded at each 
successive passage to evaluate total doublings over time. 
 
3.1.2. Determining the effects of reduced-O2 on c-Met expression 
In support of our hypothesis that reduced-O2/HGF conditioning can initiate cardiac differentiation of 
hMSCs, it has been previously shown that HGF interacts with its c-Met receptor to activate signaling 
pathways that may be involved in downstream cardiac marker expression.16,17  In addition, previous 
studies suggest reduced-O2 conditioning of both human and rat MSCs may increase c-Met receptor 
expression,1,11 but the methods used to evaluate this phenomenon have been either qualitative or semi-
quantitative analyses of early-stage time points.  If we can better understand this phenomenon, we may be 
able to exploit the increase in c-Met expression to enhance HGF/c-Met signaling, which we can then test 
as a possible cardiogenic differentiation strategy in hMSCs.  To improve upon the scope of previous 
studies, we determined the effect of reduced-O2 conditioning on the c-Met expression of hMSCs cultured 
in reduced-O2 for a broader range of time durations (1, 3, 7, 10, and 14 days).  And to improve upon the 
methods previously used, c-Met expression was determined by ELISA for a more quantitative and 
comparable evaluation.  In addition we compared the c-Met expression of hMSCs cultured in normal-O2 
versus reduced-O2 at days 3, 7, and 10.  A more comprehensive evaluation suggests that longer-term 
reduced-O2 conditioning may increase c-Met expression in hMSCs. 
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3.2. Materials and Methods 
3.2.1. Implementation of reduced-O2 culture environment 
To implement a reduced-O2 cell culture system, we used a HERAcell® 150 incubator (Thermo 
Electron Corporation, #51022545, Langenselbold, Germany) with both carbon dioxide (CO2) and 
nitrogen (N2) gas-intake valves.  CO2 supplied by a compressed gas reserve was maintained at 5% by a 
sensor-regulated intake valve.  N2 gas was supplied by a high-pressure liquid nitrogen reserve that was 
connected to a Heraeus system gauge (Thermo Electron Corporation, #50059043, Langenselbold, 
Germany), which incorporates an automatic switch to a back-up compressed N2 tank in case of 
emergencies.  The N2 composition was increased and maintained at 93%, displacing the O2 composition 
to only 2%.  O2 gas levels were maintained and checked with both a HERAcell® O2 Sensor Set (internal 
to the HERAcell® 150 incubator, Thermo Electron Corporation, Langenselbold, Germany) and a 
FYRITE® Gas Analyzer (Bacharach, Inc., Test Kit #10-5053, New Kingston, PA). 
 
3.2.2. General techniques for culturing human mesenchymal stem cells 
Human mesenchymal stem cells (hMSCs) isolated from human adult bone marrow were purchased 
from Lonza, Inc. (#PT-2501, Walkersville, MD).  Cryo-preserved vials arrived as passage-2 hMSCs, 
which had been pre-characterized by the manufacturer.  Upon thawing, passage-3 hMSCs were plated 
with a seeding density of 500,000 cells per T-75 flask and were cultured in mesenchymal stem cell 
growth medium (MSCGM, Lonza’s proprietary hMSC growth media, includes 10% fetal bovine serum; 
Lonza, Inc., #PT-3001).  Multiple flasks originating from the same vial were segregated to either normal-
O2 (20%) or reduced-O2 (2%) conditions.  Cells were maintained at 37°C, growth media was changed 
every 2 days, and cells were passaged when growth reached approximately 80-90% confluency.  
Successive cell-passages were maintained in their pre-designated oxygen concentrations, and passage 4-9 
hMSCs were used for experimentation. 
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3.2.3. Culturing hMSCs for growth kinetics 
A fresh vial of hMSCs (Lonza, Inc., #PT-2501, Walkersville, MD) was thawed and immediately 
reconstituted in 5 mL of warm MSCGM (Includes 10% fetal bovine serum; Lonza, Inc., #PT-3001, 
Walkersville, MD) in a drop-wise fashion in a 15 mL conical tube.  The tube was centrifuged at 1,000 
rpm for 5 minutes to form a pellet, the media was aspirated, the pellet was resuspended in 1 mL of fresh 
warm MSCGM, and a cell count was taken using a hemocytometer (Hausser Scientific Co., #3200, 
Horsham, PA).  The resuspended hMSCs were used to seed six T-25 vented tissue culture flasks (Becton 
Dickinson Labware, #35-3108, Franklin Lakes, NJ), with a cell-density of 167,000 cells per flask.  Three 
of the T-25 flasks were conditioned in normal-O2 conditions, and the remaining 3 T-25 flasks were 
cultured in reduced-O2 conditions.  Cells were cultured in MSCGM for the duration of experiment, media 
was changed every 2 days, and cells were passaged every 7 days (upon reaching 80-90% confluence).  
Successive cell-passages were maintained in their pre-designated oxygen concentrations.  At each 
passaging period, pellets were resuspended in 1 mL of fresh MSCGM, and 2 cell counts were performed 
for each cell suspension.  For each cell count, 20 µL of suspension was mixed with 20 µL of Trypan Blue, 
and then 10 µL of the cell/Trypan mixture was seeded onto a hemocytometer.  For each analysis, enough 
hemocytometer-areas were evaluated to count more than 100 cells, and cell counts were back-calculated 
to determine the total cell number in each suspension.  Based on the cell concentration of each 
suspension, aliquoted volumes containing 167,000 cells were then re-plated into new T-25 flasks to 
perpetuate the fidelity of each culture/experiment.  During each passaging period, 6 new T-25 flasks were 
generated from the previous 6 flasks (3 in normal-O2 and 3 in reduced-O2), to be evaluated over the next 
passage. 
 
3.2.4. Calculation of population doublings 
To assess hMSC growth kinetics, population doublings were calculated for each flask at every 
passage.  During passaging, the cells in each T-25 flask were trypsynized and centrifuged at 1,000 rpm for 
5 minutes.  Old media was aspirated and cell pellets were resuspended in 0.5 mL of DMEM 
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supplemented with 10% FBS.  For each cell suspension, 2 cell counts were taken using a hemocytometer, 
making sure to count at least 100 cells for each cell count to satisfy the limits of the hemocytometer 
chamber.  The 2 cell counts were then averaged as a single metric for the cell concentration of each cell 
suspension.  Total cell number was back-calculated based on the measured cell concentration and the 0.5 
mL resuspension volume.  The following equation was then applied to calculate the population doubling 
for each cell suspension: 
𝑝 =  𝑝𝑜 ∙  2𝑑     →      𝑑 =  ln � 𝑝𝑝𝑜�ln(2)  
p = total cell number (calculated) 
po = initial-seeding cell number (167,000 cells) 
d = # of doublings 
 
Once population doublings were calculated for each cell suspension, the triplicate of population 
doublings for each O2 concentration were averaged (n=3 for normal-O2 and n=3 for reduced-O2). 
 
3.2.5. Culturing hMSCs for c-Met expression 
A fresh vial of hMSCs (PT-2501, Lonza, Inc., Walkersville, MD) was thawed, reconstituted, 
centrifuged, resuspended, and then plated into T-75 vented tissue culture flasks (Becton Dickinson 
Labware, #35-3136, Franklin Lakes, NJ) at a concentration of 500,000 cells per flask.  At least one T-75 
flask was placed into normal-O2 conditions, and at least one T-75 flask was placed into reduced-O2 
conditions.  Cells were fed with MSCGM every 2 days, and passaged when they were between 80-90% 
confluent.  When passaged, cells were re-plated with a seeding density of 500,000 cells per flask, and 
successive passages were maintained in their pre-determined oxygen conditions.  At passage 5, three or 
more T-75 flasks were seeded with 500,000 cells per flask for each time point in both oxygen conditions, 
and then returned to their appropriate incubators.  Cells were cultured in MSCGM, and media was 
changed every 2 days.  At each time point, cells were harvested. 
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3.2.6. Cell harvest and lysis for total c-Met analysis  
Cells were harvested by washing culture flasks with sterile Dulbecco’s phosphate buffered saline 
(DPBS, without calcium or magnesium; Cellgro® Mediatech, Inc., #21-031-CV, Manassas, VA), and then 
detaching hMSCs from the flask with 6 mL of 0.25% Trypsin Ethylenediaminetetraacetic acid (Trypsin 
EDTA; Cellgro® Mediatech, Inc., #25-053-CI, Manassas, VA).  Trypsin EDTA was inactivated by 
pipetting the cell solution into 5 mL of DMEM with 10% FBS in a drop-wise fashion.  Cells were then 
centrifuged at 1,000 rpm for 5 minutes.  Media was aspirated, and cell pellets were then washed by 
resuspending them in 1 mL of phosphate buffered saline (PBS, pH 7.2-7.4).  Washed cells were then re-
centrifuged at 1,000 rpm for 5 minutes to reform the pellet. 
For cell lysis, lysis buffer was prepared with a composition of 1% NP-40 (EMD/Calbiochem, 
Rockland, MA; #492016), 20 mM Tris (pH 8.0; Sigma Aldrich, St. Louis, MO), 137 mM sodium chloride 
(NaCl; Sigma Aldrich), 10% glycerol, 2 mM EDTA (Sigma Aldrich), 1 mM sodium orthovanadate 
(Na3VO4, Sigma, #S6508), 10 μg/mL Aprotinin (Sigma, #A6279), and 10 μg/mL Leupeptin (Sigma, 
#L8511).  As samples were being harvested over multiple time points, total cell lysates were stored at -
80°C until all samples were collected. 
 
3.2.7. Assaying Total c-Met by ELISA 
Prior to ELISA analysis, samples were thawed and protein quantification was acquired using a 
NanoDropTM 2000 spectrophotometer system (Manufactured by NanoDrop Products, Wilmington, DE; 
supplied by Thermo Scientific, Waltham, MA).  Based on the protein quantifications, calculations were 
made to determine the appropriate volume needed for 40 μg of each sample. 
Samples were then tested by an enzyme-linked immunosorbent assay (ELISA), using a DuoSet® 
ELISA kit for human total c-Met (R&D Systems, Minneapolis, MN; #DYC358-2).  All formulations for 
buffers and reagents were detailed by the manufacturer, and prepared fresh in the lab.  All antibodies and 
standards were provided by the manufacturer.  Briefly, the predetermined wells of a 96-well plate were 
treated with 100 μL of mouse anti-human Total HGF-R/c-Met capture antibody (2.0 μg/mL), and allowed 
Chapter 3 | 70  
 
to incubate overnight at room temperature.  The next day, the wells were aspirated and rinsed 3 times with 
wash buffer (0.05% Tween 20 in PBS).  Wells were then treated with 300 μL of block buffer (1% Bovine 
serum albumin, 0.05% sodium azide) for 2 hours at room temperature.  After blocking, wells were rinsed 
3 times with wash buffer.  After washing, samples and standards were added to the predetermined wells, 
and incubated for 2 hours at room temperature.  Samples were prepared by adding the appropriate volume 
for 40 μg of each sample to sample buffer, for a total of 100 μL.  Standards were run in duplicate, and 
were prepared by making a seven-point standard curve using 2-fold serial dilutions with a high standard 
concentration of 8000 pg/mL reconstituted in sample buffer.  After sample/standard incubation, wells 
were again rinsed 3 times with wash buffer. Wells were then treated with 100 μL of biotinylated goat 
anti-human HGF-R/c-Met detection antibody (100 ng/mL), and allowed to incubate for 2 hours at room 
temperature.  After detection antibody, the wells were washed 3 times with wash buffer, and then 
immediately treated with 100 μL of streptavidin-conjugated horseradish peroxidase enzyme for 20 
minutes at room temperature.  After 20 minutes, wells were treated with 100 μL of substrate solution (1:1 
ratio of hydrogen peroxide and tetramethylbenzidine) for another 20 minutes at room temperature.  After 
substrate solution, wells were treated with stop solution (2 N sulfuric acid), and then imaged for optical 
density using a microplate reader. 
 
3.2.8. Quantifying Total c-Met Expression 
To quantify total c-Met expression, ELISA plates were analyzed by a microplate reader (VICTOR3TM 
Wallac 1420 Multilabel Counter, manufactured by Perkin Elmer®, Waltham, MA; #1420-011) to 
determine the optical density of wells at both 450 nm and 540 nm wavelengths.  To correct for optical 
imperfections in the plate, the 540 nm readings were subtracted from the corresponding 450 nm readings.  
As recommended by the manufacturer, a standard curve was established by plotting the log of the seven-
point HGF-R/c-Met standard concentrations versus the log of the corresponding corrected optical 
densities, and a linear best fit line was determined by regression analysis.  Assuming a good fit, the 
equation for the best fit line of the standard curve was used to back-calculate the concentration of total c-
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Met detected in each sample well.  Concentrations for each well were then normalized to the dilutions of 
each sample, which were required to bring each of the sample volumes to 100 μL during the ELISA 
procedure.  Total c-Met expression was presented in ng/mL concentrations, and samples were compared. 
 
3.2.9. Statistics 
Data are reported as mean ± standard error of the mean as multiple observations were made for each 
sample.  For growth kinetics experiments, differences between groups at each time point were determined 
using a Student’s unpaired t-test with significance established for p-values ≤ 0.05.  For total c-Met 
expression, differences between groups were determined by one-way analysis of variance (ANOVA).  A 
post hoc Tukey test was then used to perform multiple pair-wise comparisons.  Differences were 
considered significant for p-values ≤ 0.05. 
 
3.3. Results  
3.3.1. Effects of reduced-O2 on hMSC growth kinetics 
By tracking and comparing the population doublings (PDs) of hMSCs grown in normal-O2 and 
reduced-O2 over time, we examined the effect of reduced-O2 conditioning on the growth kinetics of 
hMSCs.  Cells were cultured as indicated in the methods and PDs were calculated over a number of 
passages, until senescence of the hMSCs in their respective O2 conditions.  By calculating the cumulative 
PDs over each passage, we found normal-O2 hMSCs expanded by an average 7.35 ± 0.53 PDs by passage 
11 (Figure 3.1A).  Normal-O2 hMSCs reached peak exponential growth by passage 8, with slight 
increases in PDs before senescence at passage 11 or 12.  However, reduced-O2 hMSCs expanded by an 
average 17.27 ± 1.78 PDs by passage 16, reaching peak exponential growth by passage 14 or 15.  In 
addition, cells cultured in reduced-O2 hMSCs had significantly higher cumulative PDs compared to 
normal-O2 hMSCs from passage 5 through passage 12, indicating a marked difference in population 
expansion over the same time course.  Furthermore, reduced-O2 hMSCs continued expanding well 
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beyond passage 12 (past the point of comparison to normal-O2 hMSCs), indicating an increase in 
longevity or delay in senescence.  
By analyzing the individual PDs at each passage, it is possible to analyze trends in growth rate for 
both oxygen conditions from one passage to another.  PDs were highest for both normal-O2 and reduced-
O2 hMSCs at passage 3, which declined for both oxygen conditions over successive passages (Figure 
3.1B).  The rate of PD decline was more rapid for normal-O2 hMSCs, with sustained growth between 
passages 4 and 6, and then a significant decrease at passage 7.  Reduced-O2 hMSCs appeared to respond 
to their environment for a slight increase in PDs between passages 4 and 7, with sustained growth 
between passages 8 and 12, with a steady decline over passages 13-16.  While both oxygen conditions 
showed a drop in PD after passage 3, the normal-O2 PD decline is more rapid than reduced-O2 PDs.  
Highlighting this difference, reduced-O2 PDs trend upward from passage 5 to passage 7, and reduced-O2 
PDs are significantly higher than normal-O2 PDs at passages 5, 6, 7, and 8.  Reduced-O2 hMSCs continue 
doubling well past normal-O2 senescence at passage 11, and reduced-O2 conditioning appears to sustain a 
steady growth rate of hMSCs for a significantly longer period of time (Figure 3.1). 
 
3.3.2. Effects of reduced-O2 on total c-Met expression 
Previous analyses for the effects of reduced-O2 conditioning on c-Met expression in hMSCs have 
used qualitative methods to study the effect in short periods of exposure.1,11  We improved upon these 
studies by quantifying total c-Met expression by ELISA over a time-course of 14 days (normalizing total 
c-Met expression to total protein for each sample).  Quantitative measures allowed for statistical analysis 
to determine real differences among compared groups.  First, we quantified c-Met from hMSCs that had 
been conditioned in reduced-O2 for 1, 3, 7, 10, or 14 days (Figure 3.2).  Trends indicated a steady 
expression of c-Met from day 1 (34.51 ± 5.12 ng/mL, n=6) to day 3 (35.22 ± 9.87 ng/mL, n=13).  
However, there was a sharp increase in c-Met by day 7 (85.46 ± 23.18 ng/mL, n=9), which was nearly 2.5 
times the expression found at day 1.  Total c-Met expression was sustained out to day 10 (77.86 ± 
21.31ng/mL, n=11), but then decreased to baseline levels by day 14 (34.90 ± 5.22 ng/mL, n=8).  Total c-
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Met expression at days 7 and 10 were both significantly higher than days 1, 3, or 14 (p < 0.01), but there 
was no significant difference in expression between day 7 and day 14.  In addition, there was no 
significant difference in c-Met expression at days 1, 3, or 14 (Figure 3.2). 
Based on the results for expression of c-Met in hMSCs conditioned in reduced-O2, we narrowed our 
time-frame for analyzing c-Met in hMSCs cultured in normal-O2 to include days 3, 7, and 10 (Figure 3.3).  
Trends indicated a relatively low expression of c-Met at day 3 (24.53 ± 8.70 ng/mL, n=6), followed by a 
sharp c-Met increase at day 7 (52.41 ± 10.69 ng/mL, n=8).  Day 10 expression (33.88 ± 4.64 ng/mL, n=3) 
showed a decrease in c-Met from day 7.  Statistical analysis showed that c-Met expression at day 7 was 
significantly higher than both days 3 and 10 (p < 0.01), and that there was no significant difference in 
expression between days 3 and 10. 
In a comparison between c-Met expression levels of hMSCs conditioned at either reduced-O2 or 
normal-O2, the trend of a significant increase at day 7 and a tapered decline at day 10 is observed in both 
groups (Figure 3.4).  In comparison of both conditions at day 3, reduced-O2 hMSCs appeared to show 
more c-Met expression, but statistical analysis showed there was no significant difference between 
reduced-O2 and normal-O2 hMSCs.  There was a significant increase of c-Met expression in reduced-O2 
hMSCs compared to normal-O2 hMSCs at days 7 and 10 (p < 0.01).  At day 7, reduced-O2 c-Met 
expression (85.46 ± 23.18 ng/mL, n=9) was over 1.5 times as much as normal-O2 c-Met expression 
(52.41 ± 10.69 ng/mL, n=8).  At day 10, reduced-O2 c-Met expression (77.86 ± 21.31ng/mL, n=11) was 
over 2 times as much as normal-O2 c-Met expression (33.88 ± 4.64 ng/mL, n=3). 
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Figure 3.1. Effects of oxygen concentration on hMSC growth kinetics.  (A) Conditioning hMSCs in reduced-O2 
significantly increased cumulative population doublings from passage 5 to passage 12, and extended proliferative 
capacity out to passage 16.  (B) Both oxygen conditions caused a decrease in hMSC doubling at passage 4.  Normal-
O2 hMSCs showed a short-term maintenance of doubling rate to passage 6, followed by a sharp decline to passage 8.  
Reduced-O2 hMSCs adapted for a gradual increase in doubling rate to passage 7, and then a prolonged decline in 
doubling rate to passage 16.  Differences were evaluated using a Student’s unpaired t-test at each passage, and were 
considered significant for p-values ≤ 0.05.  Error bars indicate standard error. 
 
 
 
 
Figure 3.2. Total c-Met expression of hMSCs cultured in reduced-O2 over a period of days.  Total c-Met 
expression was compared for hMSCs cultured in reduced-O2 for 1, 3, 7, 10, and 14 days.  Total c-Met expression 
was steady between day 1 (n=6) and day 3 (n=13).  Reduced-O2 conditioning of hMSCs significantly increased total 
c-Met expression at day 7 (n=9).  Increased c-Met persisted at day 10 (n=11), and then decreased back to baseline by 
day 14 (n=8).  Differences were evaluated across different time points, using a one-way ANOVA with a Tukey post-
hoc test, and were considered significant for p-values ≤ 0.05.  Error bars indicate standard error.  Samples were 
normalized to total protein. 
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Figure 3.3. Total c-Met expression of hMSCs cultured in normal-O2 over a period of days.  Total c-Met 
expression was compared for hMSCs cultured in normal-O2 for 3, 7, and 10 days.  Expression of total c-Met 
significantly increased from day 3 (n=6) to day 7 (n=8), and then decreased back to baseline by day 10 (n=3).  
Differences were evaluated using a one-way ANOVA with a Tukey post-hoc test, and were considered significant 
for p-values ≤ 0.05.  Error bars indicate standard error. 
 
 
 
Figure 3.4. Comparing total c-Met expression of hMSCs cultured in reduced-O2 versus normal-O2.  In a 
comparison of the data, both oxygen conditions significantly increased total c-Met expression at day 7.  However, 
the increased total c-Met in reduced-O2 conditions was significantly higher than the increased total c-Met in normal-
O2.  Both oxygen conditions also caused a decline of c-Met expression after day 7.  However, reduced-O2 could 
sustain elevated c-Met expression through day 10.  Differences were evaluated using a one-way ANOVA with a 
Tukey post-hoc test, and were considered significant for p-values ≤ 0.05.  Error bars indicate standard error. 
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3.4. Discussion 
In consideration of the lower physiological oxygen tensions in both the bone marrow niche and the 
myocardial infarct microenvironment, studying how marrow-derived hMSCs respond in low oxygen 
concentrations may be of great importance for better understanding the innate properties of hMSCs and 
how they will respond in oxygen deprived tissues.  More important to our overall goal of using hMSCs as 
a cell therapy to regenerate the injured heart, delivered cells must be able to endure the transition from the 
“normal”/atmospheric 20% O2 to a much lower oxygen tension of 0.4-1.7% O2.  Studies in cellular 
homeostasis with respect to reduced-O2 and hypoxic environments have shown that decreases in O2 
availability will increase cellular acidosis, oxidative stress, and reactive oxygen species; all of which 
impair normal cell biology and decrease viability.18-22  Therefore, it is likely that hMSCs cultured at 20% 
O2 in vitro will undergo significant physiological duress when transplanted into the reduced-O2 
environment of an infarct, which would hinder their longer-term survival, retention, and therapeutic 
function in vivo.  By culturing hMSCs in reduced-O2 in vitro prior to transplantation into MIs in vivo, it 
may be possible to condition cells to develop the appropriate machinery or functionality to adequately 
adapt to oxygen deficient tissues.20-22 
Several groups have begun to study the effects of culturing hMSCs in reduced-O2 conditions, finding 
that various reduced-O2 concentrations and exposure durations can cause changes in several physiological 
processes such as growth kinetics, cell signaling, growth factor secretion, and therapeutic potential.1,2,9,11  
However, discrepancies in the literature and an incomplete understanding of reduced-O2 effects lends to 
the argument that more research is necessary to learn how hMSCs respond in oxygen poor environments, 
to possibly uncover untapped mechanisms that may improve cell survival or cardiac differentiation.  The 
goal of this study was to investigate the growth kinetics and c-Met expression of hMSCs after being 
cultured in a controlled reduced-O2 conditioning system, to understand how prolonged reduced-O2 
exposure effects hMSC proliferation and the expression of a receptor believed to enhance cardiogenic 
differentiation.16,17  A reliable reduced-O2 culturing environment was implemented in the laboratory, 
using a dedicated incubator with a controlled system that regulated the gas composition for 2% O2.  With 
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the exception of feeding and passaging periods, this system allowed for constant reduced-O2 exposure 
ideal for longer-term studies and for comparisons to 20% O2 cultured hMSCs.  Growth kinetics were 
evaluated by calculating and compiling population doublings (PDs) over successive passages.  Total c-
Met expression was determined as a function of concentration, calculated by measurements of optical 
density by means of ELISA. 
The results of our growth kinetics study indicate that prolonged conditioning in 2% O2 significantly 
increased hMSC PDs from 7.35 ± 0.53 to 17.27 ± 1.78 (p < 0.01; Figure 3.1A).  In addition, 2% O2 
conditioning sustained hMSC growth to passage 16 versus only passage 12 in 20% O2, with significantly 
higher cumulative population doublings between the two oxygen conditions from passage 5 to passage 12 
(p < 0.01; Figure 3.1A).  Overall, our results are consistent with previous studies that indicate 2% O2 can 
increase hMSC growth kinetics with prolonged reduced-O2 conditioning.3,4  We designed our study with 
similar parameters as these previous studies with respect to O2 concentration, feeding regimen, and 
passaging times; however, we calculated population doublings as a more definitive indicator of fold-
expansion, and we continued our study until the cells in both O2 concentrations reached senescence.  Our 
analysis further suggests that long-term conditioning in 2% O2 can increase hMSC proliferation and 
extend their longevity, which could be further confirmed by cell cycle analysis and molecular 
characterization in future studies.  Cell cycle analysis would help to determine if the reduced-O2 
conditioning caused more hMSCs to enter the S-phase, or caused hMSCs to complete the cell cycle at a 
faster rate, or generated a sub-population of highly proliferative hMSCs.  Molecular characterization may 
help to determine if additional factors such as increased cytokine/paracrine signaling or telomerase 
activation is responsible for the increased proliferation. 
On a critical note, our results may also be consistent with previous studies that indicate short-term 
exposure to reduced-O2 may decrease hMSC growth kinetics.6,23  After only 7 days in culture at passage 
3, hMSCs in 20% O2 showed significantly more growth with 2.67 ± 0.02 PDs compared to hMSCs in 2% 
O2 with only 2.46 ± 0.03PDs (p < 0.01, Figure 3.1 A and B).  Additionally, our results show that reduced-
O2 conditioned hMSCs may undergo a prolonged lag phase between passages 3 and 5, before showing a 
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significantly higher PD compared to normal-O2 hMSCs at passages 5 through 12 (Figure 3.1B).  This 
prolonged lag phase has also been acknowledged by another study that shares our findings that longer-
term reduced-O2 conditioning increases hMSC growth kinetics.3  These differences in our own results 
illustrate how the length of reduced-O2 exposure duration can affect the interpretation of how reduced-O2 
affects hMSC growth kinetics.  However, it appears that the initial exposure to 2% O2 may cause a 
decrease or lag in hMSC growth, but prolonged reduced-O2 conditioning can significantly increase the 
growth of hMSCs for a significantly longer period of time.  Observational assessment of the cells did not 
indicate an increase in cell death during the lag phase in reduced-O2 culture, but cell viability assays were 
not performed during this period.  Response mechanisms involved in the lag phase, growth phase, or 
“switch” between phases remains unknown.  It also remains unclear whether the effects in growth kinetics 
are a positive response to a MSC-niche oxygen environment or a stress response to low oxygen tension. 
What is clear about our observations is that hMSCs need time to respond to the reduced-O2 
environment, and hMSCs appear to thrive in reduced-O2 once they have adapted accordingly.  Therefore, 
it is likely that hMSCs cultured at 20% O2 in vitro are unequipped and unprepared to respond to reduced-
O2 conditions when transplanted into MIs in vivo, which contributes to their poor survival.  Conditioning 
hMSCs in reduced-O2 in vitro prior to implantation may allow them to develop the appropriate cellular 
machinery with which to adapt more readily to the reduced-O2 environment of an MI.  Concomitantly, 
our observations suggest that reduced-O2 conditioning can dramatically increase the sheer number of 
hMSCs, as we saw the PDs increase from 7.35 ± 0.53 to 17.27 ± 1.78.  This provides new optimism for 
expanding hMSCs for their use as a potential cell therapy to replace the estimated 1 billion 
cardiomyocytes lost during an MI (Figure 3.5). 
The results of our total c-Met expression study indicate that continued exposure in 2% O2 can 
significantly increase c-Met expression in hMSCs (Figures 3.2 and 3.4).  Analysis of a time-course study 
on reduced-O2 conditioned hMSCs found that c-Met expression remained fairly constant from day 1 to 
day 3, but then significantly increased at day 7.  Increased c-Met expression was maintained through day 
10, but then significantly decreased by day 14.  These data suggest that the duration of reduced-O2 
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exposure may play a role in regulating c-Met expression levels in hMSCs, with a significant upregulation 
between days 3-10. 
To further understand reduced-O2 effects on c-Met expression, we also performed a condensed time-
course study on normal-O2 conditioned hMSCs to evaluate the c-Met expression profile within the 3-10 
day timeframe (Figures 3.3 and 3.4).  Normal-O2 conditioned hMSCs expressed relatively low levels of c-
Met at day 3, a significant increase of c-Met at day 7, and then a significant decrease of c-Met by day 10.  
These results indicate that normal-O2 conditioned hMSCs show a similar c-Met expression profile 
compared to reduced-O2 conditioned hMSCs.  Both conditions show low expression before day 7, a 
significant increase of expression at day 7, and then a decrease in expression after day 7.  However, 
reduced-O2 conditioned hMSCs appear to sustain high levels of c-Met expression from day 7 to day 10 
before dropping off at day 14, and normal-O2 conditioned hMSCs show a significant decrease in c-Met by 
day 10. 
In comparing the c-Met expression levels of hMSCs conditioned in both oxygen concentrations at 
these three time points, reduced-O2 hMSCs showed significantly more c-Met expression than normal-O2 
hMSCs at days 7 and 10, but not at day 3 (Figure 3.4).  As a whole, our analysis indicates that culturing 
hMSCs for 7 days in either oxygen condition can increase c-Met expression; however, reduced-O2 
conditioning elicits significantly more c-Met expression compared to normal-O2 conditioning at 7 days.  
In our analysis, samples were normalized to total protein to compare different batches of cells across 
controlled time points; therefore, results do not reflect c-Met concentrations based on total cell number or 
cell confluence.  During sample collection, cells were trypsinized from culture flasks to prepare total cell 
lysates.  To our knowledge, after a thorough literature search, the trypsinization process does not appear 
to remove or detriment the integrity of the c-Met receptor.  However, it is unclear whether the increase in 
c-Met corresponds with cells entering a particular phase of the cell cycle.  While a direct link between cell 
cycle and c-Met expression has not been established, it has been reported that HGF can act as a potent 
mitogen in some cell types (e.g. neuronal and endothelial cells),24,25 and that HGF signaling may help to 
mediate c-Met expression in a positive feedback loop.26  
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In further consideration, while we did not find statistical difference in c-Met expression at day 3 for 
hMSCs cultured in normal-O2 (24.53 ± 8.70 ng/mL) or reduced-O2 (35.22 ± 9.87 ng/mL).  Previous 
studies have argued that culturing hMSCs in reduced-O2 increases c-Met expression after exposure 
durations of only 16-72 hours, using qualitative techniques such as Western blotting and densitometry.1,11  
However, our quantitative analysis suggests that there is no statistical difference in c-Met expression at 
these early time points, and that true differences in c-Met expression are only realized at longer 
conditioning durations.   
In considering the role of HGF/c-Met signaling for the activation of cardiac differentiation pathways, 
our results suggest that we can leverage reduced-O2 conditioning to increase c-Met expression, which 
may allow for increased HGF/c-Met interaction and downstream cardiac-pathway activation.  Significant 
increases of c-Met expression at days 7 and 10 suggest that there may be a finite window of opportunity 
for using HGF to initiate the cardiac program in hMSCs.  Optimal timing is a common theme for 
scientists who study cardiac differentiation strategies in all stem cell types, regardless of chemical or 
mechanical induction methods.  Based on the results of this study, we incorporated a 7 day reduced-O2 
culturing period into our conditioning regimen, prior to HGF treatment for the induction of cardiac 
differentiation.   
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Figure 3.5. Cardiogenic cell expansion in reduced-O2 conditions.  In consideration of our results showing that 
reduced-O2 conditioning can significantly increase hMSC growth kinetics, it may be possible to leverage these 
effects for the expansion of cardiogenic cells.  During a typical initial seeding, 500,000 hMSCs are plated in a T-75 
flask.  As a conservative estimate, a strategy or conditioning regimen allowing for 10% cardiac differentiation would 
produce 50,000 cardiogenic cells.  If the sub-population of cardiogenic cells could be purified and expanded over 15 
doublings in reduced-O2, it may be possible to produce over 1.5 billion cardiogenic cells. 
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CHAPTER 4: Effects of reduced-O2 and HGF on expression of cardiac-specific markers in hMSCs 
4.1. Introduction 
Since the 1990’s, bone marrow derived cells have been studied extensively for their multipotent 
ability to become a number of different cell types for therapeutic tissue regeneration applications.1-5  
Based on these early successes of using bone marrow cells (BMCs) in a variety of organ systems, there 
was a natural progression to explore the use of these cells for cardiac therapy.  Orlic et al.’s seminal study 
in 2001 isolated Lin-/c-kit+ BMCs from male GFP-transgenic mice and delivered them to MIs in female 
mice to show a significant increase in ventricular function.6  Most notably, they also tracked the male 
GFP-labeled cells and found that delivered BMCs expressed cardiac-specific markers such as cardiac 
myosin, MEF2C, and Nkx2.5 in vivo.  From their results, they concluded that delivered BMCs could 
regenerate new myocardium, which contributed to the increases they observed in ventricular function.  
The study sparked optimism that BMCs could be used as a cardiac cell therapy to regenerate diseased 
myocardium, which evoked enormous scientific interest from researchers in the field.  The study also 
sparked controversy as some researchers could not reproduce Orlic et al.’s findings,7,8 while others 
reported measured successes showing BMCs could partially differentiate towards a cardiac lineage in 
vitro,9-17 express cardiac-specific markers in vivo,13,18-20 and improve cardiac function.13,18,20-25 
After Orlic et al.’s landmark study, there was a strong focus from the scientific community to 
determine mechanisms that would transdifferentiate BMCs into cardiomyocytes in vitro.  There were 
several reasons for these efforts.  One major concern was that BMCs were a mixed population of cells 
that contained a variety of multipotent cells capable of differentiating into alternative cell types such as 
osteocytes and adipocytes,26 which would be extremely detrimental in the cardiac environment.  The 
prospect of differentiating BMCs to a cardiomyocyte lineage in vitro and then separating the generated 
cardiomyocytes from the mixed batch of cells for a more pure population was a goal to alleviate this 
safety concern.  In addition, many were eager to differentiate BMCs into mature, functional 
cardiomyocyte phenotypes in vitro, in order to study electrophysiological and mechanical properties of 
the newly generated cardiomyocytes. 
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In the effort to transdifferentiate BMCs to cardiomyocytes in vitro, several strategies or combinations 
of strategies were investigated.  Some groups isolated subpopulations of BMCs such as c-kit+ cells,9 
marrow stromal cells,11,12 and mesenchymal stem cells (MSCs)10,15,16,20,27 prior to treatment, hoping to 
select for a population of BMCs that were more apt for cardiac differentiation.  In addition, some groups 
used co-culture strategies with rat neo-natal cardiomyocytes to show that a low percentage of marrow-
derived cells could partially differentiate towards a cardiomyocyte lineage by expressing cardiac-specific 
markers9,12,14 and displaying inward rectifying currents9.  Other groups have experimented with cytokine 
treatments (i.e. retinoic acid, TGF-β, FGF-2, HGF, and PDGF) to show partial cardiac differentiation by 
gene and protein expression.16,17,28  Treatment of marrow stromal cells with the DNA demethylation agent 
5-azacytidine induced about 30% differentiation, showing cardiac marker expression, propagation of 
action potentials, and spontaneous contraction.11  Some studies have combined co-culture with rat neo-
natal cardiomyocytes with cytokine treatments such as BMP4/TGF-β, 9 dimethyl sulfoxide,14 or 5-
azacytidine14 to show little or no effect on cardiac differentiation.  Our lab has used mechanical 
manipulation to make hMSC spheroids, which shows that 57% of the hMSCs can differentiate towards a 
cardiac lineage detected by sarcomeric α-Actinin expression within 2 weeks (Figure 4.1).13  Patch-
clamping analysis of our “cardiogenic” cells indicate that 16% of the differentiated hMSCs display large 
L-type Ca2+ currents, indicating that some of the differentiated hMSCs may be capable of producing 
cardiac-specific action potentials.13  The combination of cardiac protein expression and L-type Ca2+ 
currents suggest that these cells are partially differentiated to a cardiac lineage, but are not fully 
differentiated cardiomyocytes. 
Despite these successes, the current BMC and MSC differentiation techniques are insufficient 
because only a low percentage of cells differentiate and only partial differentiation has been achieved.  
Co-culture experiments can be problematic because of the challenging nature of trying to extract out the 
differentiated marrow-derived cells from the mix of rat neo-natal cardiomyocytes and undifferentiated 
cells.  On a related note, the characterization of differentiated marrow-cells in co-culture experiments has 
come under scrutiny, questioning whether “new” cardiomyocytes can be fully distinguished from neo-
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natal cardiomyocytes.  Cytokine treatments try to apply factors previously described in the developmental 
or embryonic literature, but the methods of application range dramatically.  Some groups use a “kitchen 
sink” approach,28 while others use a more limited approach with finite concentrations and arbitrary time 
points.  Unfortunately, most cytokine treatments have resulted in low-percentage cardiac differentiation, 
with only a limited number of cardiac genes and proteins being evaluated.  Methods using 5-azacytidine 
are problematic because the chemical inhibits methyltransferases, which decreases DNA methylation in 
an uncontrolled manner, affecting DNA replication and RNA transcription in a random fashion with 
unpredictable results.29  Mechanical differentiation techniques often require tedious techniques that 
demand skillful implementation.  For instance, our spheroid method uses a tedious hanging-drop 
technique (Figure 4.1, A), in which hanging cell suspensions must be carefully manipulated and fed for 
three days before being plated for cellular outgrowth.  Unfortunately, mechanical manipulation methods 
have also shown low-percentage cardiac differentiation, with a limited breadth of marker expression and 
only a small percentage of cells showing L-type calcium-channel currents. 
For the purpose of exploring novel methods that will initiate cardiac-specific differentiation of 
hMSCs and improve upon current limitations,30 we developed a simplistic in vitro conditioning regimen 
based on aspects described in the MSC literature.  As discussed in Chapter 3, some studies report that 
reduced-O2 conditioning can increase MSC differentiation potential,31-33 and we have shown that 
conditioning hMSCs in reduced-O2 for 7 days can significantly increase the expression of the c-Met 
receptor.  The c-Met receptor is a disulfide-linked heterodimeric transmembrane protein encoded by the 
c-met proto-oncogene,34 which exhibits tyrosine-kinase activity to recruit different signal transducers and 
adaptors that have been shown to affect ERK/MAPK and PI3K.16  Although the c-Met receptor was 
originally discovered in a chemical-carcinogen treated osteogenic sarcoma cell line in 1984,35 c-Met was 
only recently discovered in hMSCs in 2004.36  The c-Met receptor only elicits intracellular signaling for 
biological processes when it interacts with hepatocyte growth factor (HGF). 
HGF is a pleiotropic cytokine involved in a number of biological processes in embryogenesis and 
organ system maintenance.  HGF has been shown to be involved developmental processes in kidney 
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tubulogenesis,37 angiogenesis,38 and mammary gland formation.39  In addition, HGF can affect motility 
and morphogenesis of endothelial cells,40 act as a chemoattractant for both motor neuron axons41 and 
myoblast precursors,42 and play a role in kidney and liver regeneration.43,44 In cardiac applications, HGF 
has been shown to be involved in developmental cardiogenesis,45 and has shown cardioprotective effects 
in ischemic myocardium.46  With respect to cardiac differentiation, Roggia et al. found that HGF can 
increase cardiac marker expression of cardiomyocyte-differentiated embryonic stem cells, and increase 
the number of beating embryoid bodies.47  In addition, Forte et al. suggest that treating mouse MSCs with 
human HGF can induce cardiac gene and protein expression.16  Both studies suggest that HGF/c-Met 
signaling activates the downstream effectors phophatidylinositol 3-kinase (PI3K) and Akt, which activate 
cardiac transcription factors to initiate a cardiac program (Figure 4.2). 
We hypothesize that employing a conditioning regimen of reduced-O2 culturing and HGF treatment 
will have a combined effect to express cardiac-specific markers in hMSCs in vitro.  In Chapter 4, we will 
investigate the expression of cardiac genes and proteins in reduced-O2/HGF treated hMSCs.  Based on 
our rationale and analysis in Chapter 3, we used our 2% O2 culturing system to implement the reduced-O2 
component in our combined conditioning regimen.  Studies focusing on HGF/c-Met signaling and cardiac 
differentiation of hMSCs have previously used HGF concentrations in the range of 20-25 ng/mL.16,48  And 
based on the previous study using human HGF to induce cardiac marker expression in mouse MSCs,16 we 
supplemented DMEM/L-Glutamine medium with 20 ng/mL human HGF in our combined conditioning 
regimen. To our knowledge, the effects of a combined reduced-O2/HGF conditioning regimen on cardiac 
marker expression in hMSCs have not been reported. 
 
4.1.1. Determining the effect of reduced-O2/HGF conditioning on cardiac gene transcription of 
hMSCs in vitro 
Based on the literature for developmental cardiomyogenesis and embryonic stem cells, cardiac gene 
induction can occur within the first 3 to 7 days of differentiation.47,49-51  However, a definitive 
understanding of the order and timing of signaling events, transcription factor interaction, and regulatory 
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mechanisms required for cardiac differentiation of embryonic stem cells is still unknown.  The processes 
involved in the cardiac differentiation in MSCs are even more equivocal.  However, based on the previous 
MSC studies showing partial cardiac differentiation and the developmental biology literature regarding 
the interaction of cardiac transcription factors, we have pieced together a basic pathway for the role of 
HGF/c-Met signaling in cardiomyogenesis (Figure 4.2). 
To determine the effect of reduced-O2/HGF conditioning on the cardiac gene expression of hMSCs in 
vitro, we investigated treated hMSCs for the expression of gene transcripts corresponding with factors 
outlined in our basic cardiac pathway.  To do this, cells were first cultured in reduced-O2 for 7 days to 
increase c-Met expression, then treated for another 7 days with 20 ng/mL human HGF before being 
harvested for total RNA isolation.  cDNA was then synthesized from mRNA, and then cardiac-specific 
gene expression was detected by reverse transcription polymerase chain reaction (RT-PCR). 
The DMEM/HGF treatment media differs from traditional media used to culture hMSCs, which is 
typically a growth medium consisting of a DMEM/L-Glutamine base supplemented with 10% fetal 
bovine serum.  The growth medium we used is a proprietary formulated mesenchymal stem cell growth 
medium (MSCGM; Lonza Inc.).  Although some studies have indicated that cells can have unique 
responses when cultured in low-serum or serum-deprived media, the DMEM/HGF treatment we chose 
helps to assure that the changes we observe are HGF dependent. 
In order to better understand the effects of our reduced-O2/HGF treatment, we had to consider the 
differences in oxygen concentration, HGF supplementation, and serum deprivation.  To parse out the 
effects of these different treatment factors, we formulated 6 treatment conditions that were tested in an 
initial screen for gene expression of key cardiac genes (MEF2C, Nkx2.5, GATA-4, sarcomeric α-Actinin, 
and CaCNA1C).  The formulated treatment groups used in our initial screen are outlined in Table 4.1. 
For further characterization, we then screened reduced-O2/HGF conditioned hMSCs for a more 
inclusive set of cardiac genes with unique primers for myosin heavy chain, myosin light chain, troponin, 
and additional L-type calcium subunits.  Having already parsed the effects of oxygen concentration and 
media treatments in our initial panel of cardiac genes, we limited our treatment comparisons in this 
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experiment.  For further analysis, we compared only reduced-O2/HGF conditioned hMSCs and 
traditionally cultured hMSCs, grown in normal-O2 with growth media (MSCGM). 
 
4.1.2. Determining the effect reduced-O2/HGF conditioning on cardiac protein translation of 
hMSCs in vitro 
To complement the results for cardiac gene transcription, we investigated the effects of reduced-
O2/HGF conditioning on the cardiac protein expression of hMSCs in vitro.  We hypothesized that only a 
sub-population of reduced-O2/HGF conditioned hMSCs may express cardiac proteins, and we were also 
interested in visualization the localization of protein expression in differentiating cells.  Therefore, we 
used immunocytochemistry (ICC) as a more appropriate method to detect low protein expression (either 
due to low expression across the cell field, or only a small percentage of cells expressing protein), which 
may be undetectable by Western blot analysis on large batches of cells. 
In this experiment, we used 2 formats to accommodate the ICC protocols established in the Gaudette 
Lab.  Cells were seeded onto either 24-well plate tissue culture plastic, or sterile glass coverslips that were 
pre-fitted into 24-well plates.  Cells were conditioned as previously described in our cardiac gene analysis 
(Section 4.1.1) before being fixed.  Cells were fixed in cold methanol (stored in -20ºC) and ICC was 
performed using cardiac-specific primary antibodies for MEF2C, Nkx2.5, GATA-4, sarcomeric α-
Actinin, and Cav1.2 (L-type calcium channel marker).  Then appropriate specific fluorescent secondary 
antibodies were applied.  Cells were then counterstained for Hoechst 33342 nuclear dye, and analyzed by 
fluorescence microscopy for expression and subcellular localization.  In this analysis, we limited our 
treatment comparisons to include only reduced-O2/HGF conditioned hMSCs and traditionally cultured 
hMSCs, grown in normal-O2 with growth medium. 
 
4.1.3. Evaluating the role of HGF/c-Met signaling on cardiac marker expression 
To further assess our hypothesis that HGF/C-Met signaling is involved in the activation of 
downstream cardiac-marker expression in hMSCs, we investigated two possible control mechanisms in 
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our proposed pathway (Figure 4.2).  Previous studies suggest HGF/c-Met signaling activates different 
adapter proteins (e.g. Gab-1, SHC, and GRB2) to activate effectors such as PI3K and Akt, which further 
activates downstream cardiac transcription factors such as MEF2C, Nkx2.5, and GATA-4 to initiate 
cardiac differentiation.16,47  To test this, we treated reduced-O2/HGF conditioned hMSCs with two 
independent small-molecule inhibitors to evaluate their effects on downstream cardiac gene transcription. 
In this study, we tested small-molecule inhibitor PHA-665752, which has previously been shown to 
inhibit c-Met phosphorylation and decrease c-Met dependent cell processes such as motility and 
proliferation.52,53  Independently, we also tested small-molecule inhibitor LY294002, which has 
previously been shown to completely inhibit PI3K by competitively inhibiting its ATP binding site.54  
LY294002 has been used on several cell types including stem cells to show complete but reversible 
inhibition of PI3K, subsequent dephosphorylation of downstream effectors such as Akt, and loss of PI3K-
dependent cellular activity.33,47,54-56 
Both small-molecule inhibitors were tested separately with concentrations comparable to those 
reported in the literature.  Inhibitor treatments were applied to cells for 2 hours before the addition of 
HGF (20 ng/mL).  This treatment process was repeated every 24 hours for 7 days.  On the 7th day, cells 
were harvested for RNA isolation, cDNA synthesis, and RT-PCR analysis for cardiac-specific genes. 
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Figure 4.1. Cardiogenic cells differentiated from hMSC spheroids.  (A) We previously used the hanging drop 
technique to form hMSC spheroids.  Cell suspensions were hung from petri dish lids and fed every 24 hours from 
day 0 to day 3.  By day 3, hMSCs aggregated to form spheroids, which were then plated onto tissue culture surfaces.  
Spheroids were cultured for cellular outgrowth for 7-10 days after plating.  (B) Some of the cells growing out from 
the spheroid showed to be cardiogenic cells, characterized by positive expression of cardiac-specific proteins 
sarcomeric α-Actinin (green) and troponin T (red), as well as L-type calcium channel currents (figure modified from 
Rosen et al. Stem Cells, 2007; complete data shown in this manuscript).57 
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Figure 4.2.  Proposed signaling pathway for HGF/c-Met involvement in the cardiac differentiation program.  
Based on previous studies regarding HGF/c-Met signaling on effector proteins, as well as signaling mechanisms 
involved in developmental and stem cell cardiomyogenesis, we propose the above pathway for how HGF/c-Met 
signaling can initiate or contribute to the cardiac program in hMSCs.   
 
 
 
 
 
 
Table 4.1.  Table of conditioning regimens.  MSCGM (Mesenchymal Stem Cell Growth Media; proprietary 
formulation from Lonza, Inc.); DMEM (Dulbecco’s Modified Eagle’s Medium); FBS (fetal bovine serum); HGF 
(hepatocyte growth factor).  Reduced-O2/HGF conditions highlighted in yellow, other listed conditions tested as 
controls. 
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4.2 Materials and Methods 
4.2.1. Human mesenchymal stem cell culture 
Human mesenchymal stem cells (hMSCs) isolated from adult bone marrow were purchased from 
Lonza, Inc. (Walkersville, MD; # PT-2501).  Cryo-preserved vials arrived as passage-2 hMSCs, which 
had been pre-characterized by the manufacturer (Appendix A).  Upon thawing, hMSCs were plated as 
passage-3 with a seeding density of 500,000 cells per T-75 flask.  New vials were plated and expanded 
using mesenchymal stem cell growth medium (MSCGM; Lonza’s proprietary hMSC growth media, # PT-
3001).  Multiple flasks originating from the same vial were segregated to either normal-O2 (20%) or 
reduced-O2 (2%) conditions (as previously described in the Chapter 3).  Cells were maintained at 37°C, 
growth media was changed every 2 days, and cells were passaged when growth reached 80-90% 
confluency.  Successive cell-passages were maintained in their pre-designated oxygen concentrations, and 
passage 4-8 hMSCs were used for experimentation. 
 
4.2.2. Media Treatments 
Based on preliminary studies done on the c-Met receptor for HGF, media treatments were preceded 
by a 7-day growth period to increase c-Met expression.  Therefore, cells passaged for media treatment 
experimentation were initially seeded and cultured in MSCGM for 7 days in their respective O2 
concentrations, as described previously in the methods for hMSC culture (Section 4.2.1).  On the 7th day, 
MSCGM was removed, and appropriate media treatments were applied.  MSCGM groups received fresh 
MSCGM, DMEM groups received DMEM (with L-glutamine and 4.5 g/L glucose; Lonza, Inc.), and 
HGF groups received DMEM supplemented with 20 ng/mL human HGF (PeproTech, Rocky Hill, NJ; # 
100-39).  Treatment media was changed every 24 hours for another 7 days, and then cells were harvested 
or fixed for experimentation.  A treatment timeline is shown in Figure 4.3. 
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4.2.3. Inhibitor Treatment 
Small-molecule inhibitors were applied independently during the media treatment phase of our 
conditioning regimen (Figure 4.3).  Inhibitor media was made using DMEM supplemented with either 5 
µM PHA665752 (CalBiochem®, now part of EMD Chemicals, Philadelphia, PA; #448102) or 50 µM 
LY294002 (Gibco®, part of Invitrogen, Camarillo, CA; #PHZ1144).  Inhibitor media was made fresh at 
each application, and then applied to cells for 2 hours.  After 2 hours, an appropriate volume of HGF 
solution (Peprotech) was spiked into the applied inhibitor media to bring the HGF concentration to 20 
ng/mL.  This inhibitor treatment process was repeated every 24 hours, for 7 days. 
 
4.2.4. RNA Isolation 
RNA was isolated using a NucleoSpin® RNA/Protein total RNA and protein isolation kit (Macherey-
Nagel, Bethlehem, PA; # 740933).  Reagent preparation and RNA isolation were completed using the 
guidelines and protocols set by the manufacturer.  The kit was used to isolate RNA and protein from the 
same sample.  RNA purity was aided by filtration with a nucleic acid column, followed by rDNase 
treatment and a series of washes per the manufacturer’s protocol.  RNA samples were collected and 
stored at -80°C until processing. 
 
4.2.5. cDNA Synthesis 
Complementary DNA (cDNA) was synthesized using a SuperScriptTM First-Strand Synthesis System 
kit (Invitrogen, Carlsbad, CA; #11904-018).  All of the following reagents were prepared and supplied in 
the Invitrogen kit.  The kit is designed with SuperScriptTM II Reverse Transcriptase enzyme and 
RNaseOUTTM Recombinant RNase Inhibitor components, to reduce RNase H activity and safeguard 
against target RNA degradation.  To make cDNA, 5 μg of total RNA from each sample used.  Sample 
volume was combined with 0.5 mM dNTPs, 0.5 μg of Oligo(dT) primers, and RNase-free water for a 
total volume of 10 µL.  The mix was incubated at 65°C for 5 minutes, and then chilled on ice for 1 
minute.  A second reaction mix was prepared with 1X RT Buffer (20 mM Tris-HCl pH 8.4, 50 mM KCl), 
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5 mM MgCl2, 0.01 M DTT, and 40 units of RNaseOUTTM.  Chilled samples were treated with 9 μL of the 
second mix, and then incubated at 42°C for 2 minutes.  After 2 minutes incubation, 1 μL (50 units) of 
SuperScriptTM RT enzyme was added to each mix, and then placed back into 42°C for 50 minutes.  
Reactions were then terminated by incubating them at 70°C for 15 minutes.  After termination, reactions 
were chilled on ice and collected by brief centrifugation.  Prior to RT-PCR, all reactions were treated with 
1 μL (2 units) of RNase H and incubated at 37°C for 20 minutes. 
 
4.2.6. RT-PCR 
Gene transcription was detected by reverse transcription polymerase chain reaction (RT-PCR), using 
AccuStartTM Taq polymerase reagents from Quanta Biosciences (Gaithersberg, MD; # 95061-250), and 
deoxyribonucleotides (dNTPs) from Promega Corporation (Madison, WI; # C114G).  Each RT-PCR 
reaction mixture was prepared with 1x PCR Reaction Buffer (2.5 µL; Quanta Biosciences), 1.5 mM 
magnesium chloride (0.75 µL; Quanta Biosciences), 200 mM dNTPs (0.5 µL; Promega Corporation), 0.5 
units of Taq polymerase (0.1 µL; Quanta Biosciences), 10 pM primer solution (mixture of forward and 
reverse primers, custom made), 240 ng of sample cDNA, and enough RNase-free water to bring each 
reaction to a final volume of 25 µL (Gibco, Camarillo, CA; # 10977-015).  Preparations were run on a 
thermocycler for 30-35 cycyles. 
RT-PCR products were separated onto a 2% agarose gel by electrophoresis, and gene expression was 
determined by band detection at the appropriate size (bp) of the amplicon.  Qualitative analysis of gene 
expression was compared against the sample’s internal expression for glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and across treatments.  RT-PCR primers for cardiac-specific genes were either 
custom designed or adopted from previous studies (Table 4.2), to include genes for early-stage cardiac 
transcription factors, sarcomeric proteins, and L-type Ca2+ channel subunits.  All RT-PCR primers were 
specialty ordered through and manufactured by Eurofins MWG Operon (Huntsville, AL). 
Total RNA from human heart (Clontech, Mountain Veiw, CA; #636532) was synthesized for human 
cardiac cDNA using the same methods described above (Section 4.2.5).  Human cardiac cDNA provided 
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a positive control for cardiac gene expression, and was reported in all RT-PCR studies.  Negative, “no-
template” controls were included in all RT-PCR studies, but not reported. 
 
4.2.7. Immunocytochemistry 
For protein analysis by immunocytochemistry (ICC), hMSCs were plated in 24-well tissue culture 
plates with a seeding density of ~12,000 cells/well. Conditioning treatments were applied as described in 
Section 4.2.2, with a 7-day growth phase and a 7-day media treatment phase.  After conditioning, cells 
were washed with phosphate-buffered saline (PBS), and then fixed with cold methanol (Sigma Aldrich, 
St. Louis, MO; #M-3641) for 20 minutes at -20°C.  After fixation, wells were washed 3 times with PBS 
and plates were kept in 4°C before being processed. 
For the ICC procedure, samples were acclimated to room temperature for 3 minutes in fresh PBS 
composed of: deionized water supplemented with 8.0 g/L sodium chloride (Sigma-Aldrich, #S9888), 0.2 
g/L potassium chloride (Sigma-Aldrich, #P-4504), 1.44 g/L sodium phosphate dibasic (Sigma-Aldrich, 
#S7907), and 0.24 g/L potassium phosphate monobasic (Sigma-Aldrich #P-5379).  The samples were 
then washed twice (5 minutes each) on a rotator with a solution of PBS with 0.05% Tween 20 (Sigma-
Aldrich #P1379).  Cells being analyzed for cardiac transcription factors were then permeablized with 1.5 
N hydrochloric acid for 20 minutes at room temperature, and cells being analyzed for sarcomeric proteins 
were permeablized with Triton X-100 (Sigma-Aldrich, #T-8787) for 20 minutes at room temperature.  
Samples were then washed 3 times in PBS (5 minutes each), and then blocked for an hour at room 
temperature with 1.5% serum in PBS (Normal Goat Serum, Invitrogen, # 016201; or Normal Rabbit 
Serum, Dako, # X0902).  After blocking, samples were treated with primary antibody for MEF2C (Sigma 
Aldrich, # HPA005533), Nkx2.5 (Santa Cruz Biotechnology, Santa Cruz, CA; # SC-8697), GATA-4 
(Millipore, Billerica, MA; # P43694), Cav1.2 (Millipore, #Q01815), or sarcomeric α-actinin  (Sigma-
Aldrich, # A7811) in PBS with 1.5% serum (of secondary antibody host), overnight at 4oC.  After primary 
antibody incubation, samples were washed 3 times (5 minutes each) before being treated with secondary 
antibody (Invitrogen Alexa Fluor 488 Rabbit anti-Goat,  # A11078; Invitrogen Alexa Fluor 488 Goat anti-
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Rabbit,  # A11008; or Invitrogen Alexa Fluor 488 Rabbit anti-Mouse,  # A11059) in PBS with 1.5% 
serum (of the secondary antibody host), at room temperature for 1 hour. The samples were then washed 2 
times in PBS (5 minutes each) on a rotator, and then counterstained with Hoechst 33342 nuclear dye 
(Sigma-Aldrich, # H3570) at a concentration of 1:6000 in PBS.  The samples were then washed 2 final 
times in PBS (5 minutes each).  Once washes were removed, samples were covered with fresh PBS and 
stored at 4oC until they were imaged. 
 
4.2.8. Microscopy and post-processing 
Immunostained samples were observed and analyzed using two different inverted, fluorescent 
microscope systems.  The first was a Leica DMIL microscope, fitted with a Leica DFC420C camera, used 
in conjunction with the Leica Application Suite software (Leica Microsystems Inc., Buffalo Grove, IL).  
The second was an Olympus IX81 microscope, fitted with an Olympus Q-Color 5 camera, used in 
conjunction with the Olympus Slidebook software (Olympus America Inc., Center Valley, PA).  Images 
were post-processed for scale and re-sizing, using Image J software (National Institutes of Health, 
Bethesda, MD).  
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Figure 4.3. Conditioning timeline.  In our combined conditioning regimen, hMSCs were first cultured for a growth 
period: cells were seeded at day 0, cultured in their respective oxygen conditions, and fed every other day with 
MSCGM for 7 days.  After the 7-day growth period, hMSCs were then cultured for a treatment period: MSCGM 
was removed, cells were fed with designated treatment media, and media was changed every 24 hours for another 7 
days. 
 
 
 
Table 4.2. Table of primers and conditions for RT-PCR.  This table specifies forward and reverse primers used 
for semi-quantitative RT-PCR of cardiac transcription factors, sarcomeric proteins, and L-type calcium channel 
subunits.  Primers were either custom designed, or adopted from previous work in the literature: MYLC2A, 
MYLC2V, cTnT, and cTnI from Kehat et al.50; CACNα1D and CACNα1S from Heubach et al.58  
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4.3. Results 
4.3.1. Effects of reduced-O2/HGF conditioning on cardiac gene expression in hMSCs 
To determine if reduced-O2/HGF conditioning of hMSCs in vitro can elicit the expression of cardiac-
specific genes, we evaluated our treated hMSCs for gene transcripts corresponding with cardiac 
transcription factors, sarcomere components, and L-type calcium channel subunits.  Due to the variables 
of our conditioning regimen, we ran an initial screen for a short-list of cardiac genes on 6 different 
combinations of oxygen-level/media treatments (normal-O2/MSCGM, normal-O2/DMEM, normal-
O2/HGF, reduced-O2/MSCGM, reduced-O2/DMEM, and reduced-O2/HGF; Table 4.1).  Human cardiac 
cDNA, synthesized from human heart total RNA purchased from Clontech, was used as a positive 
control.  Our initial screen shows that a combined conditioning regimen of reduced-O2 and HGF can 
increase both the relative amount and breadth of cardiac-specific genes (Figure 4.4).  Traditionally 
cultured hMSCs grown in normal-O2/MSCGM conditions only showed low-level expression of L-type 
Ca2+ channel subunit marker, CaCNA1C.  DMEM treatment (alone, without serum) of normal-O2 hMSCs 
did not express any cardiac genes, including a loss of expression of CaCNA1C.  Treating normal-O2 
hMSCs with HGF elicited MEF2C expression, and also appeared to increase CaCNA1C signal.  
Treatment with reduced-O2 and MSCGM appeared to increase MEF2C and CaCNA1C expression, and 
also showed very low levels of sarcomeric α-Actinin.  DMEM treatment of reduced-O2 hMSCs 
maintained MEF2C and low-level α-Actinin expression, but decreased CaCNA1C.  Reduced-O2/HGF 
conditioning showed an increase in MEF2C, α-Actinin, and CaCNA1C expression, while also eliciting 
expression for Nkx2.5 and GATA-4 cardiac transcription factors.  Results indicate that HGF can elicit 
cardiac-specific genes in both normal-O2 and reduced-O2 conditions, but HGF treatment in reduced-O2 
appears to increase the magnitude and degree of cardiac gene expression.  Results also indicate that 
reduced-O2 conditions, either with or without growth media, can also elicit increases in cardiac gene 
expression for MEF2C, α-Actinin, and CaCNA1 (but not Nkx2.5 or GATA-4). 
Further cardiac gene characterization was compared between reduced-O2/HGF conditioned hMSCs 
and traditionally cultured hMSCs grown in normal-O2/MSCGM.  Again, human cardiac cDNA was 
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included in our analysis for a positive control.  Reduced-O2/HGF conditioned hMSCs showed positive 
expression for myosin heavy chain beta (MHCβ), myosin light chain 2A (MYLC2A), cardiac troponin T 
(cTnT), cardiac troponin I (cTnI), and L-type Ca2+ channel subunit marker CaCNA1D (Figure 4.5).  
Normal-O2/MSCGM hMSCs did not express any of the expanded cardiac-specific genes.  Reduced-
O2/HGF conditioned hMSCs showed cardiac gene expression that was qualitatively much lower than the 
human cardiac positive control.  Results also indicate that reduced-O2/HGF conditioned hMSCs do not 
express CaCNA1S, a marker for L-type Ca2+ channel subunit protein Cav1.1.  The Cav1.1 subunit is 
highly associated with and expressed in skeletal muscle, with minor signals detected in other tissues such 
as heart, lung, brain, and kidney.59  Our results would agree with this analysis, in that CaCNA1S is only 
slightly expressed in human cardiac muscle.  In addition, the lack of CaCNA1S expression in the reduced-
O2/HGF conditioned hMSCs suggests that either there is not enough CaCNA1S transcript to be detected, 
or they are expressing a more definitive cardiac phenotype. 
 
4.3.2. Effects of reduced-O2/HGF conditioning on cardiac protein expression in hMSCs 
To complement our cardiac gene analysis, we used immunocytochemistry (ICC) to detect cardiac 
protein expression and localization.  Results indicate that reduced-O2/HGF conditioned hMSCs can elicit 
cardiac-specific protein expression for MEF2C, Nkx2.5, GATA-4, sarcomeric α-Actinin, and the L-type 
Ca2+ channel subunit Cav1.2 (Figure 4.6).  Observational analysis shows that expression for MEF2C, 
Nkx2.5, and GATA-4 transcription factors localize to the nucleus, sarcomeric α-Actinin appears to 
localize in the cytoplasm, and Cav1.2 appears to localize throughout the cell membrane.  This data 
suggests that some of the detected cardiac genes are being translated into cardiac-specific proteins, and 
that the cardiac proteins appear to be localizing to appropriate cellular regions based on their known 
functions. 
ICC for Nkx2.5, GATA-4, sarcomeric α-Actinin, and Cav1.2 was also done on traditionally cultured 
hMSCs grown in normal-O2/MSCGM (Figure 4.7).  Results indicate that untreated, normal-O2/MSCGM 
hMSCs do not show protein expression for Nkx2.5, GATA-4, or sarcomeric α-Actinin.  Some of the 
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untreated, normal-O2/MSCGM hMSCs do express low-levels of Cav1.2, appearing to localize on the cell 
membrane. 
 
4.3.3. Applying small-molecule inhibitors to evaluate the effects of HGF/c-Met signaling on 
cardiac gene expression 
To assess the role of HGF/c-Met signaling in the activation of downstream cardiac gene transcription 
in hMSCs, we tested the effects of two small-molecule inhibitors on our reduced-O2/HGF conditioned 
hMSCs.  Both small-molecule inhibitors were tested independently, and were chosen based on their 
targeted effector proteins involved in our proposed HGF/c-Met signaling pathway (Figure 4.8).  As 
described in the methods, inhibitors were applied during the media-treatment phase of the conditioning 
regimen.  Either 5 μM of PHA665752 or 50 μM of LY294002 were applied to cells for 2 hours before 
supplementing the inhibitor media with 20 ng/mL HGF.  Inhibitors were applied in this fashion every 24 
hours, for the duration of the 7 day media-treatment phase, to compare against reduced-O2/HGF hMSCs 
that were also treated for 7 days.  
Our results show that both PHA665752 and LY294002 were ineffective in decreasing MEF2C gene 
expression (Figure 4.9).  However, both inhibitors were independently effective in decreasing gene 
expression for Nkx2.5, sarcomeric α-Actinin, MHCβ, cTnT, and cTnI.  Reduced-O2/HGF conditioned 
cells treated with 5 μM PHA665752 appeared to express low-levels of sarcomeric α-Actinin, cTnT, and 
cTnI.  This data may correlate with preliminary ELISA studies, showing that 5 μM PHA665752 could 
significantly decrease, but not completely mitigate, c-Met phosphorylation in reduced-O2 hMSCs (Figure 
4.10); indicating that PHA665752 can decrease c-Met phosphorylation to attenuate expression of cardiac 
genes.  In addition, treatment with 50 μM LY294002 attenuated the expression of cardiac genes in 
reduced-O2/HGF conditioned hMSCs. 
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Figure 4.4. Effects of different conditioning regimens on cardiac gene transcription.  In a preliminary screen, 
all six oxygen/media treatment combinations were compared for gene expression of cardiac transcription factors 
(MEF2C, Nkx2.5, and GATA-4), sarcomeric protein (α-Actinin), and an L-type calcium channel marker 
(CaCNA1C).  HGF treatment in both O2 conditions increased MEF2C, CaCNA1C.  Reduced-O2 conditioning with 
MSCGM or DMEM also increased MEF2C and CaCNA1C, and elicited low-level α-Actinin expression.  Reduced-
O2/HGF conditioning appeared to increase MEF2C, α-Actinin, and CaCNA1C signal, as well as elicit gene 
expression of both Nkx2.5 and GATA-4. 
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Figure 4.5. Effects of reduced-O2/HGF conditioning on expression of an expanded set of cardiac genes.  In a 
secondary screen for cardiac gene expression, we compared traditionally cultured normal-O2/MSCGM hMSCs 
versus reduced-O2/HGF conditioned hMSCs.  Reduced-O2/HGF conditioned hMSCs showed low-level expression 
for MHCβ, MYLC2A, MYLC2V, cTnT, cTnI, and CaCNA1D, but no expression of CaCNA1S.  Normal-
O2/MSCGM hMSCs did not show expression for any of the cardiac genes in the second screen. 
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Figure 4.6. Cardiac-marker protein expression in reduced-O2/HGF conditioned hMSCs.  Cardiac protein 
detection by immunocytochemistry showed that reduced-O2/HGF conditioned hMSCs express MEF2C, Nkx2.5, 
GATA-4 cardiac transcription factors localized to cell nuclei, sarcomeric α-Actinin in the cytoplasm, and L-type 
calcium channel subunit Cav1.2 on the cell membrane. Scale bars = 50 μm. 
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Figure 4.7. Cardiac-marker protein expression in normal-O2/MSCGM conditioned hMSCs.  Cardiac protein 
detection by immunocytochemistry showed that hMSCs grown in normal-O2/MSCGM conditions did not express 
Nkx2.5, GATA-4, or sarcomeric α-Actinin.  They did show low-level expression L-type calcium channel subunit 
Cav1.2.  MEF2C was not tested.  Scale bars = 50 μm. 
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Figure 4.8. Small-molecule inhibition of proposed HGF/c-Met cardiac signaling pathway.  Two small-
molecule inhibitors were tested independently to evaluate the involvement of HGF/c-Met signaling in cardiac 
differentiation of hMSCs.  PHA665752 inhibits c-Met phosphorylation, and LY294002 competitively inhibits ATP 
binding of PI3K. 
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Figure 4.9. Small-molecule inhibitor analysis on cardiac gene expression.  Reduced-O2/HGF conditioned 
hMSCs treated with 5 μM PHA665752 retained MEF2C expression, but showed a loss of expression for Nkx2.5 and 
MHCβ, and lowered expression for α-Actinin, cTnT, and cTnI.  Reduced-O2/HGF conditioned hMSCs treated with 
50 μM LY294002 also retained MEF2C expression, but showed a loss of all other cardiac genes. 
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Figure 4.10.  Preliminary data showing effects of PHA665752 on c-Met phosphorylation.  Prior to small-
molecule inhibitor analysis on gene expression, we ran a preliminary study to evaluate the effects of two different 
concentrations of PHA665752 on phosphorylated c-Met expression in hMSCs.  Both 1 μM and 5 μM concentrations 
of PHA665752 showed to significantly decrease c-Met phosphorylation, however the 5 μM concentration showed a 
more drastic decrease.  The 5 μM concentration treatment still indicates a low concentration of phosphorylated c-
Met.  Since the 5 μM concentration was used in our small-molecule inhibitor analysis on gene expression, it may be 
possible that the lowered c-Met phosphorylation can elicit low-level cardiac gene expression.  Differences were 
evaluated using a Student’s unpaired t-test at each passage, and were considered significant for p-values ≤ 0.05.  
Error bars indicate standard error. 
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4.4. Discussion 
Current methods for differentiating hMSCs towards a cardiac lineage have significant limitations.  
Techniques for mechanical or chemical induction are complex and tedious, signaling mechanisms remain 
undefined, and only a small percentage of hMSCs have been shown to express a limited number of 
cardiac-specific markers.  To improve upon these limitations, we developed a simplistic regimen 
combining reduced-O2 conditioning with HGF treatment.  The conditions for this regimen were based on 
MI environmental cues for low-oxygen tension and increased HGF release;60,61 as well as the previous 
studies showing that reduced-O2 conditioning could increase signaling and survival factors in 
hMSCs,48,62,63 and the studies showing that HGF is involved in cardiomyogenesis.16,45,47  In Chapter 3, we 
showed that culturing hMSCs in reduced-O2 for 7 days could significantly increase the expression for the 
c-Met receptor.  In our conditioning regimen, we incorporate a growth-phase for the increase of c-Met, 
and then a media-treatment phase for the addition of HGF (in serum-free medium).  In this chapter, we 
sought to investigate the effects of reduced-O2/HGF conditioning on cardiac-marker expression of hMSCs 
in vitro. 
While it has been reported that HGF is not required for heart development,45 knockout mice for HGF 
and the c-Met receptor are lethal during the second half of the gestation period (E12-E18) due to 
complications with placental formation and liver development.42,64,65  Although the details of heart 
development defects are not fully understood in HGF/c-Met knockout mice, these deficiencies reportedly 
contribute to cardiac arrhythmias.64  Although HGF and the c-Met receptor may not be required for heart 
development, it is speculated that HGF/c-Met may aid in the autoregulation and maintenance of early 
myocardial cells, as well as provide autocrine/paracrine signaling factors that support cardiac 
development.45  This analysis compliments the previously discussed stem cell studies, in which HGF/c-
Met signaling has also shown to improve cardiac differentiation in human ESCs and induce cardiac 
specific marker expression in mouse MSCs.16,47  HGF/c-Met signaling may play a critical role in early 
cardiomyogenesis by providing necessary paracrine factors that support and drive the cardiac 
differentiation program.  While the specific role of HGF/c-Met signaling in cardiac development and 
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differentiation is not completely understood, it is possible that the absence of HGF or c-Met could 
compromise early cardiac gene transcription.  This would be largely detrimental, as previous studies 
report knockout mice that are deficient for early cardiac genes required for heart development (e.g. 
Nkx2.5) become lethal by gestation days E9-E11.66,67 
Our results showed that a combined conditioning regimen of reduced-O2/HGF could elicit the 
expression of several cardiac genes and proteins in hMSCs.  In our combined regimen, we examined the 
effects of treating cells with 20 ng/mL HGF; a concentration we chose based on what was previously 
reported in the literature on mouse MSCs.16  However, it is possible that 20 ng/mL may not be the 
optimum concentration for eliciting cardiac specific markers in hMSCs.  Future titration studies would be 
useful to determine if higher or lower concentrations of HGF could elicit more expression of cardiac 
markers, or possibly further differentiate hMSCs towards a more mature cardiac phenotype.  In addition, 
we only looked at reduced-O2/HGF conditioned cells that were treated for 7 days.  This is to say that we 
did not evaluate conditioned cells for shorter or longer durations.  Therefore, it is possible that some of 
the effects we see in cardiac gene and protein expression could be due to timing between the different O2 
groups.  By looking at different time points in both O2 conditions, it may be possible that normal-O2 
cultured cells can elicit similar cardiac gene expression.  Analysis at different time points may also 
provide more information as to a timeline of cardiac gene transcription, and whether longer conditioning 
durations can further differentiate cells into mature cardiac phenotypes. 
In further consideration of our reduced-O2/HGF conditioning regimen, we chose to condition hMSCs 
for long durations in the reduced-O2 environment; with thawed cells being maintained in reduced-O2 
throughout their growth, and then an additional 2 weeks in reduced-O2 during the conditioning treatment.  
Our rationale for choosing longer-term reduced-O2 exposure was to pre-condition cells for implantation 
into the oxygen-poor infarct environment.  However, in our analysis of cardiac gene and protein 
expression, we did not analyze the effects of short term reduced-O2 conditioning.  It is possible that short 
term reduced-O2 durations could provide a necessary signaling cascade for cardiac differentiation; and 
then transitioning cells from reduced-O2 back to normal-O2 would prevent increased growth/proliferation 
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(as observed in our growth kinetics study, Chapter 2).  In consideration of cellular processes, it may be 
necessary attenuate the proliferation effects observed in reduced-O2 conditioning to allow for further 
cardiac differentiation.  However, it may also be possible that longer-term reduced-O2 exposure can 
provide a supporting signaling cascade necessary to elicit cardiac specific markers. 
Comparatively, our combined reduced-O2/HGF conditioning regimen of hMSCs showed an increased 
breadth of cardiac-specific marker expression than we previously achieved in our hanging-drop 
differentiation method (e.g. Nkx2.5, Gata-4, and MEF2C gene and protein expression).  In further 
consideration of the hanging drop method, it may be possible that spheroid formation is also causing a 
reduced-O2 microenvironment in which cells are secreting/receiving signaling factors.  It may even be 
possible that spheroid formation is creating a reduced-O2/HGF microenvironment that helps to elicit 
cardiac makers in hMSCs, which drives some of the spheroid cells towards a cardiogenic lineage.13 
In a qualitative assessment by immunocytochemistry, it appeared that many of the reduced-O2/HGF 
conditioned cells could express cardiac specific proteins (e.g. MEF2C, Nkx2.5, and α-Actinin).  This 
would suggest that increases in cardiac gene expression are most likely due to more hMSCs becoming 
cardiogenic, rather than stronger cardiac gene expression in a small sub-population of cardiogenic cells in 
a mixed batch of hMSCs.  From our qualitative ICC assessment, it also appears that a greater number of 
hMSCs from our reduced-O2/HGF conditioning method can express cardiac specific proteins, as 
compared with our previously described “hanging drop” method.  However, we did not take cell counts to 
determine the number cardiogenic cells in this study, and a comparative quantitative analysis would be 
needed to determine if reduced-O2/HGF conditioning was more efficient for producing cardiogenic cells 
than spheroid formation. 
Using small-molecule inhibitors to target specific control points in our proposed HGF/c-Met pathway, 
we showed that decreases in c-Met or PI3K activation could attenuate cardiac gene expression.  These 
results would suggest that the HGF/c-Met pathway and the PI3K effector protein are instrumental in 
initiating the cardiac-program in marrow-derived hMSCs.  The c-Met inhibitor (5 µM PHA665752) was 
effective for decreasing most of the cardiac genes we screened, with low expression of α-Actinin, cTnT, 
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and cTnI.  The PI3K inhibitor (50 µM LY294002) was effective for attenuating most of the cardiac genes 
we screened, as well.  However, neither inhibitor could effectively decrease the expression of MEF2C.  
These results would suggest other signaling mechanisms besides HGF/c-Met and PI3K are involved in 
MEF2C gene transcription.  In our analysis, inhibitor concentrations were chosen based on concentrations 
previously reported in the literature.  In preliminary studies, we tried to analyze the inhibitor 
concentrations to determine if the inhibitors could mitigate the phosphorylation of effector molecules.  In 
our analysis of PHA665752, we found that both 1 µM and 5 µM concentrations of inhibitor could 
significantly decrease c-Met phosphorylation.  However, 1 µM still showed a high level of c-Met 
phosphorylation which could potentially allow for downstream signaling.  The 5 µM concentration 
showed a more drastic decrease, but could not completely inhibit c-Met phosphorylation.  This may 
account for why we still see slight expression of α-Actinin, cTnT, and cTnI in the PHA665752 treated 
cells.  Complications due to biochemical processing prevented us from completing an analysis on the 
effects that the PI3K inhibitor (50 µM LY294002) had on decreasing phosphorylation of Akt.  Therefore, 
it is unclear whether the 50 µM concentration was effective for mitigating PI3K and its downstream 
signaling events.  However, we did observe that 50 µM LY294002 could attenuate the expression of 
cardiac genes.  Further titration experiments are needed to determine if different/increased doses of these 
inhibitors can decrease the phosphorylation of effector molecules, decrease MEF2C gene expression, and 
completely abate cardiac gene expression. 
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CHAPTER 5: Evaluate regional cardiac function of cell-treated Myocardial Infarcts 
5.1. Introduction 
Although we have investigated the effects of reduced-O2/HGF conditioning on cardiac-specific 
marker expression of hMSCs in vitro, we were also interested in delivering reduced-O2/HGF conditioned 
hMSCs to acute MIs in vivo to assess the potential effects on cardiac function.  Current cell therapy 
strategies for cardiac regeneration aim to overcome the chief limitation of current MI treatments by 
replacing necrotic cardiomyocytes with viable cells that can restore cardiac mechanical function.  Several 
different cell types (e.g. skeletal myoblasts,1,2 embryonic stem cells,3 bone marrow cells,4,5 mesenchymal 
stem cells,6-8 etc.) have been delivered to diseased hearts in clinical and pre-clinical studies to show 
improvement in cardiac mechanical function.  While there have been some initial studies to correlate the 
engraftment of varying numbers of implanted cells,9 conclusive evidence of a correlation between the 
number of regenerated striated cardiomyocytes and improvements in regional mechanical function has not 
been established.  This leads to a fundamental question of whether the delivered cells can increase active 
function by adding contractile elements, or improving electrical communication between native 
cardiomyocytes, or they simply improve passive function by increasing the compliance within the region 
of the developed scar.10,11  Using techniques to study regional mechanical cardiac function, however, it is 
possible to study defined regions of interest within the heart.  And by using a high spatial-resolution 
imaging technique called high density mapping (HDM), it is possible to determine area deformation 
within small infarct regions with a high degree of accuracy, precision, and repeatability.12,13  By 
correlating measured changes in heart-surface deformation with measured intracavitary pressure over the 
course of a heartbeat, we used HDM to calculate regional stroke work and systolic area contraction as 
indicators of active function in MIs treated with reduced-O2/HGF conditioned hMSCs. 
As previously described, bone marrow derived MSCs are a sub-population of BMCs that have been 
studied as a cell therapy in several in vivo applications.  In addition to their multipotent ability to 
differentiate into different cell types,14,15 MSCs have also shown to improve wound healing and tissue 
function by homing to injury sites,16-18 secreting tissue-protective cytokines,19-21 promoting 
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angiogenesis,20,22,23 and mediating inflammation.24,25  Just as BMCs, MSCs have been transplanted into 
infarcted hearts to show improvements in cardiac function in animal studies and human clinical trials.6-
8,23,26  Possible mechanisms for the enhanced function may be due to increasing myocyte content through 
MSC-cardiomyocyte differentiation,6,27,28 or limiting native myocyte loss through protective MSC 
signaling that promotes cardiomyocyte survival and maintains cardiomyocyte contractility.19,20,25,29-32  
Despite these successes using MSCs for cardiac cell therapy, complete restoration of normal cardiac 
mechanical function has not yet been achieved, and it remains unclear whether short-term improvements 
in function will persist longer term.  
For any of the cell types used in cardiac cell therapy, one of the chief limitations that needs to be 
addressed is the survival of the implanted cells.33  In the dynamic environment of the infarcted heart, 
decreased blood supply causes ischemia, which reduces oxygen tensions to the range of 0.4-1.7% O2.34  
Reduced oxygen tension in MIs is a major factor contributing to the low survival of implanted cells, as a 
result of increased oxidative stress that has shown to trigger autophagy and apoptosis mechanisms in both 
native myocytes and delivered MSCs.35-37  If delivered MSCs cannot survive, they cannot sustain delivery 
of cardioprotective factors nor regenerate enough infarcted myocardium for long-term functional 
improvement.  One of the main reasons implanted MSCs experience increased oxidative stress is because 
they have been cultured and prepared at atmospheric 20% O2 in vitro prior to delivery, and they do not 
have the appropriate cellular machinery to adapt to reduced oxygen tensions in an MI.  Conditioning 
MSCs in reduced-O2 prior to implantation can enhance redox mechanisms,37 which may enable them to 
adapt more readily to the reduced-O2 MI environment.  In vitro studies have shown that conditioning 
MSCs in reduced-O2 can increase migration,38,39 prosurvival markers,38,40,41 proangiogenic markers,20,41 
and cardioprotective factor secretion.40,41  When implanted into MIs in vivo, reduced-O2 preconditioned 
MSCs showed increased recruitment to the infarct,39,42 increased MSC survival,43 and increased 
angiogenesis.42,43  In addition, reduced-O2 conditioned MSCs showed therapeutic benefit in MIs by 
reducing infarct size,42,43 increasing wall thickness,42 and improving global cardiac function indices such 
as increased systolic pressure,43 decreased end-diastolic pressure,43 increased fractional shortening,42 and 
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increased ejection fraction.42  While these results are encouraging, only a limited number of studies have 
been performed using reduced-O2 conditioned MSCs to treat the infarcted heart.  Continued investigation 
is needed to confirm these outcomes and to further understand the therapeutic potential of delivering 
reduced-O2 conditioned MSCs to MIs.   
In contribution to this body of literature, we designed our in vivo study to compare the functional 
outcomes of MIs treated with unconditioned hMSCs, reduced-O2 conditioned hMSCs, and reduced-
O2/HGF conditioned hMSCs.  Furthermore, we sought to analyze the regional cardiac mechanics of the 
cell-treated infarcts, which is more definitive than global heart measures for understanding the function 
within the implant regions.  As described previously, MIs generally occur within small regions of the 
heart.  By using specialized techniques for determining the mechanical function in these defined regions, 
it is possible to study the effects of dysfunction and treatment within infarct areas.  As discussed in 
Sections 2.6 and 2.10, several techniques have been developed for studying regional cardiac mechanics 
(e.g. echocardiography, MRI, NOGA, sonomicrometry, and HDM).  In our study, we used HDM to 
determine regional function across the infarcted area for a whole field analysis with high spatial 
resolution.  In this system, silicon carbide particles (40 µm in diameter) were applied directly to the 
epicardial surface, which created a densely speckled contrast on the heart when illuminated with white 
light.  Using a high speed camera to capture images of the speckled surface over the course of a heartbeat, 
HDM uses a sub-pixel algorithm to interpolate discrete signals with respect to sampling rate and time.   
By dividing a region of interest into subimages, HDM detects sub-pixel motion to determine the 
displacement of each subimage between consecutive images through Fourier transform.12  Using a phase-
correlation algorithm to increase computational efficiency beyond the capabilities of conventional particle 
tracking or digital correlation techniques, displacements can be determined at hundreds of locations to 
provide a whole field measurement.13  With a demonstrated accuracy of 0.09 pixels and precision of 0.04 
pixels,12 HDM is an ideal system for studying regional cardiac mechanics in treated and untreated infarct 
regions within the rat heart. 
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5.1.1. Evaluating regional cardiac function of MIs treated with conditioned hMSCs 
To determine whether reduced-O2/HGF conditioned hMSCs can improve cardiac function, we 
delivered pre-conditioned cells to rat MIs in vivo.  During the initial procedure, MIs were induced in the 
left ventricle (LV) of male athymic rats by temporarily ligating the left anterior descending coronary 
artery for 1 hour.  LVs were reperfused for 15 minutes following ligation, and then 1 million cells were 
delivered to the infarct region by intramyocardial injection.  Following the initial procedure, rats were 
maintained for either 1 week or 1 month time points.  At the end of the survival periods, we performed a 
second procedure to record functional data from the infarct region using HDM, before sacrificing the 
animals and excising the hearts for histological analysis.  From the collected data, we calculated regional 
stroke work (RSW) and systolic area contraction (SAC) to compare MI treatments. 
For both the 1 week and 1 month groups, we compared the functional data of MIs treated with 
DMEM (delivery media), unconditioned hMSCs, reduced-O2 conditioned hMSCs, and reduced-O2/HGF 
conditioned hMSCs.  For reference, we also performed HDM on normal, non-infarcted rat hearts. 
Our analysis shows that all cell treatments can improve regional mechanical function of MIs, and that 
improved function could be sustained from 1 week to 1 month in each treatment.  However, reduced-
O2/HGF conditioned hMSCs could significantly improve function compared to both unconditioned 
hMSCs and reduced-O2 conditioned hMSCs. 
 
5.2. Materials and Methods 
5.2.1. Surgical Procedures and Infarct Model 
To determine the effect of implanted cells on the regional mechanical function of an MI, we 
developed an infarct model in athymic rats.  All animals used in this study received humane care in 
compliance with the “Guide for the Care and Use of Laboratory Animals” prepared by the National 
Academy of Sciences and published by the National Institutes of Health (NIH publication no. 85-23, 
revised 1985).  The Institutional Animal Care and Use Committee (IACUC) at Worcester Polytechnic 
Institute reviewed and approved the protocols followed in this study (IACUC # 10-20). 
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Seven-ten week old male Rowett nude athymic rats (Charles River Laboratories, Wilmington, MA; 
Strain code: 316, RNU), weighing 250-350 grams, were anesthetized with an intraperotineal injection of 
Ketamine (100 mg/kg; Manufactured by Bioniche Teoranta, Galway, Ireland; Distributed by Vedco Inc, 
St. Joseph, MO) and Xylazine (10 mg/kg; Manufactured by IVX Animal Health Corporation, St. Joseph, 
MO).  Rats were then intubated with a 16 gauge angiocatheter and maintained under general anesthesia 
using inhalational isofluorane.  A digital pulse-oximeter was used to monitor pO2 and heart rate, which 
was maintained between 200-250 beats per minute.  A left-side thoracotomy between the 4th and 5th 
intercostal spaces was performed to access the thoracic cavity and expose the left ventricle (LV), and the 
pericardium was resected. 
Myocardial infarcts were induced by temporary suture ligation of the left anterior descending (LAD) 
coronary artery for 1 hour.  After 1 hour, suture ligations were removed and hearts were allowed to 
reperfuse for 15 minutes.  After reperfusion, cells were delivered to the infarct region by intramyocardial 
injection.  Infarct regions were identified by a discoloration of the ischemic tissue, which showed to be a 
pale pink color that was distinct from the red color of the surrounding healthy myocardium.  For all 
procedures, a suspension of 1 million cells in 50 µL of DMEM was delivered using a Hamilton surgical 
syringe (Hamilton Company, Reno, NV; #80601), by making five 10 μL injections in the pale-colored 
infarct region.  Following cell delivery, the chest wall was closed with biodegradable suture (4-0 Vicryl; 
Ethicon, Guaynabo, Puerto Rico; #J304H), and animals were observed until normal vital signs were 
recovered.  The animals were then maintained under vivarium staff care for the duration of the survival 
periods. 
Following the 1-week and 1-month recovery periods, the animals were returned to the operating 
room, anesthetized, intubated, and maintained under general anesthesia as described in the initial 
procedure.  Hearts were again exposed by making a left-side thoracotomy between the 4th and 5th 
intercostal space to access the thoracic cavity, and any developed adhesions in the thoracic cavity were 
carefully dissected.  A pressure transducer (Millar Instruments, Houston, TX; Model #: SPR-524) was 
placed into the LV by implantation through the apex of the heart.  Once pressure recordings from the 
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transducer were confirmed, functional data was recorded using the HDM system.  After data acquisition, 
rats were euthanized with Beuthanasia-D (0.25 mL/kg; Schering-Plough Animal Health, Kenilworh, NJ), 
and hearts were excised for histological analysis. 
 
5.2.2. Cell preparation and delivery 
In preparing hMSCs for in vivo delivery, the same general cell culture techniques and specialized 
conditioning treatments were used as previously described in Chapter 4 (Section 4.2.2, Table 4.1, and 
Figure 4.3).  Briefly, cryovials of cells were thawed, counted, and split into T-75 flasks for growth in 
either normal-O2 or reduced-O2 conditions.  Flasks were seeded and fed every other day with growth 
medium (MSCGM) for 7 days.  After the 7th day, growth media was removed and different media 
treatments were applied.  Media treatments were changed every day for another 7 days.  However, on the 
6th day of the initial growth-media treatment, hMSCs were fed with MSCGM supplemented with an 8.2 
nM concentration of 655 ITKTM quantum dot nano-particles (Invitrogen, #Q21321MP).  Quantum dots 
are passively endocytosed by hMSCs and can be used as a cell-tracking technique, which will be 
discussed further in Chapter 6.  After a 24-hour incubation in quantum dot supplemented MSCGM, cells 
were washed twice with sterile PBS (without calcium or magnesium; Cellgro, Manassas, VA; # 21-031-
CV), and then treated for media conditioning.  Quantum dot cell-loading was assessed the 7th day of the 
initial growth-media treatment, to ensure sufficient loading and uniformity in all flasks across O2/media 
treatments. 
After hMSCs were media-conditioned for 7 days, cells were removed from their designated O2 
incubators, washed with sterile PBS, and then detached from culture plates with 0.25% trypsin (Cellgro).  
Cells were exposed to 5% fetal bovine serum media to deactivate trypsin, then immediately centrifuged at 
1,000 rpm for 5 minutes.  After centrifugation, the excess media/trypsin solution was aspirated, and the 
cell pellets were resuspended in 1 mL of sterile DMEM (Lonza, Inc.).  Cells were counted using a 
hemocytometer, cell concentrations were determined, and then 1 million cells were aliquoted from the 
cell suspension into another sterile conical tube.  The 1 million-cell aliquot was centrifuged again at 1,000 
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rpm for 5 minutes, and the old DMEM was aspirated.  The 1 million-cell pellet was resuspended in 50 μL 
of fresh sterile DMEM, transferred into sterile 0.5-mL microcentrifuge tube, which was then sealed and 
transported to the operating room. 
Just prior to cell implantation, a sterile 27-gauge surgical needle (Becton Dickenson) was fixed to 
100μL-Hamilton surgical syringe.  The syringe was back-filled with ~30 μL of sterilized mineral oil to 
account for dead-space in the needle flange.  Once the syringe was prepared, the 50 μL cell suspension 
was uncapped, mixed by gentle pipetting, and then drawn into the syringe for delivery. 
 
5.2.3. Measurement of regional mechanical function 
Regional function was determined by high-density mapping (HDM), as previously described in the 
analysis of rabbit, porcine, and canine hearts.6,44-47  After the LV was exposed and the pressure transducer 
was implanted during the terminal procedure, gross anatomical observations were made to determine a 
region of interest (ROI) for analysis (Figure 5.1).  Once the ROI was identified, silicon carbide particles 
(~40 µm in diameter) were applied to the epicardial surface of the heart to create a unique random light 
intensity pattern.  A complementary metal-oxide semiconductor camera (CMOS camera; Photron, San 
Diego, CA) was then focused onto the ROI (Figure 5.1).  The camera system settings were adjusted to 
acquire 8-bit grayscale images with a 1280 x 1024 pixel resolution, at a frame rate of 250 Hz for 4 
seconds.  Synchronous LV pressure readings were digitally recorded from the Millar pressure transducer 
that was connected to an analog-to-digital converter (National Instruments, Austin, TX; Model #: PCI-
6023E).  Both the CMOS camera and the pressure transducer were connected to a single data acquisition 
board, and were triggered simultaneously using an external TTL trigger. 
 
5.3.4. Image post-processing 
As described in the chapter introduction, HDM uses a sub-pixel phase correlation algorithm to obtain 
displacements of the epicardial surface at multiple locations within the ROI.  To do this, the ROI was 
divided into subimages by configuring the HDM software to analyze a 64 x 64 pixel subimage size.  By 
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analyzing the coordinate pixel-shifts of the unique light intensity distribution over consecutive images, u 
and v displacements of each subimage could be calculated from one frame to the next (Figure 5.2A).  
Based on the calculated displacements of 4 adjacent subimages, changes in area in successive frames 
were computed using Green’s theorem (Figure 5.2B): 
 
𝐴 = 12�(𝑥𝑖𝑦𝑖+1 − 𝑥𝑖+1𝑦𝑖)4
𝑖=1
 
 
where i indicates the subimage, and x and y indicate subimage coordinates.  Then by normalizing the 
initial area to 1, changes in area were then used to calculate area stretch ratios over the cardiac cycle.  
Combining these area calculations with synchronous pressure measurements, regional area work loops 
were created for each sampled heartbeat (Figure 5.3).  Regional stroke work (RSW) was calculated by 
integrating area with respect to pressure over one cardiac cycle: 
 
𝑅𝑆𝑊 =  �𝐴 ∙ 𝑑𝑃  
 
We report RSW both with and without normalization to pressure.  RSW with normalization to pressure is 
reported as a unitless value, whereas RSW without normalization to pressure is reported in mm Hg.  RSW 
is an index of the amount of work being performed by the ROI.  Since the integral is path-dependent, a 
positive value for RSW (counter-clockwise work loop) indicates that the region is contracting in 
synchrony with normal myocardium and performing work.  A negative value for RSW (clockwise work 
loop) indicates that the region is non-synchronous with normal myocardium, and that the surrounding 
myocardium is performing work on the ROI.  Systolic area contraction (SAC) of the ROI was calculated 
as the difference between end-diastolic area (EDA) and end-systolic area (ESA), with end-diastolic area 
normalized to 1, and then reported as percent normalized contraction based on the following equation: 
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𝑆𝐴𝐶 =  �𝐸𝐷𝐴 − 𝐸𝑆𝐴
𝐸𝐷𝐴
�  ×  100 =  �1 − 𝐸𝑆𝐴1 �  × 100  
 
5.3.5. Statistics 
RSW and SAC values were determined for 4 individual heartbeats in each rat, and then average RSW 
and SAC values were calculated.  Averaged RSW and SAC values for rats in each treatment group were 
then averaged again, and data are reported as mean ± standard error of the mean.  One-way analysis of 
variance (ANOVA) was used to determine RSW and SAC differences in treatment groups at the 1-week 
and 1-month time points.  ANOVA was also used to determine if the values for RSW and SAC were 
different between the 1-week and 1-month treatment groups.  A post hoc Tukey test was then used to 
perform multiple pair-wise comparisons.  Differences were considered significant for p-values ≤ 0.05. 
RSW and SAC values for normal, non-infarcted hearts were determined in the same manner as the 
other treatment groups.  In a separate analysis, RSW and SAC values for normal heart were determined to 
be significantly higher than all other treatment groups by one-way ANOVA.  For reference, normal heart 
data is included on our graphical representations.  
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Figure 5.1. Identifying regions of interest in vivo.  During terminal surgeries, hearts were exposed by left 
thoracotomy and any adhesions were removed.  Rib spreaders were used for better access to the left ventricle (LV), 
and regions of interest (ROIs) were selected before the application of silicon carbide particles and retro-reflective 
beads (A, C, and E).  Normal hearts without infarct presented with healthy, red-colored, contracting myocardium 
and ROIs were focused anywhere on the LV (A).  Infarcted hearts, whether treated with media or cells, presented 
with a pale, discolored region in the LV, and ROIs were focused within these defect areas (C and E).  Once ROIs 
were chosen, silicon carbide particles and retro-reflective beads were applied, and high-speed cameras were focused 
onto the epicardial surface (B, D, and F).  During analysis, sub-regions within ROIs could be analyzed, and border-
zone regions could be neglected.    
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Figure 5.2. Using High Density Mapping (HDM) to determine regional mechanical function.  HDM was used 
to determine deformations of the epicardial surface of rat hearts in vivo.  (A) ROIs with a unique light intensity 
distribution was selected, for analysis in a series of subsequent images.  The ROI was divided into sub-images, and a 
Fourier transform was used to determine the x and y coordinates of the light intensity peak in each sub-image.  The 
coordinates for each sub-image were compared to the coordinates for the same sub-image in subsequent images, and 
resulting displacements were determined.  (B) The area of each set of 4 adjacent sub-images was computed, and all 
areas were summed to find the total change in area across frames. 
 
 
 
 
Figure 5.3. Schematics of pressure-area work loops.  (A) By correlating computed area changes with pressure 
changes recorded from the left ventricular cavity, we could establish pressure-area work loops for each cardiac 
cycle.  Within each pressure-area work loop, we could identify end-diastole (point A) and end-systole (point B), and 
end-diastolic areas were always normalized to 1.  (B)  Regional stroke work (RSW) was calculated by integrating 
the area with respect to pressure; positive work was shown by counter-clockwise progression of pressure-area 
points, and negative work was shown by clockwise progression of pressure-area points.  Positive work indicates that 
ROIs were contracting in contribution to total work in the heart, whereas negative work indicates that work was 
being done on the ROI by surrounding myocardium.  (C) Systolic area contraction (SAC) was calculated by finding 
the difference between the end-diastolic area (EDA, area at end-diastole) and the end-systolic area (ESA, area at 
end-systole).  
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5.3. Results  
After 1-week and 1-month survival periods, pressure recordings and HDM were used to study ROIs 
within left ventricular infarcts.  Infarct regions were identified based on gross anatomical observations of 
the LV, where necrotic MI regions produced a white-colored scar area that contrasted with the red/pink 
color of healthy myocardium (Figure 5.4).  A high speed CMOS camera was focused onto the MI regions, 
and data was acquired at 250 frames/second for 4 seconds, with 1280x1024 pixel resolution.  In post-
procedure analysis, the HDM program was used to correlate cumulative area stretch ratios with 
intracavitary pressure measurements, to produce area work loops for each analyzed heartbeat (Figure 5.4).  
RSW and SAC were calculated as described in the methods (Figure 5.3).  Four heartbeats were analyzed 
and averaged for each animal, and then values for animals in the same treatment group were averaged.  
Regional cardiac mechanical data is reported as mean ± standard error of the mean, and results are 
summarized in in Table 5.1. 
 
Regional Stroke Work 
In analyzing the regional mechanical data without normalization to pressure after 1 week, the mean 
RSW of DMEM treated MIs was 0.97 ± 0.44 mm Hg (n = 7; Figure 5.5).  Treating MIs with traditional, 
normal-O2/MSCGM hMSCs significantly increased infarct function with a mean RSW of 3.37 ± 0.47 mm 
Hg (n = 9; p ≤ 0.001).  MIs treated with reduced-O2/MSCGM hMSCs significantly increased infarct 
function compared to both DMEM (p ≤ 0.01) and normal-O2/MSCGM hMSC treatments, with a mean 
RSW of 5.44 ± 0.31 mm Hg (n = 8; p ≤ 0.001).  Furthermore, MIs treated with reduced-O2/HGF hMSCs 
showed to significantly increase regional mechanical function compared to all other MI treatment groups, 
with a mean RSW of 7.48 ± 0.30 (n = 10).  While all MI groups resulted in significantly decreased 
function compared to normal non-infarcted hearts (RSW: 21.482 ± 1.71 mm Hg, n = 6), MIs treated with 
reduced-O2/HGF hMSCs was effective in restoring ~35% of normal regional work after 1 week (as 
compared to the normal-heart analysis). 
Chapter 5 | 128  
 
After 1 month, the mean RSW of DMEM treated MIs was 2.54 ± 0.35 mm Hg (n = 7; Figure 5.6).  
The mean RSW of MIs treated with traditional normal-O2/MSCGM hMSCs was 4.08 ± 0.89 mm Hg (n = 
7), and the mean RSW of MIs treated with reduced-O2/MSCGM hMSCs was 4.98 ± 0.52 mmHg (n = 6).  
Our analysis indicates that there was no significant difference in RSW at 1 month across the following 
MI-treatment groups: DMEM, normal-O2/MSCGM hMSCs, or reduced-O2/MSCGM hMSCs.  MIs 
treated with reduced-O2/HGF hMSCs had a mean RSW of 7.44 ± 0.79 (n = 6), which was significantly 
higher than DMEM (p ≤ 0.001) or normal-O2/MSCGM hMSC treatments (p ≤ 0.01), but showing no 
significant difference compared to the reduced-O2/MSCGM hMSC treatment.  Compared to normal non-
infarcted heart function, all MI treatments showed significantly decreased RSW at 1 month. 
In a comparison of individual treatment groups at 1-week versus 1-month, there was no significant 
difference in RSW for any MI treatment between time points (Figure 5.7).  Our results indicate that 1-
week improvements in RSW could be sustained out to 1 month. 
 
Normalized Regional Stroke Work 
Since different treatment conditions contributed to LV pressure variation (Figure 5.4), we also 
analyzed RSW with normalization to pressure (Figure 5.8).  After 1 week, the mean normalized RSW of 
DMEM treated MIs was 0.011 ± 0.004 (n = 7).  MIs treated with traditional normal-O2/MSCGM hMSCs 
resulted in a mean normalized RSW of 0.035 ± 0.006 (n = 9), which again showed a significant increase 
in function compared to DMEM treatment.  MIs treated with reduced-O2/MSCGM conditioned hMSCs 
had a mean normalized RSW of 0.046 ± 0.003 (n = 8), which also showed a significant increase in 
function compared to DMEM.  However, our analysis indicates there was no statistical difference 
between MIs treated with normal-O2/MSCGM hMSCs or reduced-O2/MSCGM hMSCs.  The mean 
normalized RSW for MIs treated with reduced-O2/HGF conditioned hMSCs was 0.069 ± 0.004 (n = 10), 
and again showed to significantly increase regional function compared to all other MI treatment groups.  
Again, all MI treatments at 1 week showed significantly decreased work compared to normal non-
infarcted hearts, with a mean normalized RSW of 0.160 ± 0.008 (n = 6).  However, in normalizing for 
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pressure, our analysis indicates that reduced-O2/HGF conditioned hMSCs may be able to restore normal 
regional work upwards of ~43% after 1 week.  
After 1 month, the mean normalized RSW of DMEM treated MIs was 0.021 ± 0.002 (n = 7; Figure 
5.9).  The mean normalized RSW of MIs treated with traditional normal-O2/MSCGM hMSCs was 0.034 
± 0.007 (n = 7), and the mean normalized RSW of MIs treated with reduced-O2/MSCGM hMSCs was 
0.038 ± 0.005 (n = 6).  As with non-normalized RSW, our analysis showed there was no significant 
difference in normalized RSW for MIs treated with DMEM, normal-O2/MSCGM hMSCs, or reduced-
O2/MSCGM hMSCs at 1 month.  MIs treated with reduced-O2/HGF hMSCs had a mean normalized RSW 
of 0.07 ± 0.008 (n = 6).  Reduced-O2/HGF hMSCs significantly increased normalized RSW compared to 
DMEM (p ≤ 0.001), normal-O2/MSCGM hMSCs (p ≤ 0.01), and reduced-O2/MSCGM hMSCs (p ≤ 0.01).  
As with non-normalized RSW, all MI treatments at 1 month showed significantly decreased normalized 
RSW compared to normal non-infarcted heart function. 
In a comparison of individual treatment groups at 1-week versus 1-month, there was no significant 
difference in normalized RSW for any MI treatment between time points (Figure 5.10).  Our results 
indicate that 1-week improvements in normalized RSW could be sustained out to 1 month. 
 
Systolic Area Contraction 
By taking the difference of the normalized area at end-diastole and end-systole, SAC was calculated 
as a measure of contractile shortening in the region of interest.  At 1 week, DMEM treated MIs resulted in 
a mean SAC of 1.04 ± 0.48% (n = 7; Figure 5.11).  MIs treated with normal-O2/MSCGM hMSCs had a 
mean SAC of 3.76 ± 0.85% (n = 9), which was nearly statistically different than the DMEM treatment (p 
= 0.055).  Treatment with reduced-O2/MSCGM hMSCs resulted in a mean SAC of 5.39 ± 0.66% (n = 8), 
which was significantly different than the DMEM treatment (p ≤ 0.01), but not statistically different than 
normal-O2/MSCGM hMSCs.  MIs treated with reduced-O2/HGF hMSCs resulted in a mean SAC of 8.93 
± 0.63% (n = 10).  Treatment with reduced-O2/HGF hMSCs showed a significant increase in SAC 
compared to DMEM (p ≤ 0.001), normal-O2/MSCGM hMSCs (p ≤ 0.001), and reduced-O2/MSCGM 
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hMSCs (p ≤ 0.01).  All MI treatment groups resulted in significantly decreased SAC values compared to 
normal non-infarcted hearts (19.53 ± 1.18%, n = 6).  Treatment with reduced-O2/HGF hMSCs may be 
able to restore contractility to ~46% of normal heart function. 
At 1 month, the mean SAC of DMEM treated MIs was 1.97 ± 0.42% (n = 7; Figure 5.12).  Treatment 
with normal-O2/MSCGM hMSCs resulted in a mean SAC of 5.99 ± 1.11% (n = 7), which was 
significantly higher than the DMEM treatment (p ≤ 0.05).  MIs treated with reduced-O2/MSCGM hMSCs 
showed a mean SAC of 4.51 ± 0.89% (n = 6), which showed no statistical difference to either DMEM or 
normal-O2/MSCGM hMSCs.  Treatment with reduced-O2/HGF hMSCs resulted in a mean SAC of 10.63 
± 1.56% (n = 6), which was significantly higher than DMEM (p ≤ 0.001), normal-O2/MSCGM hMSCs (p 
≤ 0.05), and reduced-O2/MSCGM hMSCs (p ≤ 0.01).  All MI treatment groups at 1 month indicated 
significantly decreased SAC values compared to normal non-infarcted heart function. 
In a comparison of individual treatment groups at 1-week versus 1-month, there was no significant 
difference in SAC for any MI treatment between time points (Figure 5.13).  Our results indicate that 1-
week improvements in SAC could be sustained out to 1 month. 
 
 
Table 5.1. Summary of Mechanical Data. RSW (Regional stroke work; measured in mm Hg).  Normalized RSW 
is unitless.  SAC (systolic area contraction; percent normalized area).  DMEM (Dulbecco’s Modified Eagles 
Medium).  MSCGM (Mesenchymal Stem Cell Growth Media; proprietary of Lonza Inc.).  HGF (hepatocyte growth 
factor).  MI (myocardial infarct).  
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Figure 5.4. Gross anatomy and corresponding pressure-area work loops.  Once terminal procedures were 
completed, hearts were excised (A, D, G, J) and left ventricular defect areas were re-identified (marked with yellow, 
dotted line).  Hearts were bisected between the base (marked “B”) and apex (marked “A”), generally cutting through 
the identified defect region (B, E, H, K).  Some of the cross-sections of bisected hearts also showed necrotic areas 
within the mid-myocardium.  Mechanical data was analyzed by HDM to establish pressure-area work loops that 
correspond to each heart (C, F, I, L). 
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Figure 5.5. Regional stroke work (RSW, mm Hg) after 1-week survival. 
 
 
 
 
Figure 5.6. Regional stroke work (RSW, mm Hg) after 1-month survival.  
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Figure 5.7. Comparison of regional stroke work at 1-week and 1-month survival time points. 
 
 
 
 
 
 
 
Figure 5.8. Normalized regional stroke work after 1 week survival. 
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Figure 5.9. Normalized regional stroke work after 1-month survival 
 
 
 
 
 
 
 
Figure 5.10. Comparison of normalized regional stroke work at 1-week and 1-month survival time points. 
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Figure 5.11. Systolic area contraction (SAC) after 1-week survival. 
 
 
 
 
 
 
 
Figure 5.12. Systolic area contraction (SAC) after 1-month survival. 
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Figure 5.13. Comparison of systolic area contraction (SAC) at 1-week and 1-month survival time points.  
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5.4. Discussion 
In this study, we implanted reduced-O2/HGF conditioned hMSCs to rat MIs in vivo to study the 
effects on regional cardiac mechanics.  We found that reduced-O2/HGF conditioned hMSCs could 
significantly improve regional stroke work and systolic area contraction at both 1-week and 1-month time 
points, compared to MIs treated with DMEM, normal-O2/MSCGM hMSCs, or reduced-O2/MSCGM 
hMSCs.  While treating MIs with reduced-O2/HGF conditioned hMSCs could not restore regional 
mechanical function to the levels observed in healthy non-infarcted hearts, our results suggest that our 
novel treatment regimen could pre-condition hMSCs to be more effective in vivo than conventional 
hMSCs.   
More work is necessary to understand the possible mechanisms responsible for the increases in 
regional mechanical function.  In Chapter 6, we will evaluate the retention of reduced-O2/HGF hMSCs, 
and their expression of cardiac-specific proteins in vivo.  Previous qualitative studies suggest that 
increased cell retention can increase cardiac function, however, a quantitative correlation between cell 
number and function has not been determined.  Logically, it would make sense that the engraftment of 
more cells could increase function by improving the passive mechanics of an MI, delivering more 
cardioprotective factors for native myocyte survival, and limiting infarct size.  As another mechanism 
lending to the observed increases in mechanical function, it may be possible that some of the implanted 
cells differentiate further in vivo for a more mature cardiomyocyte phenotype.  This would suggest that 
implanted cells may be able to fully differentiate in contractile cells, to increase cardiac mechanics 
through active function, after 2 months in vivo.6 
While our functional results are promising, there are several factors to consider in the design of future 
in vivo studies.  In our experimental design, we treated acute MIs 15 minutes after the removal of a 
temporary ligation.  Previous studies have shown that delivering cells 1 week after an MI can enhance cell 
survival and functional outcomes.  In future studies, it may be more appropriate to deliver cells at the 1-
week post-infarct time point.  Also in our studies, we only delivered 1 million cells to the infarct region.  
While it remains unclear as to the optimal cell number for implantation, it is unlikely that the 1 million 
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delivered cells can repopulate or regenerate the 1 billion cardiomyocytes lost during an MI.  Furthermore, 
more cells will be needed in order to achieve similar levels of functional recovery in adult humans that we 
observed in rats.  By delivering more redcued-O2/HGF hMSCs to the infarcts, it may be possible to 
further enhance functional recovery.  On a related note, there is a need to improve cell delivery techniques 
that will allow for better cell engraftment.  In our study, we delivered cells by the standard IM injection 
technique, which is prone to high levels of cell loss.  New delivery techniques must be developed to limit 
cell loss, so that more cells can be retained for contribution to functional outcomes. 
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CHAPTER 6: Determine retention and cardiac differentiation of delivered cells 
6.1. Introduction 
Cellular therapy for cardiac applications has the potential for regenerating new myocardium for the 
restoration of healthy, functional tissue in diseased hearts.  One of the main goals of cardiac cell therapy 
is to deliver viable, contractile cells that will contribute to active mechanical function, evoking a new 
optimism for treating the millions of people suffering from myocardial infarction (MI) and heart failure 
(HF).1,2  As discussed in Chapter 2, several cell types have been investigated for the use in 
cardiomyoplasty.1,3  Regardless of the chosen cell type, however, one of the most significant hurdles that 
remains in cardiac cell therapy is improving the retention and survival of implanted cells.4,5  The infarcted 
heart is a dynamic environment: undergoing ischemia, inflammation, and cellular turnover while still 
being mechanically stretched by healthy, myocardium in the board-zone of the infarct.  All of these 
factors have been shown to detriment the engraftment and survival of both native cardiomyocytes and 
delivered cells.5-12  And if implanted cells cannot adhere and sustain healthy function, they will not be 
able to deliver therapeutic factors or contribute to active contraction to restore normal heart function.  To 
overcome this hurdle, different strategies have been investigated to improve the retention and viability.  
Some groups have tried to improve retention and viability by developing and evaluating new methods of 
cell delivery.  While other groups have devised in vitro strategies, either by cellular pre-conditioning 
methods to bolster delivered-cell resistance to apoptosis, or by increasing cell recruitment to injury sites 
when implanted in vivo. 
In the evaluation of cardiomyoplasty techniques, the current methods for mesenchymal stem cell 
(MSC) delivery include intravenous (IV),13,14 intracoronary (IC),15 and intramyocardial (IM) injection,15 
as well as cell-seeded biomaterial scaffold implantation.16-18  However, the current methods are 
inefficient, demonstrating low cell retention in the diseased heart or poor integration with native 
myocardium.  Though IV delivery was identified as the least invasive technique, only 1% of the delivered 
MSCs migrated to the heart, while a majority of the cells were found to reside in the lungs.13  The IC 
infusion technique was used in conjunction with angioplasty, in an attempt to improve targeted delivery 
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to the heart.  However, only 3% of the delivered MSCs were found to engraft in the heart, while a 
majority of the cells exited the heart through the bloodstream into pulmonary circulation.15  IM 
implantation is the most invasive of the injection techniques, but allows for direct, localized delivery 
controlled by the surgeon.  Unfortunately, IM injection only increased engraftment to 11%, largely due to 
cell death and extravasation after needle retraction.15  Cell-dosage and timing of treatment are also 
confounding factors with the injection techniques.  Wolf et al. showed that engraftment percentage may 
depend significantly on the number of MSCs delivered, although the reported engraftment assessment 
still only estimated 1-3% retention (based on measurements of body weight and heart weight).19  In a 
study to evaluate the optimal temporal delivery post-MI, Hu et al. determined that delivery at 1-week 
improved retention compared to either 1-hour or 2-week delivery time points.20  However, this temporal 
assessment was based on limited histological evidence, and a full assessment of retention was not 
performed.  The argument for delivery after 1-week post-MI is further strengthened by work which shows 
that apoptosis indices are significantly reduced at 7 days.5 
To overcome the poor engraftment of injection techniques, cell-graft constructs or cell-seeded 
biomaterials have also been investigated for more efficient delivery of cells.  Materials such as 
collagen,16,17 fibrin,21 gelatin,22 alginate,23 and extracellular matrix18 have been cell-seeded and implanted 
in the heart.  Oftentimes, the use of biomaterials adds another layer of complexity to the process.  Cells 
need time to adhere onto the material and seeding efficiencies may be difficult to determine, therefore 
making it difficult to determine the number of cells being delivered to the heart upon implantation.  
Despite these challenges, scaffold-based cell delivery has been shown to increase cell engraftment in the 
heart to ~23%.17  However, delivered cells tend to be retained within the scaffold volume, instead of 
integrating and coupling with native myocardium.24  As cell-seeded biomaterials are typically implanted 
onto the epicardial surface of the heart, less than 1% of delivered cells have been found to traverse to the 
endocardium where most MIs occur.17  Although biomaterial delivery increases the engraftment of 
implanted cells, it remains unclear whether the cells can incorporate into diseased regions for therapeutic 
or regenerative effects.   
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In addition to technical delivery approaches, others have explored biological approaches to increasing 
the retention of delivered cells.  The biological approaches have been aimed at enhancing the resistance to 
apoptosis once cells are implanted in the MI or increasing cell recruitment to the infarct site.  Some 
groups have genetically modified MSCs for the increase of both Akt and ILK,25-27 which have been 
shown to block or inhibit stress- and anoikis-related apoptotic pathways.  These studies showed that Akt 
or ILK transfected cells could improve cardiac function and angiogenesis in MIs, with a cell retention 
increase of ~2.5-4 times that of non-transfected MSCs.  However, retention studies were performed with 
limited histological analysis, and total cell engraftment was not assessed.  Beyond genetic modification, 
reduced-O2 conditioning of MSCs has also been shown to increase prosurvival factors such as Akt, HIF-
1α, survivin, and additional growth factors.9,27-29  In addition, reduced-O2 conditioning has been shown to 
increase the expression of MSC proteins that play a role in cell migration and homing to injured 
myocardium.28-32  Reduced-O2 conditioning increased MSC retention by ~3 times that of unconditioned 
MSCs,32 and decreased delivered-MSC apoptosis by ~25%.9  However, total cell engraftment of reduced-
O2 conditioned MSCs has not been analyzed.  Additionally, the c-Met receptor has been shown to play a 
critical role in MSC motility and migration to injured tissue sites,30,33 which is attributed to increases of 
HGF in these compromised regions.  HGF has been shown to play roles in cardiomyogenesis,34,35 cardiac 
cell survival,36,37 and cardioprotective effects in ischemic myocardium.38  In addition, HGF has also been 
shown to signaling for increased cell survival, retention, and myogenicity in other cell types used in 
cardiac repair (e.g. skeletal myoblasts).39 
In contribution to this body of literature, we determined the retention of our implanted reduced-
O2/HGF conditioned hMSCs after 1 week.  For comparison, we also determined the retention of 
implanted normal-O2/MSCGM hMSCs at the same time point.  To further characterize the fate of 
reduced-O2/HGF conditioned hMSCs in vivo, we also stained histological sections to determine if our 
conditioned cells expressed cardiac-specific markers.  To aid us in our analysis of delivered-cell retention 
and differentiation, we used a novel cell-tracking technique using quantum dot nanoparticles (QDs), 
which was previously developed in our lab. 40  Cells were passively loaded with QDs prior to 
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implantation in vivo.  QDs are endocytosed by hMSCs, presenting as a punctate signal that resides within 
the cytoplasm (Figure 6.1).  During histological analysis, delivered cells were identified by co-localizing 
QD-signal with nuclei counter-stained with Hoechst dye.  Following 1-week survival periods, excised 
hearts were sectioned from base to apex, and sequential sections were analyzed. 
 
6.1.1. Determining the retention of reduced-O2/HGF conditioned hMSCs delivered to a 
myocardial infarct 
As discussed above, cell retention is a major limitation of current cardiac cell therapy applications.  
However, limited analysis has shown that conditioning MSCs in reduced-O2 can increase cell retention 
within an MI.  An increase in cell retention suggests that reduced-O2 conditioned MSCs may have more 
appropriate cellular mechanisms conducive for better survival in the dynamic MI environment, by being 
able to adapt to oxygen deprived tissues and oxidative stress to overcome associated apoptosis 
mechanisms.11,41  In addition, we showed that reduced-O2 conditioning of hMSCs can increase c-Met 
receptor expression (Chapter 3).  Increased c-Met has been shown to improve hMSC motility and 
migration to injury sites,30 which may also play a role in increased hMSC retention.29 
In our analysis, we determined the cell retention of reduced-O2/HGF hMSCs compared to normal-
O2/MSCGM hMSCs after 1 week.  To determine these outcomes, cell-treated infarcted hearts from our 1-
week in vivo studies were excised for histology.  Three hearts from both treatment groups were bisected 
between the apex and base, at the approximate midline of the infarct, and then fixed in 4% 
paraformaldehyde.  Cryosections (~8 μm thick) were made from the mid-infarct, out to either the base or 
the apex.  Sections were pre-screened under a fluorescent microscope for QD signal, to determine the 
range of the cell-implant region.  Positive sections were counter-stained with Hoechst nuclear dye, and 
then analyzed by fluorescent-detection microscopy.  QD-positive cells were then counted in every 20th 
section. 
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6.1.2. Determining the cardiac-specific protein expression of reduced-O2/HGF conditioned 
hMSCs delivered to a myocardial infarct 
The ultimate goal of cardiomyoplasty is to replace diseased myocardium with new, contractile cells 
that can regenerate active mechanical function.  The hope is that delivered cells can fully differentiate into 
mature cardiomyocyte phenotypes that integrate with healthy native myocardium.  Therefore, we sought 
to determine the expression of cardiac-markers of reduced-O2/HGF conditioned hMSCs after 1 week in 
vivo.  As discussed in Chapter 3, some studies report that reduced-O2 conditioning can increase MSC 
differentiation potential.42-44  Also in Chapter 3, we showed that conditioning hMSCs with reduced-
O2/HGF could increase cardiac gene and protein expression in vitro.  And when implanted into MIs in 
vivo, reduced-O2/HGF conditioned hMSCs significantly improved regional mechanical function after 1 
week, with increases in systolic area contraction that would suggest there may be myocardial shortening 
within our analyzed regions of interest.  To determine if reduced-O2/HGF conditioned cells express 
cardiac markers in vivo, sequential cryosections (~8 µm) from the hearts in our retention study were pre-
screened for under a fluorescent microscope for QD-signal (cell tracking nanoparticles).  QD-positive 
sections were then immunostained for cardiac-specific sarcomeric α-actinin and myosin heavy chain.  
Cryosections were then counterstained with Hoechst nuclear dye, and then analyzed by fluorescent-
detection microscopy for protein expression and localization. 
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Figure 6.1. Quantum-dot loading of hMSCs for cell-tracking in vivo.  (A) Quantum-dot (QD) nano-particles are 
endocytosed by hMSCs with high efficiency (scale bar = 100 μm).  (B) Delivered hMSCs are identified by co-
localizing cytoplasmic QD-signal with Hoechst-stained nuclei (scale bar = 25 μm). Figure adapted from Rosen et 
al., 2007.40 
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6.2. Materials and Methods 
6.2.1. Quantum-Dot loading of hMSCs 
In order to track delivered cells to determine cell retention and cardiac differentiation, hMSCs were 
pre-loaded with quantum dot nanoparticles (QDs; Invitrogen, #Q21321MP) prior to implantation.  In 
preparation for in vivo delivery, hMSCs were treated with MSCGM supplemented with an 8.2 nM 
concentration of 655 ITKTM QDs on day 6 of the growth-media phase.  QDs are passively endocytosed by 
hMSCs and reside in the cellular cytoplasm (Figure 6.1).  Quantum dot cell-loading was assessed the 7th 
day of the initial growth-media treatment, to ensure sufficient loading and uniformity in all flasks across 
O2/media treatments.  After a 24-hour incubation in quantum dot supplemented MSCGM, cells were 
washed twice with sterile PBS (without calcium or magnesium; Cellgro, Manassas, VA; # 21-031-CV), 
and then treated for media conditioning.   
Upon implantation, hMSCs retain QDs for the duration of several weeks.  In the event of cell 
disruption, QDs are washed away through the lymphatic system.  During histological analysis, QD-signal 
can be viewed under fluorescent-microscopy without additional histological staining techniques, and can 
be clearly distinguished from autofluorescence of native and diseased myocardium. 
 
6.2.2. Histological Preparation 
Excised hearts were bisected between the apex and base, with a midline cut through the infarct area 
(Figure 6.2).  Hearts were fixed in 4% paraformaldehyde for 24 hours, then transferred to 30% sucrose 
and stored at 4°C until being processed for sectioning.  For sectioning, each half of the rat heart was 
embedded in freezing O.C.T. Compound (Sakura Finetek USA Inc., Torrance, CA).  Eight µm 
cryosections were cut from the embedded apex and base segments using a Leica CM3050 cryostat (-20°C 
specimen temperature; Leica Microsystems, Bannockburn, IL).  Sections were cut from the midline bisect 
to the end of both the apex and base, so that each heart was fully sectioned (Figure 6.2).  Sections were 
collected on positively-charged glass slides (3 sections/slide; VWR® Micro Slides; VWR International, 
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West Chester, PA).  Slides were placed in slide boxes organized by experiment, and then stored in a 
freezer (≤ -20°C) to preserve the heart tissue sections. 
 
6.2.3. Cell Retention Analysis 
In this analysis, infarcted hearts treated reduced-O2/HGF conditioned hMSCs (n = 3) were compared 
to infarcted hearts treated with normal-O2/MSCGM conditioned hMSCs (n = 3) at the 1-week survival 
point.  Cryosectioned heart slides were pre-screened for QD-signal prior to cell retention analysis.  To do 
this, slides were removed from the freezer and immediately analyzed with an upright fluorescent 
microscope (Leica DMLB2) for the presence of QDs within the tissue.  Starting with the first slide 
originating from the midline bisect, every 20th slide in both the apex and base directions were pre-
screened in this fashion.  After all slides were pre-screened, the established range of QD-positive slides 
was then analyzed for cell retention.   
The range of QD-positive slides (every 20th slide from the midline, out to the last QD-positive slide in 
both the apex and base) was stained with Hoechst nuclear dye (1:6000 in PBS; Invitrogen Molecular 
Probes, Eugene, OR; # H3570), washed 3 times in PBS, and then coverslipped with Cytoseal-60TM 
mounting media (Richard Allan Scientific, Kalamazoo, MI).  Each heart section was then analyzed with 
the Leica DMLB2 fluorescent microscope, systematically acquiring 40x images of QD-signal regions 
throughout entire sections.  During data acquisition, pictures for each “40x area” were captured for both 
Hoechst-signal and QD-signal.  Hoechst and QD images were then overlapped using Image J software 
(National Institutes of Health, Bethesda, MD).  Implanted cells were identified by co-localizing QD-
signal with Hoechst-stained nuclei.   
Images were analyzed and QD-positive cells were counted by three individuals.  Total QD-positive 
cell counts were calculated from each individual, and then an average QD-positive cell count was 
determined for each heart section (mean ± standard deviation).  Total QD-positive cell counts from each 
section were plotted against location in the heart (from apex to base), and linear interpolation was used to 
estimate the number of QD-positive cells present in the sections between those analyzed.  From these 
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interpolations, the total numbers of QD-positive hMSCs were approximated for each heart, and the two 
treated MI groups were compared. 
 
6.2.4. Immunohistochemistry 
For immunohistochemical analysis for cardiac-specific marker expression in implanted reduced-
O2/HGF conditioned hMSCs, sequential cryosections were stained from the same hearts used in our cell 
retention analysis.  Prior to immunocytochemistry, heart sections were again pre-screened on an upright 
microscope (Leica DMLB2) for the presence of QD-signal.  Sections showing positive signal were then 
processed for immunostaining of cardiac-specific sarcomeric α-Actinin and myosin heavy chain (MHC). 
Slides were first rehydrated at room temperature for 3 minutes in PBS.  Sections being prepared for 
sarcomeric α-Actinin were permeablized with cold acetone at -20°C for 10 minutes.  Sections being 
prepared for MHC were permeablized with cold methanol at -20° for 20 minutes.  The sections were then 
washed 3 times (5 minutes each) on a rotator with a solution of PBS with 0.05% Tween 20 (Sigma-
Aldrich #P1379).  Sections were blocked for an hour at room temperature with 1.5% serum in PBS 
(Normal Goat Serum, Invitrogen, # 016201; or Normal Rabbit Serum, Dako, # X0902).  After blocking, 
sections were treated with primary antibody for sarcomeric α-actinin (Sigma-Aldrich, # A7811) or MHC 
(Chemicon, part of Millipore; # MAB1552) in PBS with 1.5% serum (of secondary antibody host), 
overnight at 4oC.  After primary antibody incubation, sections were washed 3 times (5 minutes each) 
before being treated with secondary antibody (Invitrogen Alexa Fluor 488 Rabbit anti-Goat,  # A11078; 
Invitrogen Alexa Fluor 488 Goat anti-Rabbit,  # A11008; or Invitrogen Alexa Fluor 488 Rabbit anti-
Mouse,  # A11059) in PBS with 1.5% serum (of the secondary antibody host), at room temperature for 1 
hour. The sections were then washed 2 times in PBS (5 minutes each) on a rotator, and then 
counterstained with Hoechst 33342 nuclear dye (Sigma-Aldrich, # H3570) at a concentration of 1:6000 in 
PBS.  The slides were then washed 3 final times in PBS (5 minutes each), and then coverslipped with 
Cytoseal-60TM.  Sections were then analyzed using a confocal microscope, for co-localization of QD-
positive cells with either sarcomeric α-Actinin or MHC signal. 
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6.2.5. Microscopy and post-processing 
For pre-screening and cell retention analysis, sections were analyzed using a Leica DMLB2 
fluorescent microscope, fitted with a Leica DFC480 camera, used in conjunction with the Leica 
Application Suite software (Leica Microsystems Inc., Buffalo Grove, IL).  Immunohistochemistry 
analysis was performed using a Leica TCS SP5 Spectral Confocal based on a Leica DM16000 Inverted 
research microscope, equipped with Leica Application Suite AF software.  Images were post-processed 
for scale and re-sizing, using Image J software (National Institutes of Health, Bethesda, MD). 
 
6.2.6. Statistical Analysis 
Data for cell retention analysis is reported as mean ± standard deviations as multiple observations 
were made for each sample.  Differences between the 2 treated-MI groups were determined using a 
Student’s unpaired t-test with significance established for p-values ≤ 0.05. 
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Figure 6.2. Schematic of histological preparation.  For histological analysis, hearts were excised and bisected 
between the base (“B”) and the apex (“A”).  Apexes and bases were frozen in O.C.T media, and 8 μm cryosections 
were cut from the midline out to each end.  Three sections were collected onto each slide.  Every 20th slide was 
analyzed for cell retention, leaving 480 μm of tissue between each analyzed slide.  Subsequent slides were analyzed 
by immunohistochemistry for cardiac-specific proteins.  
Chapter 6 | 152  
 
6.3. Results 
For our histological analysis, excised hearts were bisected within the myocardial infarct (MI) region, 
and then 8 µm cryosections were cut from the midline to ends of both the apex and base, so that each 
heart was fully sectioned (Figure 6.2).  Prior to cell retention or immunohistochemical analysis, selected 
slides were pre-screened under an upright fluorescent microscope to identify quantum-dot (QD) loaded 
hMSCs.  For cell retention studies, MIs treated reduced-O2/HGF conditioned hMSCs (n = 3) were 
compared to MIs treated with normal-O2/MSCGM conditioned hMSCs (n = 3) at the 1-week survival 
time point.  Every 20th slide in both the apex and base directions were pre-screened and then counter-
stained with Hoechst nuclear dye, and then QD-positive cells were counted in each section.  With about 
480 µm of tissue being skipped between slides, a linear interpolation was used between counted sections 
for a total cell count of QD-positive hMSCs.  For immunohistochemical studies, cryosections from 
infarcted hearts treated reduced-O2/HGF conditioned hMSCs were stained for cardiac-specific markers.  
Sequential sections from the cell retention study were used, and QD-positive cells were identified and 
analyzed for marker expression with a confocal microscope. 
 
6.3.1. Cell retention of reduced-O2/HGF conditioned hMSCs implanted into a myocardial 
infarct after 1 week 
To analyze cell retention, hMSCs were loaded with QD-nanoparticles prior to implantation in order to 
track delivered cells within the myocardium.  During cell preparation, quantum dot cell-loading was 
assessed to ensure sufficient loading and uniformity in all flasks across O2/media treatments.  During 
implantation, 1 million QD-loaded cells were delivered to each heart.  Delivered cells were identified in 
analyzed cryosections by co-localizing QD-signal with Hoechst counterstained nuclei.  Qualitative 
analysis indicated that there were more QD-positive cells in MIs treated with reduced-O2/HGF 
conditioned hMSCs compared to MIs treated with traditional normal-O2/MSCGM hMSCs (Figure 6.3).  
For a more quantitative analysis, every 20th slide was analyzed in 3 hearts treated with reduced-O2/HGF 
hMSCs and 3 hearts treated with normal-O2/MSCGM hMSCs.  QD-positive cells were counted in each 
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section by 3 individuals, and then averaged cell numbers were calculated for every analyzed section 
throughout each heart.  Plotting average cell number over the distance in each heart, results indicated that 
there were more QD-positive cells in MIs treated with reduced-O2/HGF conditioned hMSCs compared to 
MIs treated with traditional normal-O2/MSCGM hMSCs (Figure 6.4).  Assuming a linear interpolation for 
QD-positive cells in the tissue between analyzed cryosections, total QD-positive cell counts were 
calculated in each heart.  Cell counts for the hearts in each group were averaged, and the two treated MI 
groups were compared using a Student’s t-test.  Results showed that 13.5% of the reduced-O2/HGF 
hMSCs were retained (135,216 ± 42,044 cells), which was significantly higher than the 3.9% retention of 
the normal-O2/MSCGM hMSCs (38,952 ± 30,261 cells; p < 0.02; Figure 6.5). 
 
6.3.2. Cardiac differentiation of reduced-O2/HGF conditioned hMSCs in vivo 
To determine cardiac-marker expression in vivo, sequential cryosections from infarcted hearts treated 
reduced-O2/HGF conditioned hMSCs were stained for either sarcomeric α-Actinin or myosin heavy chain 
(MHC), and then counterstained with Hoechst nuclear dye.  Again, delivered cells were identified by co-
localizing QD-signal with Hoechst stained nuclei.  Our results indicate that some of implanted reduced-
O2/HGF hMSCs can express sarcomeric α-Actinin (Figure 6.6) and MHC (Figure 6.7) after 1 week, 
though co-localization of the two cardiac proteins was not determined.  In addition, we found a number of 
retained reduced-O2/HGF hMSCs that do not express either cardiac-specific protein.  In further analysis 
of immunostained sections, reduced-O2/HGF hMSCs showing positive cardiac-marker expression tended 
to reside near or within MI border-zone regions. 
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Figure 6.3. Representative histological sections for cell retention analysis.  For cell retention analysis, infarcted 
hearts treated with normal-O2/MSCGM hMSCs were compared to infarcted hearts treated with reduced-O2/HGF 
hMSCs.  Cryosections were counterstained with Hoechst nuclear dye.  Whole sections were scanned QD-signal, and 
then regions of QD-signal were analyzed at a higher magnification to count QD-positive cells.  The representative 
images in this figure illustrate our qualitative results, indicating a higher retention of reduced-O2/HGF hMSCs than 
normal-O2/MSCGM hMSCs, depicted by a higher QD-signal content.   
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Figure 6.4. Representative cell retention data.  For a quantitative assessment, QD-positive cells were counted in 3 
infarcted hearts treated with normal-O2/MSCGM hMSCs and 3 infarcted hearts treated with reduced-O2/HGF 
hMSCs.  For each heart, QD-positive hMSCs were counted in every 20th slide, throughout the entire heart (apex to 
base).  Each slide was counted by 3 individuals, and cell counts were summed and plotted over the cryosection 
distance.  The representative data in this graph depicts one heart treated with normal-O2/MSCGM hMSCs versus 
one heart treated with reduced-O2/HGF hMSCs.  Overall, it appears that more reduced-O2/HGF hMSCs were 
retained at throughout the analyzed hearts.  Data is reported as mean ± standard deviation.  Individual hearts from 
each group were not intended to be compared head-to-head, therefore statistical analysis was not performed in this 
comparison.  
 
 
 
 
 
Figure 6.5. Compiled cell retention analysis.  Using a linear interpolation between counted cryosections, a total 
QD-positive cell count was determined for each heart.  Total QD-positive cell counts for hearts in both groups were 
averaged, respectively.  Our quantitative analysis shows a significantly higher retention of reduced-O2/HGF hMSCs 
than normal-O2/MSCGM hMSCs. Differences were evaluated using a Student’s unpaired t-test, and were considered 
significant for p-values ≤ 0.05.  Error bars indicate standard deviation. 
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Figure 6.6. Sarcomeric α-Actinin expression of implanted reduced-O2/HGF conditioned hMSCs. 
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Figure 6.7. Myosin Heavy Chain expression of implanted reduced-O2/HGF conditioned hMSCs. 
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6.4. Discussion 
To account for the possible mechanisms responsible for the increases in regional mechanical function 
observed in Chapter 5, we also evaluated delivered-cell retention and cardiac-specific marker expression 
in vivo.  In a comparative study of cell-treated MIs at 1-week, there was a significantly higher retention of 
reduced-O2/HGF hMSCs than traditionally cultured normal-O2/MSCGM hMSCs.  During cell delivery, 
we made 5 IM injections of (10 µL each) to implant 1 million cells within the infarcted myocardium.  In 
our retention study, we analyzed every 20th slide in each heart, leaving ~480 µm of sectioned tissue 
between analyzed slides for additional assays (e.g. immunohistochemistry of implanted cells).  To 
determine total cell retention, we assumed a linear interpolation between analyzed cryosections to account 
for delivered cells in the unanalyzed tissue.  Given that our delivery method consisted of 5 injection 
locations that were chosen randomly within the infarct region, a linear interpolation model may not be 
optimum for determining delivered cells in unanalyzed tissue (and ultimately, total cell retention).  
However, a preliminary analysis of sequential slides revealed that cryosections immediately before and 
after the analyzed sections were found to contain similar numbers of QD-loaded hMSCs to the sections 
that were counted.  However, we also knew that the number of delivered cells had to increase/decrease 
throughout the 480 µm of unanalyzed tissue, depending on the differences in cell counts at each analyzed 
section.  In our assumption, we also neglected to consider the phenomena of delivered-cell proliferation 
and migration.  However, we made sure to section each heart entirely from base to apex, and analyze 
cryosections through the entire distance of the infarct region.  Of the cryosections that were analyzed, 
whole-section scans were made to identify and count multiple regions of QD-loaded cells.  While there 
were definite increases/decreases of QD-loaded cells from one analyzed section to another, we were 
confident that we could identify multiple injection sites, and our preliminary analysis of sequential 
sections gave us confidence that a linear interpolation would provide a reasonably accurate assessment.  
Previous studies suggest that increased retention of delivered cells can further enhance cardiac 
function, by adding more elements that contribute to both passive and active mechanics.  In addition, a 
higher retention of cells would tend to suggest an increased delivery of signaling factors that would limit 
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infarct size and cardiomyocyte death.  These may be contributing factors for the realized improvements in 
regional mechanical functional.  In a future study, an assessment of delivered-cell retention could also be 
done in the 1-month hearts to investigate whether delivered cells are retained longer-term.  It may be 
possible that there are less hMSCs in 1-month hearts than 1-week hearts, which may suggest that cells are 
lost over time but serve a short-term benefit for lasting functional recovery.  It is also possible that there 
are more hMSCs in 1-month hearts due to delivered-cell proliferation.  However, if more cells are present 
at 1-month, our functional results indicate that they did not significantly affect regional mechanics.  
Alternatively, it may be possible that there are a similar number of hMSCs in 1-month and 1-week hearts, 
foregoing mechanisms of cell death or proliferation.  In this case, delivered hMSCs may serve a more 
long-term functional role by fully differentiating into contractile cardiomyocytes or by supporting native 
cardiomyocytes in a cardioprotective capacity. 
Our immunohistochemical analysis of cell-treated hearts at 1-week showed that some of the 
implanted reduced-O2/HGF hMSCs appeared to stain positive for sarcomeric α-Actinin and myosin heavy 
chain.  However, it is unclear whether the proteins are arranged in a typical sarcomeric phenotype.  The 
data would suggest that these cells have the appropriate cellular machinery to form contractile elements.  
However, it is possible that they still are only partially differentiated in vivo.  There is a possibility that 
our QD-loaded cells have fused with native cardiomyocytes in vivio, as reported in previous studies.45-47  
In our confocal microscopy analysis, however, the inset regions we analyzed indicated α-actinin and 
myosin heavy chain staining was co-localized with Hoechst-stained nuclei surrounded by quantum dot 
signal.  It is still possible that our delivered cells fused with native cardiomyocytes and have become 
integrated within the myocardium, but our analysis would also strongly suggest that our delivered cells 
are expressing cardiac specific markers independently of surrounding myocytes.  
Further analysis on 1-month hearts may reveal whether implanted cells can display mature cardiac 
phenotypes with more time in vivo.  In addition, it remains unclear how many of the delivered reduced-
O2/HGF hMSCs express these markers.  Even with Figures 6.6 and 6.7, there is evidence of QD-loaded 
hMSCs that do not express sarcomeric α-Actinin or myosin heavy chain.  In future histological analysis, it 
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may be possible to count the number of hMSCs expressing cardiac-specific proteins.  In addition, it may 
be possible to correlate the number of cardiogenic hMSCs with the observed increases in regional 
mechanical function.  In doing this, it may be possible to gauge how many regenerated or new 
cardiomyocytes are needed in order to achieve quantifiable improvements in cardiac function. 
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CHAPTER 7: Conclusions and Future Work 
 
7.1. Conclusions 
This body of work aims to forward the approach of using exogenous hMSCs as a cell therapy for the 
dysfunctional heart.  Since 2001, several preclinical and clinical studies have shown that hMSCs derived 
from adult bone marrow may have a limited capacity to regenerate myocardium and restore cardiac 
function.  However, it remains unclear whether delivered hMSCs simply supply the heart with therapeutic 
signaling factors for cardioprotection, or whether hMSCs can fully differentiate into mature phenotypes 
that contribute to active mechanical function.  Several differentiation strategies have been investigated to 
show that hMSCs can at least partially differentiate towards a cardiomyocyte lineage both in vitro and in 
vivo, showing cardiac-specific marker expression and calcium channel currents.  Furthermore, partially-
differentiated cardiogenic hMSCs have been implanted into canine hearts in vivo to show improved 
cardiac function compared undifferentiated, fully multipotent hMSCs.1,2  These results demonstrate a 
unique paradigm in cell therapy, in which the implantation of partially-differentiated cells may have a 
greater capacity for mature, organ-specific phenotypes and functional roles. 
Conditioning primitive hMSCs to adopt cardiac-specific genes and proteins will provide cells with the 
appropriate cellular machinery to further differentiate into mature phenotypes in vivo.  In addition, the 
conditioned hMSCs with cardiogenic phenotype may be able to respond and adapt to cardiac 
microenvironmental cues for better retention, integration, and contribution to function.  In 2008, our lab 
showed how mechanical manipulation of hMSCs by hanging drops could partially differentiate hMSCs 
towards a cardiac lineage and improve mechanical function of MIs in vivo.1  Most recently, Behfar et al. 
showed that conditioning hMSCs with a “kitchen sink” cocktail of cytokines could induce cardiopoiesis, 
also expressing cardiac-markers in vitro and improving MI function in vivo.3  Recent reviews suggest that 
conditioning hMSCs towards a cardiac lineage prior to implantation may improve both direct and indirect 
mechanisms of cardiac repair.4-6  However, current strategies for cardiac differentiation of hMSCs are 
insufficient.  Mechanical and chemical induction methods are technically challenging and tedious, while 
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several of the cardiac-differentiation mechanisms of these techniques remain undefined.  These 
limitations contribute to the fact that current cardiac-differentiation strategies for hMSCs result in only a 
small number of cells becoming cardiogenic.  Exploring new hMSC conditioning regimens may help to 
overcome the limitations of current differentiation methods.  A simplistic strategy with fewer steps and 
factors may be more clinically applicable due to the ease of implementation; and a better understanding of 
how these simpler strategies induce cardiac-mechanisms may allow for an increased number of 
cardiogenic cells or degree of cardiac differentiation. 
In this thesis we introduced a novel in vitro conditioning regimen, carefully designed to incorporate 
environmental cues found in MIs in vivo (e.g. decreased oxygen tension7 and increased cell-signaling 
factors8-10).  We exploited these cues for a simple strategy using reduced-O2 culturing and HGF treatment 
to initiate cardiac differentiation of hMSCs in vitro.  For the basis of this work, we hypothesized that 
applying a combined conditioning treatment of reduced-O2 and HGF to hMSCs in vitro will enhance 
cardiac-specific gene and protein expression.  Additionally, we hypothesized that the transplantation of 
conditioned hMSCs into an in vivo MI model will result in differentiation of delivered hMSCs and 
improved cardiac mechanical function.  To test these hypotheses, we formulated three major objectives.  
In the first objective, we evaluated the effects of reduced-O2 conditioning on hMSC growth kinetics and 
c-Met receptor expression.  In the second objective, we determined the effects of reduced-O2/HGF 
conditioning on cardiac-specific marker expression in hMSCs.  And in the final objective, we implanted 
reduced-O2/HGF conditioned hMSCs into MIs in vivo to evaluate regional cardiac mechanics, as well as 
delivered-cell retention and cardiac-marker expression. 
In our initial studies, we showed that conditioning hMSCs in reduced-O2 can significantly increase 
the number of population doublings and the number of passages compared to hMSCs traditionally grown 
in ambient oxygen conditions.  Our analysis suggests that hMSCs may respond more positively to low-
oxygen niche environments, and that hMSCs grown in reduced-O2 are healthier, less inclined to senesce, 
and possibly more plastic or “stem-like” in their propensity to proliferate.  Our initial studies also showed 
that hMSCs conditioned in reduced-O2 could significantly increase expression of the c-Met receptor after 
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7 days in culture.  As c-Met has been previously implicated in cardiomyogenesis,11,12 our results suggest 
that there may be a finite window for initiating the cardiac program in hMSCs.  This is an ongoing theme 
for scientists who study cardiac differentiation strategies in all stem cell types.  Trying to find the 
optimum treatment to initiate cardiac differentiation is often highly dependent on timing, whether 
delivering certain growth factors by a chemical induction or forming embryoid bodies by a mechanical 
induction. 
By exploiting the effects of conditioning hMSCs in reduced-O2 to increase the expression of c-Met, 
we then investigated the effects of reduced-O2/HGF conditioning on cardiac-specific marker expression in 
hMSCs in vitro.  Our results showed that a combined conditioning regimen of reduced-O2/HGF could 
elicit the expression of several cardiac genes and proteins in hMSCs, with an increased breadth of 
cardiac-specific marker expression than we previously achieved in our hanging-drop differentiation 
method.  However, we did not analyze the effects of short term reduced-O2 conditioning.  It is possible 
that short term reduced-O2 durations could provide a necessary signaling cascade for cardiac 
differentiation.  In consideration of cellular processes, it may be necessary attenuate the proliferation 
effects of reduced-O2 conditioning (described in Chapter 2), as proliferation often offsets the cellular 
processes needed for differentiation.  Short-term exposure to reduced-O2 may initiate necessary cardiac 
signaling events, but then transitioning the cells back to a less proliferative normal-O2 environment may 
allow for further cardiac differentiation. 
Using small-molecule inhibitors to target specific control points in our proposed HGF/c-Met pathway, 
we showed that decreases in c-Met or PI3K activation could attenuate cardiac gene expression.  These 
results would suggest that the HGF/c-Met pathway and the PI3K effector protein are instrumental in 
initiating the cardiac-program in marrow-derived hMSCs. 
We then implanted conditioned hMSCs to MIs in vivo and found that reduced-O2/HGF conditioned 
hMSCs could significantly improve regional stroke work and systolic area contraction at 1-week and 1-
month time points, compared to MIs treated with DMEM, normal-O2/MSCGM hMSCs, or reduced-
O2/MSCGM hMSCs.  To account for the possible mechanisms responsible for the increases in regional 
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mechanical function, we also evaluated delivered-cell retention and cardiac-specific marker expression in 
vivo.  In a comparative study of MI treated hearts, there was a significantly higher retention of reduced-
O2/HGF conditioned hMSCs than traditionally cultured normal-O2/MSCGM hMSCs.  It is possible that 
the significant increases in cell retention of reduced-O2/HGF conditioned hMSCs could account for the 
increases in cardiac mechanical function.  With higher cell retention, it likely that delivered cells can 
attenuate scar formation and increase passive cardiac mechanics.4,5  In addition, a significantly higher 
retention of delivered cells can supply more paracrine factors and cytokines to the infarcted heart, which 
may provide necessary signaling factors for native myocyte proliferation or native stem cell 
recruitment/differentiation. 
However, our immunohistochemical analysis showed that some of the implanted reduced-O2/HGF 
hMSCs stained positive for sarcomeric α-Actinin and myosin heavy chain.  These results suggest that 
some of our implanted cells may be further differentiating towards a cardiomyocyte phenotype.  Further 
analysis is needed to determine whether these cells are displaying sarcomere formation and spacing, as an 
indication of mature cardiomyocyte differentiation.  Although these results are encouraging, only a small 
percentage of the delivered cells appear display cardiac protein expression indicative of sarcomere 
formation.  Therefore, it may be unlikely that the increases we observed in cardiac mechanical function 
can be attributed to our delivered cells becoming functional, contractile cardiomyocytes.  It is more likely 
that our delivered cells increased myocyte content in infarcted hearts by delivering signaling factors that 
either served a cardioprotective role to enhance the cell survival of native myocytes, or induced native 
myocytes to proliferate, or recruited native stem cells to differentiate into new myocytes. 
As a whole, these data suggest that reduced-O2/HGF conditioned hMSCs may be able to differentiate 
to a contractile cardiac phenotype, which may be capable of contributing active mechanical function in 
the diseased heart.  With respect to the overall goal of cardiomyoplasty, this data adds support for the 
argument that conditioned “cardiogenic” hMSCs may be better than unconditioned hMSCs for replacing 
necrotic myocardium and restoring cardiac function.  In a qualitative assessment by 
immunocytochemistry, it appears that our conditioning regimen can increase the number of hMSCs that 
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express cardiac specific markers.  However, conditioned hMSCs do not show sarcomere formation in 
vitro, which suggests that they are partially differentiated “cardiogenic” cells.  In consideration of using 
reduced-O2/HGF conditioned hMSCs as a potential cardiac cell therapy, it may be more advantageous to 
implant partially differentiated cardiogenic cells in vivo rather than fully differentiated cardiac cells.  
Partially differentiated cardiogenic cells are more likely to adapt to specific cardiac regions (e.g. ventricle, 
atrium, epicardium, or endocardium) for more site-appropriate cardiac cell types; whereas fully 
differentiated cardiac cells may cause functional complications (e.g. arrhythmias) if implanted in the 
wrong regions of the heart.  In further consideration of being able to deliver enough cells to regenerate the 
lost cardiomyocytes resulting from an MI, our results from Chapter 3 would indicated that reduced-O2 
conditioning can significantly increase the expansion of hMSCs.  Combined with our reduced-O2/HGF 
conditioning regimen, it is likely that we can generate billions of cardiogenic hMSCs for a potential 
cardiac cell therapy.  At this point, it is unclear whether our partially differentiated cardiogenic cells can 
maintain cardiac-specific marker expression over successive cell passages.  Therefore, it is likely that we 
would first have to expand the hMSCs in reduced-O2 and growth medium, and then apply our reduced-
O2/HGF conditioning regimen for cardiogenic differentiation.  Additionally, further analysis would be 
needed to determine whether late-passage hMSCs can still be conditioned for cardiac-specific marker 
expression. 
With this being said, many fundamental scientific questions remain unanswered.  It is still unclear 
whether enough hMSCs are being retained to regenerate an entire infarct.  Likewise, it remains uncertain 
if enough hMSCs can fully differentiate to a mature cardiomyocyte phenotype, to significantly increase 
enough contractile mass to restore healthy cardiac function.  As of yet, there have not been any studies to 
correlate increased myocyte content with improvements in function.  Furthermore, additional studies are 
needed to determine if cardiogenic hMSCs are incorporating with host tissue for synchronous electrical 
and mechanical function.  These questions necessitate further investigation. 
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7.2. Future Work 
In order to address some of these outstanding questions regarding the use of hMSCs as a cardiac cell 
therapy, several aspects can be investigated in future in vitro and in vivo studies.  Despite the reported 
successes of partially differentiating hMSCs toward a more cardiogenic phenotype, it remains unclear if 
hMSCs can fully differentiate into mature cardiomyocytes.  And while reduced-O2/HGF treated hMSCs 
show an increased breadth and expression of cardiac-specific genes and proteins, they do not demonstrate 
a striated contractile phenotype in vitro.  In addition, it remains unclear if reduced-O2/HGF conditioned 
hMSCs can fully differentiate into cardiomyocytes in vivo to contribute to active contraction, and whether 
the determined increases in function can be sustained longer-term. 
Our small-molecule inhibitor experiments suggest that both c-Met and PI3K signaling are involved in 
cardiac differentiation of hMSCs.  However, a complete picture of the signaling events required to drive 
the cardiac program in hMSCs remains largely undefined.  Behfar et al. have also done some preliminary 
work to suggest that transforming growth factor β1, bone morphogenetic protein-4, Activin A, retinoic 
acid, insulin-like growth factor-1, fibroblast growth factor-2 (FGF-2), alpha-thrombin, and interleukin-6 
(IL-6) may also be involved in the cardiac-pathway of hMSCs.3  In consideration of these findings, we 
concede that there may be several key signaling events taking place in our system in addition to the 
HGF/c-Met pathway.  In also considering that conditioned hMSCs have been shown to increase the 
secretion of prosurvival and growth factors,13-15 it is likely that secreted factors may also have autocrine 
effects on the hMSCs.  We have done some preliminary studies on the supernatants of reduced-O2/HGF 
conditioned hMSCs, to quantify some of the cytokines involved in the Behfar study by ELISA.  In our 
preliminary studies, we have found that reduced-O2/HGF conditioned hMSCs can significantly increase 
the secretion of Activin A, FGF-2, and IL-6 compared to hMSCs grown in normal-O2 or reduced-O2 
conditions (data not shown).  This preliminary data suggests that reduced-O2/HGF conditioning may elicit 
additional autocrine signaling cascades that may also contribute to the cardiac program in hMSCs.  More 
work is needed to evaluate reduced-O2/HGF conditioned hMSCs for the additional cytokines implicated 
in the Behfar study.  An understanding of these factors and subsequent autocrine signaling pathways may 
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help to clarify the mechanisms involved in cardiac differentiation of hMSCs.  Furthermore, it may be 
possible to exploit one or more of these factors to generate cardiogenic hMSCs with more mature 
myocyte phenotypes.  
With induction timing playing an intricate role in cardiogenesis,16-18 it is possible that reduced-O-
2/HGF conditioning for 7 days is not a sufficient amount of time for complete cardiac differentiation in 
hMSCs.  One simple future study would be to condition hMSCs with reduced-O2/HGF for longer time 
points over the course of a month, to evaluate the presence of additional sarcomeric proteins and 
phenotypic presentation.  From our in vitro differentiation study, we showed that reduced-O2/HGF 
conditioned hMSCs can express markers corresponding with the L-type calcium channel.  Another 
potential study would be to evaluate the functionality of the L-type calcium channel in reduced-O2/HGF 
conditioned hMSCs using calcium dye imaging or patch clamping techniques.  In addition, reduced-
O2/HGF hMSCs could be screened for additional cardiac ion-channel markers expression and 
functionality.  Another potential in vitro aspect would be to investigate the effects of either mechanical or 
electrophysiological stimulation on redueced-O2/HGF conditioned hMSCs.  Previous studies have shown 
that inducing mechanical stretch or electrophysiological stimulation on cells in vitro can elicit functional 
properties similar to those generated in vivo.19-21  In-house systems are readily available for these studies, 
such as the Flexcell® equibiaxial-stretch cell culturing system for mechanical stimulation, or the C-PaceTM 
electric pulse system for continuous electrical stimulation.  Cells could be stimulated using parameters 
similar to in vivo conditions, and then cells could be evaluated for viability, orientation, cardiac-marker 
expression, and phenotypic presentation.  
For in vivo analysis, there are several future work studies that can be generated from our initial 
experiments.  Logically, we would want to analyze the 1-month excised hearts for cell retention and 
cardiomyocyte marker expression, and compare them with our 1-week results.  Histochemical trichrome 
techniques could be used to determine the infarct size of 1-week and 1-month hearts; and it may be 
possible to determine MI volume by using a similar linear interpolation model to the one we used in our 
cell retention study.  In addition, cryosections from 1-week and 1-month hearts treated with reduced-
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O2/HGF hMSCs can be stained for more cardiac markers (e.g. troponin I, connexin 43, and ventricular 
myosin light chain).  Advanced multi-stain immunohistochemical techniques can also be applied to 
determine if implanted reduced-O2/HGF hMSCs can express two or more cardiac markers in 
combination. 
From a functional standpoint, immunostained cryosections could also be analyzed to count the 
number of cardiac-positive hMSCs in both 1-week and 1-month hearts.  In doing this, it may be possible 
to correlate the number of delivered cardiogenic cells with functional increases observed at the 1-week 
and 1-month time points.  Furthermore, additional in vivo studies can be designed to analyze the 
functional and histological effects of cell-treated MIs for longer survival time points.  All of these 
functional studies would most likely require the development of novel analytical techniques (e.g. image 
analysis methods, correlation algorithms, or longer-term cell tracking systems).  However, they would 
advance the field by beginning to address some of the outstanding limitations regarding cell therapy for 
cardiac applications. 
 
 
  
Chapter 7 | 171  
 
7.3. References 
 
 
1 Potapova, I. A. et al. Enhanced recovery of mechanical function in the canine heart by seeding an 
extracellular matrix patch with mesenchymal stem cells committed to a cardiac lineage. Am J Physiol Heart 
Circ Physiol 295, H2257-2263, (2008). 
2 Potapova, I. et al. Functional Regeneration of the Canine Ventricle Using Adult Human Mesenchymal 
Stem Cells Committed In Vitro to a Cardiac Lineage. Circ Res 99, E19, (2006). 
3 Behfar, A. et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal 
stem cells in chronic myocardial infarction. J Am Coll Cardiol 56, 721-734, (2010). 
4 Gaudette, G. R. & Cohen, I. S. Cardiac regeneration: materials can improve the passive properties of 
myocardium, but cell therapy must do more. Circulation 114, 2575-2577, (2006). 
5 Cohen, I. S. & Gaudette, G. R. Regenerating the heart: new progress in gene/cell therapy to restore normal 
mechanical and electrical function. Dialogues in Cardiovascular Medicine 14, 19, (2009). 
6 Marban, E. & Malliaras, K. Boot camp for mesenchymal stem cells. J Am Coll Cardiol 56, 735-737, 
(2010). 
7 Chacko, S. M. et al. Myocardial oxygenation and functional recovery in infarct rat hearts transplanted with 
mesenchymal stem cells. Am J Physiol Heart Circ Physiol 296, H1263-1273, (2009). 
8 Vanhoutte, D., Schellings, M., Pinto, Y. & Heymans, S. Relevance of matrix metalloproteinases and their 
inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 69, 604-613, (2006). 
9 Sutton, M. G. & Sharpe, N. Left ventricular remodeling after myocardial infarction: pathophysiology and 
therapy. Circulation 101, 2981-2988, (2000). 
10 Chang, S. A. et al. Impact of Myocardial Infarct Proteins and Oscillating Pressure on the Differentiation of 
Mesenchymal Stem Cells: Effect of Acute Myocardial Infarction on Stem Cell Differentiation. Stem Cells, 
(2008). 
11 Roggia, C., Ukena, C., Bohm, M. & Kilter, H. Hepatocyte growth factor (HGF) enhances cardiac 
commitment of differentiating embryonic stem cells by activating PI3 kinase. Exp Cell Res 313, 921-930, 
(2007). 
12 Rappolee, D. A., Iyer, A. & Patel, Y. Hepatocyte growth factor and its receptor are expressed in cardiac 
myocytes during early cardiogenesis. Circulation research 78, 1028-1036, (1996). 
13 Sadat, S. et al. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. 
Biochem Biophys Res Commun 363, 674-679, (2007). 
14 Kanichai, M., Ferguson, D., Prendergast, P. J. & Campbell, V. A. Hypoxia promotes chondrogenesis in rat 
mesenchymal stem cells: a role for AKT and hypoxia-inducible factor (HIF)-1alpha. J Cell Physiol 216, 
708-715, (2008). 
15 Chacko, S. M. et al. Hypoxic preconditioning induces the expression of prosurvival and proangiogenic 
markers in mesenchymal stem cells. Am J Physiol Cell Physiol 299, C1562-1570, (2010). 
16 Xu, C., Police, S., Rao, N. & Carpenter, M. K. Characterization and enrichment of cardiomyocytes derived 
from human embryonic stem cells. Circ Res 91, 501-508, (2002). 
17 Sartiani, L. et al. Developmental changes in cardiomyocytes differentiated from human embryonic stem 
cells: a molecular and electrophysiological approach. Stem Cells 25, 1136-1144, (2007). 
18 Kehat, I. et al. Human embryonic stem cells can differentiate into myocytes with structural and functional 
properties of cardiomyocytes. J Clin Invest 108, 407-414, (2001). 
19 Shimko, V. F. & Claycomb, W. C. Effect of Mechanical Loading on Three-Dimensional Cultures of 
Embryonic Stem Cell-Derived Cardiomyocytes. Tissue Eng, (2007). 
20 McMahon, L. A., Campbell, V. A. & Prendergast, P. J. Involvement of stretch-activated ion channels in 
strain-regulated glycosaminoglycan synthesis in mesenchymal stem cell-seeded 3D scaffolds. J Biomech 
41, 2055-2059, (2008). 
21 Kawano, S., Otsu, K., Shoji, S., Yamagata, K. & Hiraoka, M. Ca(2+) oscillations regulated by Na(+)-
Ca(2+) exchanger and plasma membrane Ca(2+) pump induce fluctuations of membrane currents and 
potentials in human mesenchymal stem cells. Cell Calcium 34, 145-156, (2003). 
 
 
